{"matching_results": 31352, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1128, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 935}, {"key": "negative", "matching_results": 180}, {"key": "neutral", "matching_results": 13}]}]}, {"key": "tickerreport.com", "matching_results": 934, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 835}, {"key": "negative", "matching_results": 98}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "watchlistnews.com", "matching_results": 934, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 791}, {"key": "negative", "matching_results": 143}]}]}, {"key": "wkrb13.com", "matching_results": 913, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 790}, {"key": "negative", "matching_results": 122}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 858, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 725}, {"key": "negative", "matching_results": 133}]}]}, {"key": "dailypolitical.com", "matching_results": 817, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 716}, {"key": "negative", "matching_results": 99}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "freelancer.com.co", "matching_results": 751, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 683}, {"key": "negative", "matching_results": 62}, {"key": "neutral", "matching_results": 6}]}]}, {"key": "theolympiareport.com", "matching_results": 679, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 567}, {"key": "negative", "matching_results": 111}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 599, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 497}, {"key": "negative", "matching_results": 102}]}]}, {"key": "marketscreener.com", "matching_results": 492, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 326}, {"key": "negative", "matching_results": 158}, {"key": "neutral", "matching_results": 8}]}]}]}], "results": [{"id": "w1GroXBQ78s46SUyNWnedjqB07K0I48UqVVivuJECo349upa0R-K2RCupzAYIT_7", "result_metadata": {"score": 35.202938}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Peptic Ulcer Drugs", "keywords": [{"text": "Peptic Ulcer Drugs"}]}, "sentence": "Peptic Ulcer Drugs to Undertake Strapping Growth During 2016 2022 \u2013", "object": {"text": "Strapping Growth", "keywords": [{"text": "Growth"}]}, "action": {"verb": {"text": "Undertake", "tense": "future"}, "text": "to Undertake", "normalized": "to Undertake"}}], "concepts": [{"text": "Peptic ulcer", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}], "categories": [{"score": 0.655078, "label": "/health and fitness"}, {"score": 0.426431, "label": "/health and fitness/drugs"}, {"score": 0.414593, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Peptic Ulcer Drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.982644}, {"text": "Strapping Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.545618}]}, "crawl_date": "2018-11-09T12:59:16Z", "url": "https://www.findmarketresearch.org/2018/08/peptic-ulcer-drugs-market-to-undertake-strapping-growth-during-2016-2022/", "host": "findmarketresearch.org", "text": "Top players in the global peptic ulcer drugs market covered in this report are Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-08-30T10:33:00+05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.706883, "label": "negative"}, "text": "Duodenal ulcers", "relevance": 0.720843, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"count": 4, "sentiment": {"score": -0.564443, "label": "negative"}, "text": "North America", "relevance": 0.479161, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": -0.562516, "label": "negative"}, "text": "gastritis", "relevance": 0.393384, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Gastritis", "dbpedia_resource": "http://dbpedia.org/resource/Gastritis"}}, {"count": 2, "sentiment": {"score": -0.639897, "label": "negative"}, "text": "GERD", "relevance": 0.384408, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 2, "sentiment": {"score": -0.393651, "label": "negative"}, "text": "Mn", "relevance": 0.37578, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.273937, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.564443, "label": "negative"}, "text": "aspirin", "relevance": 0.267808, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.257897, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.256218, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.253218, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": -0.455789, "label": "negative"}, "text": "Daewoong Pharmaceutical Co.", "relevance": 0.249278, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.228986, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.224355, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.21853, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Yuhan Corporation", "relevance": 0.211654, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cadila Healthcare Ltd.", "relevance": 0.203921, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca plc.", "relevance": 0.203644, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co. Ltd.", "relevance": 0.197867, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "25.8%", "relevance": 0.197867, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "41.2%", "relevance": 0.197867, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "41.5%", "relevance": 0.197867, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "79.2%", "relevance": 0.197867, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.8%", "relevance": 0.197867, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.0%", "relevance": 0.197867, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.197867, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.639375, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Peptic ulcer", "keywords": [{"text": "Peptic ulcer"}]}, "sentence": "Peptic ulcer refers to the group of gastrointestinal disorders including gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD).", "object": {"text": "to the group of gastrointestinal disorders including gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD)", "keywords": [{"text": "Duodenal ulcers"}, {"text": "gastroesophageal reflux disease"}, {"text": "gastric ulcers"}, {"text": "gastrointestinal disorders"}], "entities": [{"type": "HealthCondition", "text": "gastritis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Gastritis", "dbpedia_resource": "http://dbpedia.org/resource/Gastritis"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "refer", "tense": "present"}, "text": "refers", "normalized": "refer"}}, {"subject": {"text": "gastritis, gastric ulcers, and Duodenal ulcers", "keywords": [{"text": "Duodenal ulcers"}, {"text": "gastric ulcers"}, {"text": "gastritis"}], "entities": [{"type": "HealthCondition", "text": "gastritis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Gastritis", "dbpedia_resource": "http://dbpedia.org/resource/Gastritis"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}]}, "sentence": "Peptic ulcer refers to the group of gastrointestinal disorders including gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD).", "object": {"text": "gastrointestinal disorders", "keywords": [{"text": "gastrointestinal disorders"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "those which reduce gastric ulcer secretion such as PPI and H2 receptor antagonists, acid neutralization agents such as antacids and antibiotics against H. pylori infection", "keywords": [{"text": "H2 receptor antagonists"}, {"text": "gastric ulcer secretion"}, {"text": "acid neutralization agents"}, {"text": "H. pylori infection"}]}, "sentence": " Drugs used for the treatment of peptic ulcer include those which reduce gastric ulcer secretion such as PPI and H2 receptor antagonists, acid neutralization agents such as antacids and antibiotics against H. pylori infection.", "object": {"text": "Drugs used for the treatment of peptic ulcer", "keywords": [{"text": "peptic ulcer"}, {"text": "Drugs"}, {"text": "treatment"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "those"}, "sentence": " Drugs used for the treatment of peptic ulcer include those which reduce gastric ulcer secretion such as PPI and H2 receptor antagonists, acid neutralization agents such as antacids and antibiotics against H. pylori infection.", "object": {"text": "gastric ulcer secretion such as PPI", "keywords": [{"text": "gastric ulcer secretion"}, {"text": "PPI"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "reduce", "normalized": "reduce"}}, {"subject": {"text": "these drugs", "keywords": [{"text": "drugs"}]}, "sentence": " However, these drugs are often used in combination for effective treatment.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "these drugs", "keywords": [{"text": "drugs"}]}, "sentence": " However, these drugs are often used in combination for effective treatment.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " Depending upon the product type, peptic ulcer drugs market is segmented into proton pump inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), antacids, H2 antagonists, antibiotics, and ulcer protective drugs.", "object": {"text": "segmented into proton pump inhibitors", "keywords": [{"text": "proton pump inhibitors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "sentence": " On the basis of indications, the market has been segmented into gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD).", "object": {"text": "segmented into gastritis, gastric ulcers, duodenal ulcers", "keywords": [{"text": "duodenal ulcers"}, {"text": "gastric ulcers"}, {"text": "gastritis"}], "entities": [{"type": "HealthCondition", "text": "gastritis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Gastritis", "dbpedia_resource": "http://dbpedia.org/resource/Gastritis"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "sentence": " On the basis of indications, the market has been segmented into gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD).", "object": {"text": "into gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD)", "keywords": [{"text": "duodenal ulcers"}, {"text": "gastric ulcers"}, {"text": "gastroesophageal reflux disease"}, {"text": "gastritis"}], "entities": [{"type": "HealthCondition", "text": "gastritis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Gastritis", "dbpedia_resource": "http://dbpedia.org/resource/Gastritis"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"type": "HealthCondition", "text": "Duodenal ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "the global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " By distribution channel, the global peptic ulcer drugs market is segmented into hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-Commerce.", "object": {"text": "segmented into hospital pharmacies, private clinics, drug stores, retail pharmacies", "keywords": [{"text": "hospital pharmacies"}, {"text": "retail pharmacies"}, {"text": "drug stores"}, {"text": "private clinics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " By distribution channel, the global peptic ulcer drugs market is segmented into hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-Commerce.", "object": {"text": "into hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-Commerce", "keywords": [{"text": "hospital pharmacies"}, {"text": "retail pharmacies"}, {"text": "drug stores"}, {"text": "private clinics"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The global peptic ulcer drugs treatment market", "keywords": [{"text": "peptic ulcer drugs"}, {"text": "treatment market"}]}, "sentence": " The global peptic ulcer drugs treatment market was valued at US$ 32,200 Mn in 2014.", "object": {"text": "valued at US$ 32,200 Mn in 2014", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The global peptic ulcer drugs treatment market", "keywords": [{"text": "peptic ulcer drugs"}, {"text": "treatment market"}]}, "sentence": " The global peptic ulcer drugs treatment market was valued at US$ 32,200 Mn in 2014.", "object": {"text": "at US$ 32,200 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "was valued", "normalized": "be value"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America led the global market 2014, accounting for 41.2% share of total global market revenue.", "object": {"text": "for 41.2% share of total global market revenue", "keywords": [{"text": "global market revenue"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "41.2"}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "accounting", "normalized": "account"}}, {"subject": {"text": "treatment options for peptic ulcers", "keywords": [{"text": "peptic ulcers"}, {"text": "treatment options"}]}, "sentence": " The surge in use of non-steroidal anti-inflammatory drugs (NSAID) such as aspirin and growing awareness regarding treatment options for peptic ulcers are factors expected to drive the growth of the peptic ulcer drugs market in North America.", "object": {"text": "factors expected", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The market in Europe", "keywords": [{"text": "market"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " The market in Europe accounted for a second largest share of 25.8%, primarily due to easy availability of successful treatment options for peptic ulcers in the region.", "object": {"text": "for a second largest share of 25.8%, primarily due to easy availability of successful treatment options for peptic ulcers in the region", "keywords": [{"text": "successful treatment options"}, {"text": "peptic ulcers"}, {"text": "easy availability"}, {"text": "largest share"}], "entities": [{"type": "Quantity", "text": "25.8"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "Revenue from the global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " Revenue from the global peptic ulcer drugs market is projected to expand at a steady CAGR of 2.8% over the forecast period and is expected to be valued at US$ 40,004.3 Mn by 2022 end.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is expected to remain the dominant market, contributing 41.5% share to the global peptic ulcer drugs market in terms of revenue.", "object": {"text": "41.5% share", "keywords": [{"text": "share"}], "entities": [{"type": "Quantity", "text": "41.5"}]}, "action": {"verb": {"text": "contribute", "tense": "present"}, "text": "contributing", "normalized": "contribute"}}, {"subject": {"text": "The PPI and H2 antagonist product segments", "keywords": [{"text": "H2 antagonist product"}, {"text": "PPI"}, {"text": "segments"}]}, "sentence": " The PPI and H2 antagonist product segments collectively accounted for 79.2% revenue share in 2014.", "object": {"text": "for 79.2% revenue share", "keywords": [{"text": "revenue share"}], "entities": [{"type": "Quantity", "text": "79.2"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "The gastric ulcer indication segment", "keywords": [{"text": "gastric ulcer indication"}, {"text": "segment"}]}, "sentence": " The gastric ulcer indication segment was valued at US$ 5,279.8 Mn in 2014 and is expected to register the highest CAGR of 3.0% over the forecast period.", "object": {"text": "valued at US$ 5,279.8 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The gastric ulcer indication segment", "keywords": [{"text": "gastric ulcer indication"}, {"text": "segment"}]}, "sentence": " The gastric ulcer indication segment was valued at US$ 5,279.8 Mn in 2014 and is expected to register the highest CAGR of 3.0% over the forecast period.", "object": {"text": "at US$ 5,279.8 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "was valued", "normalized": "be value"}}, {"subject": {"text": "the highest CAGR of 3.0%", "keywords": [{"text": "highest CAGR"}], "entities": [{"type": "Quantity", "text": "3.0"}]}, "sentence": " The gastric ulcer indication segment was valued at US$ 5,279.8 Mn in 2014 and is expected to register the highest CAGR of 3.0% over the forecast period.", "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "Factors", "keywords": [{"text": "Factors"}]}, "sentence": " Factors driving the growth of the global peptic ulcer drugs market include growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, increasing a number of generic manufacturers of peptic ulcer drugs, changes in disease management etc.", "object": {"text": "the growth of the global", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, increasing a number of generic manufacturers of peptic ulcer drugs, changes in disease management etc", "keywords": [{"text": "peptic ulcer drugs"}, {"text": "peptic ulcers"}, {"text": "R&D stimulation"}, {"text": "generic manufacturers"}]}, "sentence": " Factors driving the growth of the global peptic ulcer drugs market include growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, increasing a number of generic manufacturers of peptic ulcer drugs, changes in disease management etc.", "object": {"text": "Factors driving the growth of the global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}, {"text": "Factors"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "increasing smoking rate, and progressive population of geriatrics", "keywords": [{"text": "smoking rate"}, {"text": "progressive population"}, {"text": "geriatrics"}]}, "sentence": " Furthermore, factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the growth of the global peptic ulcer drugs market over the forecast period.", "object": {"text": "anticipated to promote the growth of the global peptic ulcer drugs market over the forecast period", "keywords": [{"text": "peptic ulcer drugs"}, {"text": "forecast period"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "increasing smoking rate, and progressive population of geriatrics", "keywords": [{"text": "smoking rate"}, {"text": "progressive population"}, {"text": "geriatrics"}]}, "sentence": " Furthermore, factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the growth of the global peptic ulcer drugs market over the forecast period.", "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "are anticipated to promote", "normalized": "be anticipate to promote"}}, {"subject": {"text": "factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics", "keywords": [{"text": "stress-induced ulcers"}, {"text": "smoking rate"}, {"text": "progressive population"}, {"text": "prevalence"}]}, "sentence": " Furthermore, factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the growth of the global peptic ulcer drugs market over the forecast period.", "object": {"text": "the growth of the global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "action": {"verb": {"text": "promote", "tense": "future"}, "text": "are anticipated to promote", "normalized": "be anticipate to promote"}}, {"subject": {"text": "changes in pricing policies of drugs", "keywords": [{"text": "drugs"}, {"text": "changes"}, {"text": "policies"}]}, "sentence": " However, side effects of peptic ulcer drugs, poor pipeline productivity, and changes in pricing policies of drugs are factors expected to hamper the growth of the global peptic ulcer drugs market during this period.", "object": {"text": "factors expected", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}], "entities": []}, "sentence": " Top players in the global peptic ulcer drugs market covered in this report are Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline Plc.", "object": {"text": "in this report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "cover", "tense": "past"}, "text": "covered", "normalized": "cover"}}], "concepts": [{"text": "Peptic ulcer", "relevance": 0.937746, "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}, {"text": "Gastroesophageal reflux disease", "relevance": 0.69923, "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}, {"text": "H2 antagonist", "relevance": 0.595013, "dbpedia_resource": "http://dbpedia.org/resource/H2_antagonist"}, {"text": "Helicobacter pylori", "relevance": 0.586702, "dbpedia_resource": "http://dbpedia.org/resource/Helicobacter_pylori"}, {"text": "Stomach", "relevance": 0.471454, "dbpedia_resource": "http://dbpedia.org/resource/Stomach"}, {"text": "Antacid", "relevance": 0.469173, "dbpedia_resource": "http://dbpedia.org/resource/Antacid"}, {"text": "Cyclooxygenase", "relevance": 0.413536, "dbpedia_resource": "http://dbpedia.org/resource/Cyclooxygenase"}, {"text": "Gastroenterology", "relevance": 0.386157, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Aspirin", "relevance": 0.339773, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Dyspepsia", "relevance": 0.304815, "dbpedia_resource": "http://dbpedia.org/resource/Dyspepsia"}, {"text": "Gastritis", "relevance": 0.284084, "dbpedia_resource": "http://dbpedia.org/resource/Gastritis"}], "categories": [{"score": 0.949787, "label": "/health and fitness/disease/gerd and acid reflux"}], "relations": [{"type": "hasAttribute", "sentence": "Peptic ulcer refers to the group of gastrointestinal disorders including gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD).", "score": 0.821358, "arguments": [{"text": "group", "location": [27, 32], "entities": [{"type": "Person", "text": "group"}]}, {"text": "gastrointestinal disorders", "location": [36, 62], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders"}]}]}, {"type": "hasAttribute", "sentence": "Request to Sample Report @ https://www.persistencemarketresearch.com/samples/3704", "score": 0.448214, "arguments": [{"text": "Sample Report @", "location": [3315, 3330], "entities": [{"type": "Organization", "text": "Sample Report @", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://www.persistencemarketresearch.com/samples/", "location": [3331, 3381], "entities": [{"type": "Web", "text": "https://www.persistencemarketresearch.com/samples/"}]}]}, {"type": "hasAttribute", "sentence": "Peptic ulcer refers to the group of gastrointestinal disorders including gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD).", "score": 0.625207, "arguments": [{"text": "group", "location": [27, 32], "entities": [{"type": "Person", "text": "group"}]}, {"text": "gastritis", "location": [73, 82], "entities": [{"type": "HealthCondition", "text": "gastritis"}]}]}, {"type": "hasAttribute", "sentence": "Peptic ulcer refers to the group of gastrointestinal disorders including gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD).", "score": 0.496246, "arguments": [{"text": "ulcers", "location": [113, 119], "entities": [{"type": "Person", "text": "ulcers"}]}, {"text": "gastrointestinal disorders", "location": [36, 62], "entities": [{"type": "HealthCondition", "text": "gastrointestinal disorders"}]}]}, {"type": "managerOf", "sentence": "Depending upon the product type, peptic ulcer drugs market is segmented into proton pump inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), antacids, H2 antagonists, antibiotics, and ulcer protective drugs.", "score": 0.204322, "arguments": [{"text": "H2", "location": [628, 630], "entities": [{"type": "Person", "text": "H2"}]}, {"text": "antagonists", "location": [631, 642], "entities": [{"type": "Person", "text": "antagonists"}]}]}, {"type": "hasAttribute", "sentence": "On the basis of indications, the market has been segmented into gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD).", "score": 0.652662, "arguments": [{"text": "ulcers", "location": [768, 774], "entities": [{"type": "Person", "text": "ulcers"}]}, {"text": "gastritis", "location": [749, 758], "entities": [{"type": "HealthCondition", "text": "gastritis"}]}]}, {"type": "residesIn", "sentence": "The market in Europe accounted for a second largest share of 25.8%, primarily due to easy availability of successful treatment options for peptic ulcers in the region.", "score": 0.60332, "arguments": [{"text": "ulcers", "location": [1576, 1582], "entities": [{"type": "Person", "text": "ulcers"}]}, {"text": "region", "location": [1590, 1596], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}]}, {"type": "hasAttribute", "sentence": "The gastric ulcer indication segment was valued at US$ 5,279.8 Mn in 2014 and is expected to register the highest CAGR of 3.0% over the forecast period.", "score": 0.511133, "arguments": [{"text": "Mn", "location": [2087, 2089], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "ulcer", "location": [2036, 2041], "entities": [{"type": "HealthCondition", "text": "ulcers"}]}]}, {"type": "hasAttribute", "sentence": "Top players in the global peptic ulcer drugs market covered in this report are Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline Plc.", "score": 0.806284, "arguments": [{"text": "players", "location": [2992, 2999], "entities": [{"type": "Person", "text": "players"}]}, {"text": "ulcer", "location": [3021, 3026], "entities": [{"type": "HealthCondition", "text": "ulcers"}]}]}, {"type": "productOf", "sentence": "Top players in the global peptic ulcer drugs market covered in this report are Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline Plc.", "score": 0.532235, "arguments": [{"text": "GlaxoSmithKline Plc", "location": [3283, 3302], "entities": [{"type": "Product", "text": "GlaxoSmithKline Plc"}]}, {"text": "Yuhan Corporation", "location": [3260, 3277], "entities": [{"type": "Organization", "text": "Yuhan Corporation"}]}]}], "keywords": [{"text": "peptic ulcer drugs", "sentiment": {"score": -0.452347, "label": "negative"}, "relevance": 0.983809}, {"text": "global peptic ulcer", "sentiment": {"score": -0.43827, "label": "negative"}, "relevance": 0.651413}, {"text": "ulcer drugs market", "sentiment": {"score": -0.456786, "label": "negative"}, "relevance": 0.627623}, {"text": "ulcer protective drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332544}, {"text": "ulcer drugs treatment", "sentiment": {"score": -0.435829, "label": "negative"}, "relevance": 0.329996}, {"text": "peptic ulcers", "sentiment": {"score": -0.609166, "label": "negative"}, "relevance": 0.321274}, {"text": "gastric ulcer secretion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.297439}, {"text": "gastric ulcer indication", "sentiment": {"score": -0.351473, "label": "negative"}, "relevance": 0.263555}, {"text": "gastroesophageal reflux disease", "sentiment": {"score": -0.741661, "label": "negative"}, "relevance": 0.236561}, {"text": "non-steroidal anti-inflammatory drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.224065}, {"text": "gastric ulcers", "sentiment": {"score": -0.674954, "label": "negative"}, "relevance": 0.212308}, {"text": "duodenal ulcers", "sentiment": {"score": -0.738812, "label": "negative"}, "relevance": 0.212248}]}, "extracted_metadata": {"sha1": "2b21dd3a13c086dd5245a48d464568a76f3ce65b", "filename": "1541768356287.zip-2e487e3892f4a9185e9dc49809d21f7a.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/peptic-ulcer-drugs-market.asp", "https://www.persistencemarketresearch.com/samples/3704"], "title": "Peptic Ulcer Drugs to Undertake Strapping Growth During 2016 2022 \u2013", "forum_title": "Research Insights \u2013 Page 31 \u2013 Find Market Research"}, {"id": "u4nAGgCg0RNuo-fUQAFs4YSdvuG5lmK034yQEDW1Qg3c_eiglUD7ckAfHLKsQ8JN", "result_metadata": {"score": 34.421158}, "author": "Seal Rock Therapeutics, Inc.", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Non-alcoholic fatty liver disease", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}], "categories": [{"score": 0.630798, "label": "/health and fitness/disease/cancer"}, {"score": 0.453057, "label": "/health and fitness/therapy"}, {"score": 0.414034, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "employedBy", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "score": 0.485089, "arguments": [{"text": "ASK1 Inhibitor", "location": [48, 62], "entities": [{"type": "Person", "text": "ASK1 Inhibitor"}]}, {"text": "Seal Rock Therapeutics Advancing Differentiated", "location": [0, 47], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}], "keywords": [{"text": "Differentiated ASK1 Inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.96316}, {"text": "Seal Rock Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.869618}, {"text": "Lead Candidate S-015", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.715194}, {"text": "Nonalcoholic Steatohepatitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620981}]}, "crawl_date": "2018-11-09T13:07:18Z", "url": "https://www.prnewswire.com:443/news-releases/seal-rock-therapeutics-advancing-differentiated-ask1-inhibitor-lead-candidate-srt-015-in-nonalcoholic-steatohepatitis-nash-300747392.html", "host": "prnewswire.com", "text": "Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "main_image_url": "https://mma.prnewswire.com/media/782258/Seal_Rock_Therapeutics_Inc_Logo.jpg?p=facebook", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T13:00:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.342035, "label": "positive"}, "text": "Seal Rock Therapeutics", "relevance": 0.830496, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "relevance": 0.691074, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.621638, "label": "positive"}, "text": "SRT-015", "relevance": 0.625654, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.307008, "label": "positive"}, "text": "Seal Rock Therapeutics, Inc.", "relevance": 0.537838, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer of Seal Rock Therapeutics", "relevance": 0.512325, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.405581, "label": "negative"}, "text": "NASH", "relevance": 0.439452, "type": "Person"}, {"count": 3, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Neil McDonnell", "relevance": 0.409587, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.422937, "label": "negative"}, "text": "fatty liver", "relevance": 0.40486, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}, {"count": 1, "sentiment": {"score": -0.337896, "label": "negative"}, "text": "non-alcoholic fatty liver disease", "relevance": 0.399719, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}, {"count": 2, "sentiment": {"score": -0.520894, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.399064, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "director", "relevance": 0.36662, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Takeda", "relevance": 0.356755, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock", "relevance": 0.350724, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna Therapeutics", "relevance": 0.340935, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.574233, "label": "negative"}, "text": "fibrotic diseases", "relevance": 0.337713, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pathway Therapeutics", "relevance": 0.331896, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver fibrosis", "relevance": 0.328336, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 2, "sentiment": {"score": -0.184157, "label": "negative"}, "text": "SEATTLE", "relevance": 0.32242, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kathleen Elias", "relevance": 0.312026, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.499214, "label": "negative"}, "text": "metabolic disease", "relevance": 0.307057, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Business Development", "relevance": 0.302509, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Brown", "relevance": 0.299903, "type": "Person", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Artur Plonowski", "relevance": 0.299711, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Exelixis", "relevance": 0.29728, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Julie Rathbun Rathbun Communications", "relevance": 0.291548, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President Research & Translational Medicine", "relevance": 0.289225, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "senior vice president", "relevance": 0.288687, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Keystone Symposia Integrated Pathways of Disease", "relevance": 0.287037, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.27493, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "vice president", "relevance": 0.26924, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.371387, "label": "positive"}, "text": "New Mexico", "relevance": 0.261151, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}, {"count": 1, "sentiment": {"score": -0.580282, "label": "negative"}, "text": "obesity", "relevance": 0.259235, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.258213, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0.310571, "label": "positive"}, "text": "Santa Fe", "relevance": 0.256871, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "diabetes", "relevance": 0.256239, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 2, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "Terry Porter", "relevance": 0.255353, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "managing director", "relevance": 0.254984, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.248286, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan", "relevance": 0.246681, "type": "Company", "disambiguation": {"subtype": [], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatocellular carcinoma", "relevance": 0.245744, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Scientific Officer", "relevance": 0.24393, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna", "relevance": 0.23637, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cytokinetics", "relevance": 0.235771, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.233149, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatomegaly", "relevance": 0.225941, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pioglitazone", "relevance": 0.224989, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "metformin", "relevance": 0.223631, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Metacrine", "relevance": 0.221537, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "CEO", "relevance": 0.221043, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazano", "relevance": 0.220165, "type": "Person"}], "sentiment": {"document": {"score": -0.14083, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a discovery stage company", "keywords": [{"text": "discovery stage company"}]}, "sentence": "SEATTLE Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "best-in-class treatments", "keywords": [{"text": "best-in-class treatments"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "SEATTLE Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies,", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "discovery stage company"}, {"text": "best-in-class treatments"}, {"text": "available therapies"}], "entities": [{"type": "Location", "text": "SEATTLE", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Seal Rock Therapeutics, Inc."}, {"type": "HealthCondition", "text": "fibrotic diseases"}]}, "sentence": "SEATTLE Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued", "keywords": [{"text": "preclinical proof-of-concept findings"}, {"text": "differentiated inhibitor"}, {"text": "recent worldwide patent"}, {"text": "nonalcoholic steatohepatitis"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}]}, "sentence": " SRT-015 is a potent, liver-selective ASK1 inhibitor for NASH.", "object": {"text": "a potent, liver-selective ASK1 inhibitor for NASH", "keywords": [{"text": "liver-selective ASK1 inhibitor"}, {"text": "NASH"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "action": {"verb": {"text": "optimize", "tense": "past"}, "text": "was internally discovered and optimized", "normalized": "be internally discover and optimize"}}, {"subject": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities demonstrated by other investigative approaches", "keywords": [{"text": "investigative approaches"}, {"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "avoid", "tense": "present"}, "text": "avoid", "normalized": "avoid"}}, {"subject": {"text": "by other investigative approaches", "keywords": [{"text": "investigative approaches"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities", "keywords": [{"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}, {"text": "Gubra"}, {"text": "model"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "efficacy", "keywords": [{"text": "efficacy"}]}, "action": {"verb": {"text": "promise", "tense": "present"}, "text": "has demonstrated promising", "normalized": "have demonstrate promise"}}, {"subject": {"text": "statistically significant positive effects on both metabolic parameters and liver-specific pathology", "keywords": [{"text": "significant positive effects"}, {"text": "metabolic parameters"}, {"text": "liver-specific pathology"}]}, "sentence": " This includes statistically significant positive effects on both metabolic parameters and liver-specific pathology.", "object": {"text": "This"}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " In addition, SRT-015 significantly reduced hepatomegaly, liver fibrosis, steatosis and inflammation, all key drivers for NASH.", "object": {"text": "hepatomegaly, liver fibrosis, steatosis and inflammation", "keywords": [{"text": "liver fibrosis"}, {"text": "steatosis"}, {"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "hepatomegaly"}, {"type": "HealthCondition", "text": "liver fibrosis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "object": {"text": "presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019", "keywords": [{"text": "Keystone Symposia Integrated"}, {"text": "Santa Fe"}, {"text": "NAFLD meeting"}, {"text": "New Mexico"}], "entities": [{"type": "PrintMedia", "text": "Keystone Symposia Integrated Pathways of Disease"}, {"type": "Location", "text": "Santa Fe", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"type": "Location", "text": "New Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "a unique property", "keywords": [{"text": "unique property"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "the circulation or other tissues", "keywords": [{"text": "circulation"}, {"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "reduce risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "other tissues", "keywords": [{"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "helps reduce", "normalized": "help reduce"}}, {"subject": {"text": "Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "Chief Executive Officer"}, {"text": "Neil McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "JobTitle", "text": "Chief Executive Officer of Seal Rock Therapeutics"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "Company", "text": "SRT-015"}, {"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "we"}, "sentence": " \"Our preclinical findings are proving very robust, and we are pleased to be advancing with IND-enabling activities for SRT-015.\"", "object": {"text": "advancing with IND-enabling activities for SRT-015", "keywords": [{"text": "IND-enabling activities"}, {"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "object": {"text": "the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof", "keywords": [{"text": "ASK1 inhibitor compounds"}, {"text": "international PCT patent"}, {"text": "publication"}, {"text": "application"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The Patent Cooperation Treaty (PCT)", "keywords": [{"text": "Patent Cooperation Treaty"}, {"text": "PCT"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "151 countries", "keywords": [{"text": "countries"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine", "keywords": [{"text": "Chief Scientific Officer"}, {"text": "Vice President Research"}, {"text": "Neil McDonnell"}, {"text": "Artur Plonowski"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "Person", "text": "Artur Plonowski"}, {"type": "JobTitle", "text": "Chief Scientific Officer"}, {"type": "Person", "text": "Kathleen Elias"}, {"type": "JobTitle", "text": "Vice President Research & Translational Medicine"}]}, "sentence": " Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "object": {"text": "Seal Rock Therapeutics' founders", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "founders"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. McDonnell", "keywords": [{"text": "Dr. McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "object": {"text": "as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda", "keywords": [{"text": "senior vice president"}, {"text": "therapeutic area leader"}, {"text": "metabolic diseases"}, {"text": "Takeda"}], "entities": [{"type": "JobTitle", "text": "CEO"}, {"type": "Company", "text": "Metacrine"}, {"type": "JobTitle", "text": "senior vice president"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin)", "keywords": [{"text": "diabetes drugs"}, {"text": "pioglitazone"}, {"text": "metformin"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "has been involved", "normalized": "have be involve"}}, {"subject": {"text": "Dr. Plonowski", "keywords": [{"text": "Dr. Plonowski"}], "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones", "keywords": [{"text": "NASH start-up"}, {"text": "Akarna Therapeutics"}, {"text": "Allergan"}, {"text": "pharmacology"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Akarna Therapeutics"}, {"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"type": "Quantity", "text": "$50 million"}, {"type": "Quantity", "text": "$1 billion"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "acquired by Allergan in 2016", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Allergan", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "was acquired", "normalized": "be acquire"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "object": {"text": "the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals,", "keywords": [{"text": "metabolic disease pharmacology"}, {"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "HealthCondition", "text": "metabolic disease", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "preclinical research"}, {"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}, {"text": "efforts"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry", "keywords": [{"text": "Senior Vice President"}, {"text": "Terry Porter"}, {"text": "Business Development"}, {"text": "PhD"}], "entities": [{"type": "Person", "text": "Terry Porter"}, {"type": "JobTitle", "text": "Senior Vice President, Business Development"}, {"type": "Person", "text": "David Brown", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"type": "JobTitle", "text": "director"}]}, "sentence": " Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "object": {"text": "Additional members of the Seal Rock leadership team", "keywords": [{"text": "Seal Rock leadership"}, {"text": "Additional members"}, {"text": "team"}], "entities": [{"type": "Organization", "text": "Seal Rock"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. Porter", "keywords": [{"text": "Dr. Porter"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "object": {"text": "as vice president of search & evaluation within global business development at Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "vice president"}, {"text": "global business development"}, {"text": "search"}], "entities": [{"type": "JobTitle", "text": "vice president"}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Prior to that, he was managing director at the corporate advisory group AquaPartners.", "object": {"text": "managing director at the corporate advisory group AquaPartners", "keywords": [{"text": "corporate advisory group"}, {"text": "director"}, {"text": "AquaPartners"}], "entities": [{"type": "JobTitle", "text": "managing director"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "action": {"verb": {"text": "create", "tense": "past"}, "text": "created", "normalized": "create"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "object": {"text": "the external science and technology group", "keywords": [{"text": "external science"}, {"text": "technology group"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Brown", "keywords": [{"text": "Dr."}], "entities": [{"type": "Person", "text": "David Brown"}]}, "sentence": " Dr. Brown recently directed the medicinal chemistry team at Pathway Therapeutics, which led to the selective PI3Kdelta kinase inhibitor PWT143/MEI-401.", "object": {"text": "the medicinal chemistry team", "keywords": [{"text": "medicinal chemistry team"}]}, "action": {"verb": {"text": "direct", "tense": "past"}, "text": "directed", "normalized": "direct"}}, {"subject": {"text": "he"}, "sentence": " Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "object": {"text": "12 years", "entities": [{"type": "Quantity", "text": "12 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "About NASH NASH", "keywords": [{"text": "NASH NASH"}]}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "a form of non-alcoholic fatty liver disease", "keywords": [{"text": "non-alcoholic fatty liver"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a form of non-alcoholic fatty liver disease (NAFLD)", "keywords": [{"text": "non-alcoholic fatty liver"}, {"text": "form"}, {"text": "disease"}, {"text": "NAFLD"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "it"}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one of the most common chronic liver diseases", "keywords": [{"text": "common chronic liver"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "associated with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "is associated", "normalized": "be associate"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "typically characterized as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "Fatty liver", "keywords": [{"text": "Fatty liver"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "sentence": " Fatty liver is generally non-progressive or progresses slowly compared to steatohepatitis.", "object": {"text": "generally non-progressive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.966912, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Fatty liver", "relevance": 0.942769, "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.910469, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Patent Cooperation Treaty", "relevance": 0.755734, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Cooperation_Treaty"}, {"text": "Hepatitis", "relevance": 0.743877, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Obesity", "relevance": 0.626023, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Hepatology", "relevance": 0.624318, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Steatosis", "relevance": 0.493374, "dbpedia_resource": "http://dbpedia.org/resource/Steatosis"}, {"text": "Liver", "relevance": 0.472576, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Pharmacology", "relevance": 0.465836, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Cancer", "relevance": 0.46463, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Metabolic syndrome", "relevance": 0.457634, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Inborn error of metabolism", "relevance": 0.423778, "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}, {"text": "Hepatocellular carcinoma", "relevance": 0.416425, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Liver disease", "relevance": 0.408235, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Liver transplantation", "relevance": 0.404947, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Medicine", "relevance": 0.398108, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Patent", "relevance": 0.395361, "dbpedia_resource": "http://dbpedia.org/resource/Patent"}, {"text": "Hepatitis C", "relevance": 0.395353, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Drug discovery", "relevance": 0.383833, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Vice President of the United States", "relevance": 0.38269, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Metformin", "relevance": 0.378662, "dbpedia_resource": "http://dbpedia.org/resource/Metformin"}, {"text": "Metabolism", "relevance": 0.377148, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Steatohepatitis", "relevance": 0.371157, "dbpedia_resource": "http://dbpedia.org/resource/Steatohepatitis"}, {"text": "Chronic liver disease", "relevance": 0.352756, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_liver_disease"}, {"text": "Patent law", "relevance": 0.352387, "dbpedia_resource": "http://dbpedia.org/resource/Patent_law"}, {"text": "Patent application", "relevance": 0.336682, "dbpedia_resource": "http://dbpedia.org/resource/Patent_application"}, {"text": "Drug design", "relevance": 0.333359, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Hepatitis B", "relevance": 0.324479, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Management occupations", "relevance": 0.313108, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Gastroenterology", "relevance": 0.311671, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Drug development", "relevance": 0.311527, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Pre-clinical development", "relevance": 0.310646, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Chief executive officer", "relevance": 0.307448, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Therapy", "relevance": 0.306829, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Liver biopsy", "relevance": 0.306823, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Enzyme inhibitor", "relevance": 0.284671, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_inhibitor"}, {"text": "Classification of Pharmaco-Therapeutic Referrals", "relevance": 0.272764, "dbpedia_resource": "http://dbpedia.org/resource/Classification_of_Pharmaco-Therapeutic_Referrals"}, {"text": "Medicinal chemistry", "relevance": 0.265145, "dbpedia_resource": "http://dbpedia.org/resource/Medicinal_chemistry"}, {"text": "Paris Convention for the Protection of Industrial Property", "relevance": 0.258086, "dbpedia_resource": "http://dbpedia.org/resource/Paris_Convention_for_the_Protection_of_Industrial_Property"}, {"text": "President of the United States", "relevance": 0.257418, "dbpedia_resource": "http://dbpedia.org/resource/President_of_the_United_States"}, {"text": "Richard Nixon", "relevance": 0.255696, "dbpedia_resource": "http://dbpedia.org/resource/Richard_Nixon"}, {"text": "President pro tempore of the United States Senate", "relevance": 0.254874, "dbpedia_resource": "http://dbpedia.org/resource/President_pro_tempore_of_the_United_States_Senate"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.248346, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "John Adams", "relevance": 0.244207, "dbpedia_resource": "http://dbpedia.org/resource/John_Adams"}, {"text": "Vice president", "relevance": 0.241681, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "Patent Law Treaty", "relevance": 0.238119, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Law_Treaty"}, {"text": "Lactic acidosis", "relevance": 0.236029, "dbpedia_resource": "http://dbpedia.org/resource/Lactic_acidosis"}, {"text": "Gerald Ford", "relevance": 0.235351, "dbpedia_resource": "http://dbpedia.org/resource/Gerald_Ford"}, {"text": "Protein", "relevance": 0.231956, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}], "categories": [{"score": 0.68726, "label": "/health and fitness/disease"}, {"score": 0.422339, "label": "/health and fitness/therapy"}, {"score": 0.383632, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "timeOf", "sentence": "SEATTLE Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.910658, "arguments": [{"text": "today", "location": [168, 173], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [174, 183], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "\" Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "score": 0.994464, "arguments": [{"text": "Seal Rock Therapeutics", "location": [1708, 1730], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [1731, 1740], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "score": 0.40795, "arguments": [{"text": "founders", "location": [2050, 2058], "entities": [{"type": "Person", "text": "founders"}]}, {"text": "Seal Rock Therapeutics", "location": [2026, 2048], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.300954, "arguments": [{"text": "leader", "location": [2321, 2327], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "area", "location": [2316, 2320], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "hasAttribute", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.580563, "arguments": [{"text": "leader", "location": [2321, 2327], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "cardiovascular", "location": [2332, 2346], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "employedBy", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.799635, "arguments": [{"text": "leader", "location": [2321, 2327], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "Takeda", "location": [2373, 2379], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "score": 0.758695, "arguments": [{"text": "partner", "location": [2550, 2557], "entities": [{"type": "Person", "text": "Orexigen"}]}, {"text": "Takeda", "location": [2541, 2547], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.528062, "arguments": [{"text": "director of pharmacology", "location": [2655, 2679], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "Akarna Therapeutics", "location": [2683, 2702], "entities": [{"type": "Organization", "text": "Akarna Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.474504, "arguments": [{"text": "Allergan", "location": [2746, 2754], "entities": [{"type": "Organization", "text": "Allergan"}]}, {"text": "acquired", "location": [2734, 2742], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.97932, "arguments": [{"text": "2016", "location": [2758, 2762], "entities": [{"type": "Date", "text": "2016"}]}, {"text": "acquired", "location": [2734, 2742], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.802833, "arguments": [{"text": "he", "location": [2826, 2828], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "cardiovascular", "location": [2837, 2851], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.592035, "arguments": [{"text": "Keystone Symposia Integrated Pathways", "location": [1088, 1125], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "meeting", "location": [1155, 1162], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.489941, "arguments": [{"text": "he", "location": [2826, 2828], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "metabolic disease", "location": [2863, 2880], "entities": [{"type": "HealthCondition", "text": "metabolic diseases"}]}]}, {"type": "partOf", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.849637, "arguments": [{"text": "pharmacology group", "location": [2881, 2899], "entities": [{"type": "Organization", "text": "Business Development"}]}, {"text": "Takeda Pharmaceuticals", "location": [2903, 2925], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "score": 0.74674, "arguments": [{"text": "director of preclinical research", "location": [3113, 3145], "entities": [{"type": "Person", "text": "Elias"}]}, {"text": "Takeda", "location": [3149, 3155], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "score": 0.763089, "arguments": [{"text": "she", "location": [3318, 3321], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "heart failure", "location": [3443, 3456], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "partOfMany", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.79386, "arguments": [{"text": "members", "location": [3550, 3557], "entities": [{"type": "Person", "text": "members"}]}, {"text": "leadership team", "location": [3575, 3590], "entities": [{"type": "Person", "text": "leadership team"}]}]}, {"type": "employedBy", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.365905, "arguments": [{"text": "leadership team", "location": [3575, 3590], "entities": [{"type": "Person", "text": "leadership team"}]}, {"text": "Seal Rock", "location": [3565, 3574], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.67597, "arguments": [{"text": "David Brown", "location": [3668, 3679], "entities": [{"type": "Person", "text": "David Brown"}]}, {"text": "PhD", "location": [3682, 3685], "entities": [{"type": "GeopoliticalEntity", "text": "PhD"}]}]}, {"type": "employedBy", "sentence": "Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "score": 0.571629, "arguments": [{"text": "vice president", "location": [3740, 3754], "entities": [{"type": "Person", "text": "Terry Porter"}]}, {"text": "Takeda Pharmaceuticals", "location": [3816, 3838], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, he was managing director at the corporate advisory group AquaPartners.", "score": 0.786842, "arguments": [{"text": "managing director", "location": [3862, 3879], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [3906, 3911], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "employedBy", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.477414, "arguments": [{"text": "member", "location": [3947, 3953], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [3992, 3997], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "partOf", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.78002, "arguments": [{"text": "group", "location": [3992, 3997], "entities": [{"type": "Organization", "text": "AquaPartners"}]}, {"text": "GlaxoSmithKline", "location": [4001, 4016], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.658529, "arguments": [{"text": "NASH", "location": [1140, 1144], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Disease", "location": [1129, 1136], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "agentOf", "sentence": "During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "score": 0.667072, "arguments": [{"text": "GSK", "location": [4135, 4138], "entities": [{"type": "Organization", "text": "GSK"}]}, {"text": "acquisition", "location": [4154, 4165], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "residesIn", "sentence": "Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "score": 0.421297, "arguments": [{"text": "candidates", "location": [4424, 4434], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "areas", "location": [4442, 4447], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "hasAttribute", "sentence": "About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "score": 0.608891, "arguments": [{"text": "NASH NASH", "location": [4484, 4493], "entities": [{"type": "Person", "text": "NASH NASH"}]}, {"text": "disease", "location": [4533, 4540], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "score": 0.790092, "arguments": [{"text": "NAFLD", "location": [4654, 4659], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "diabetes", "location": [4717, 4725], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}]}, {"type": "agentOf", "sentence": "NAFLD is typically characterized as either fatty liver or steatohepatitis.", "score": 0.969466, "arguments": [{"text": "NAFLD", "location": [4749, 4754], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "characterized", "location": [4768, 4781], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "agentOf", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.702372, "arguments": [{"text": "NASH", "location": [4915, 4919], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "characterized", "location": [4972, 4985], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "hasAttribute", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.561306, "arguments": [{"text": "individuals", "location": [5080, 5091], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "cirrhosis", "location": [5117, 5126], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.694633, "arguments": [{"text": "NASH", "location": [5200, 5204], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "liver transplantation", "location": [5246, 5267], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.676101, "arguments": [{"text": "women", "location": [5302, 5307], "entities": [{"type": "Person", "text": "women"}]}, {"text": "liver transplantation", "location": [5246, 5267], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "locatedAt", "sentence": "About Seal Rock Therapeutics Seal Rock Therapeutics is a privately held, discovery stage company based in Seattle focused on the development of best-in-class treatments for inflammatory and fibrotic diseases with no available therapies.", "score": 0.734803, "arguments": [{"text": "company", "location": [5504, 5511], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "Seattle", "location": [5521, 5528], "entities": [{"type": "GeopoliticalEntity", "text": "Seattle"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.67241, "arguments": [{"text": "NASH", "location": [1140, 1144], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "meeting", "location": [1155, 1162], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "employedBy", "sentence": "The company's lead product candidate, SRT-015, is a differentiated ASK1 inhibitor for NASH.", "score": 0.408221, "arguments": [{"text": "candidate", "location": [5679, 5688], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "company", "location": [5656, 5663], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}]}, {"type": "hasAttribute", "sentence": "For more information, please visit www.sealrocktx.com Media Contact: Julie Rathbun Rathbun Communications Julie@rathbuncomm.com 206-769-9219 SOURCE Seal Rock Therapeutics, Inc. Related Links http://www.sealrocktx.com", "score": 0.671673, "arguments": [{"text": "SOURCE Seal Rock Therapeutics, Inc.\nRelated Links", "location": [6021, 6070], "entities": [{"type": "Organization", "text": "SOURCE Seal Rock Therapeutics, Inc.\nRelated Links"}]}, {"text": "http://www.sealrocktx.com", "location": [6071, 6096], "entities": [{"type": "Web", "text": "http://www.sealrocktx.com"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.960106, "arguments": [{"text": "NAFLD", "location": [1149, 1154], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "meeting", "location": [1155, 1162], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.854132, "arguments": [{"text": "meeting", "location": [1155, 1162], "entities": [{"type": "EventMeeting", "text": "meeting"}]}, {"text": "Santa Fe", "location": [1167, 1175], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.995901, "arguments": [{"text": "Santa Fe", "location": [1167, 1175], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}, {"text": "New Mexico", "location": [1177, 1187], "entities": [{"type": "GeopoliticalEntity", "text": "New Mexico"}]}]}, {"type": "agentOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.920089, "arguments": [{"text": "Neil McDonnell", "location": [1497, 1511], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "said", "location": [1492, 1496], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.577847, "arguments": [{"text": "Chief Executive Officer", "location": [1514, 1537], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "Seal Rock Therapeutics", "location": [1541, 1563], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Seal Rock Therapeutics", "sentiment": {"score": 0.324521, "label": "positive"}, "relevance": 0.977008}, {"text": "vice president", "sentiment": {"score": -0.535413, "label": "negative"}, "relevance": 0.552925}, {"text": "discovery stage company", "sentiment": {"score": -0.574233, "label": "negative"}, "relevance": 0.54821}, {"text": "Rock Therapeutics Seal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547105}, {"text": "senior vice president", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.544671}, {"text": "Gubra therapeutic NASH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54316}, {"text": "ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.539688}, {"text": "SEATTLE Seal Rock", "sentiment": {"score": 0.307008, "label": "positive"}, "relevance": 0.534737}, {"text": "NASH NASH", "sentiment": {"score": -0.337896, "label": "negative"}, "relevance": 0.532349}, {"text": "fatty liver", "sentiment": {"score": -0.380416, "label": "negative"}, "relevance": 0.525715}, {"text": "Seal Rock leadership", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514076}, {"text": "liver-selective ASK1 inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510665}, {"text": "SOURCE Seal Rock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507924}, {"text": "business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.505737}, {"text": "fatty liver disease", "sentiment": {"score": -0.337896, "label": "negative"}, "relevance": 0.504851}, {"text": "preclinical proof-of-concept findings", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.504166}, {"text": "PI3Kdelta kinase inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498737}, {"text": "chronic liver diseases", "sentiment": {"score": -0.694965, "label": "negative"}, "relevance": 0.498446}, {"text": "ASK1 inhibitor compounds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498002}, {"text": "preclinical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497377}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": -0.520894, "label": "negative"}, "relevance": 0.496446}, {"text": "metabolic disease pharmacology", "sentiment": {"score": -0.499214, "label": "negative"}, "relevance": 0.495389}, {"text": "worldwide patent application", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.492864}, {"text": "differentiated ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.489949}, {"text": "best-in-class treatments", "sentiment": {"score": -0.574233, "label": "negative"}, "relevance": 0.489856}, {"text": "NASH start-up", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.489034}, {"text": "inflammation therapeutic areas", "sentiment": {"score": -0.409165, "label": "negative"}, "relevance": 0.48743}, {"text": "Akarna Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487135}, {"text": "Vice President Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484904}, {"text": "international PCT patent", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484889}, {"text": "worldwide business development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484244}, {"text": "Neil McDonnell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484161}, {"text": "global business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.481536}, {"text": "Pathway Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481081}, {"text": "fibrotic diseases", "sentiment": {"score": -0.574233, "label": "negative"}, "relevance": 0.480422}, {"text": "international patent law", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.479857}, {"text": "therapeutic area leader", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.477547}, {"text": "available therapies", "sentiment": {"score": -0.574233, "label": "negative"}, "relevance": 0.477426}, {"text": "obesity drug Contrave", "sentiment": {"score": -0.205465, "label": "negative"}, "relevance": 0.477402}, {"text": "myosin activator therapeutic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477326}, {"text": "Rathbun Rathbun Communications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477266}, {"text": "Patent Cooperation Treaty", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476709}, {"text": "drug development efforts", "sentiment": {"score": -0.486984, "label": "negative"}, "relevance": 0.4766}, {"text": "significant positive effects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47636}, {"text": "major pharmaceutical markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47553}, {"text": "Symposia Integrated Pathways", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474889}, {"text": "corporate advisory group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474217}, {"text": "liver fibrosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473592}, {"text": "differentiated inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472622}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471151}]}, "extracted_metadata": {"sha1": "e9c363a16da6ee30ab48c0e2c200b5b585ededa0", "filename": "1541768838063.zip-4fe81488493fb260139c0ea3244f0448.xml", "file_type": "json"}, "external_links": ["http://www.sealrocktx.com/"], "title": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "forum_title": "PR Newswire:"}, {"id": "qNtU627APXbrl995mon13gDJjgRhYAkqBZQ3ATyw9PZR118fXX_VPX8sVM1eQ0FP", "result_metadata": {"score": 34.23307}, "author": "PRESS RELEASE PR Newswire", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Non-alcoholic fatty liver disease", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}], "categories": [{"score": 0.630798, "label": "/health and fitness/disease/cancer"}, {"score": 0.453057, "label": "/health and fitness/therapy"}, {"score": 0.414034, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "employedBy", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "score": 0.485089, "arguments": [{"text": "ASK1 Inhibitor", "location": [48, 62], "entities": [{"type": "Person", "text": "ASK1 Inhibitor"}]}, {"text": "Seal Rock Therapeutics Advancing Differentiated", "location": [0, 47], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}], "keywords": [{"text": "Differentiated ASK1 Inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.96316}, {"text": "Seal Rock Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.869618}, {"text": "Lead Candidate S-015", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.715194}, {"text": "Nonalcoholic Steatohepatitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620981}]}, "crawl_date": "2018-11-09T13:32:49Z", "url": "https://markets.businessinsider.com/news/stocks/seal-rock-therapeutics-advancing-differentiated-ask1-inhibitor-lead-candidate-srt-015-in-nonalcoholic-steatohepatitis-nash-1027711468", "host": "markets.businessinsider.com", "text": "Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "main_image_url": "https://mma.prnewswire.com/media/782258/Seal_Rock_Therapeutics_Inc_Logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T08:00:00-06:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0.342035, "label": "positive"}, "text": "Seal Rock Therapeutics", "relevance": 0.818195, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.621638, "label": "positive"}, "text": "SRT-015", "relevance": 0.481513, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.266427, "label": "positive"}, "text": "Seal Rock Therapeutics, Inc.", "relevance": 0.444106, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer of Seal Rock Therapeutics", "relevance": 0.423869, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.405581, "label": "negative"}, "text": "NASH", "relevance": 0.418827, "type": "Person"}, {"count": 3, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Neil McDonnell", "relevance": 0.341067, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.422937, "label": "negative"}, "text": "fatty liver", "relevance": 0.337518, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}, {"count": 1, "sentiment": {"score": -0.369421, "label": "negative"}, "text": "non-alcoholic fatty liver disease", "relevance": 0.332891, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}, {"count": 2, "sentiment": {"score": -0.520894, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.332564, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Takeda", "relevance": 0.297314, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock", "relevance": 0.292161, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna Therapeutics", "relevance": 0.283799, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.570696, "label": "negative"}, "text": "fibrotic diseases", "relevance": 0.28146, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pathway Therapeutics", "relevance": 0.277204, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver fibrosis", "relevance": 0.272591, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "director", "relevance": 0.269572, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.0960923, "label": "negative"}, "text": "SEATTLE", "relevance": 0.269135, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kathleen Elias", "relevance": 0.26047, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.499214, "label": "negative"}, "text": "metabolic disease", "relevance": 0.256029, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Business Development", "relevance": 0.252258, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Brown", "relevance": 0.250992, "type": "Person", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Artur Plonowski", "relevance": 0.250227, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Exelixis", "relevance": 0.248812, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President Research & Translational Medicine", "relevance": 0.240792, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "senior vice president", "relevance": 0.240457, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Keystone Symposia Integrated Pathways of Disease", "relevance": 0.238938, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.229276, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "vice president", "relevance": 0.225035, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Julie Rathbun", "relevance": 0.22088, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.371387, "label": "positive"}, "text": "New Mexico", "relevance": 0.217859, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Rathbun Communications", "relevance": 0.217342, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.580282, "label": "negative"}, "text": "obesity", "relevance": 0.217099, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.21636, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0.310571, "label": "positive"}, "text": "Santa Fe", "relevance": 0.214199, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "diabetes", "relevance": 0.214124, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 2, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "Terry Porter", "relevance": 0.213717, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "managing director", "relevance": 0.213446, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.207821, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan", "relevance": 0.206252, "type": "Company", "disambiguation": {"subtype": [], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatocellular carcinoma", "relevance": 0.206054, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Scientific Officer", "relevance": 0.203543, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna", "relevance": 0.197773, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cytokinetics", "relevance": 0.197443, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.19555, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatomegaly", "relevance": 0.188427, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pioglitazone", "relevance": 0.188117, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "metformin", "relevance": 0.186997, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Metacrine", "relevance": 0.185239, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "CEO", "relevance": 0.184802, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Domantis", "relevance": 0.18442, "type": "Company"}], "sentiment": {"document": {"score": -0.127672, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a discovery stage company", "keywords": [{"text": "discovery stage company"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": "SEATTLE , Nov. 9, 2018 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "best-in-class treatments", "keywords": [{"text": "best-in-class treatments"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "SEATTLE , Nov. 9, 2018 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies,", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "discovery stage company"}, {"text": "best-in-class treatments"}, {"text": "available therapies"}], "entities": [{"type": "Location", "text": "SEATTLE", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Seal Rock Therapeutics, Inc."}, {"type": "Company", "text": "Seal Rock Therapeutics"}, {"type": "HealthCondition", "text": "fibrotic diseases"}]}, "sentence": "SEATTLE , Nov. 9, 2018 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued", "keywords": [{"text": "preclinical proof-of-concept findings"}, {"text": "differentiated inhibitor"}, {"text": "recent worldwide patent"}, {"text": "nonalcoholic steatohepatitis"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}]}, "sentence": " SRT-015 is a potent, liver-selective ASK1 inhibitor for NASH.", "object": {"text": "a potent, liver-selective ASK1 inhibitor for NASH", "keywords": [{"text": "liver-selective ASK1 inhibitor"}, {"text": "NASH"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "action": {"verb": {"text": "optimize", "tense": "past"}, "text": "was internally discovered and optimized", "normalized": "be internally discover and optimize"}}, {"subject": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities demonstrated by other investigative approaches", "keywords": [{"text": "investigative approaches"}, {"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "avoid", "tense": "present"}, "text": "avoid", "normalized": "avoid"}}, {"subject": {"text": "by other investigative approaches", "keywords": [{"text": "investigative approaches"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities", "keywords": [{"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}, {"text": "Gubra"}, {"text": "model"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "efficacy", "keywords": [{"text": "efficacy"}]}, "action": {"verb": {"text": "promise", "tense": "present"}, "text": "has demonstrated promising", "normalized": "have demonstrate promise"}}, {"subject": {"text": "statistically significant positive effects on both metabolic parameters and liver-specific pathology", "keywords": [{"text": "significant positive effects"}, {"text": "metabolic parameters"}, {"text": "liver-specific pathology"}]}, "sentence": " This includes statistically significant positive effects on both metabolic parameters and liver-specific pathology.", "object": {"text": "This"}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " In addition, SRT-015 significantly reduced hepatomegaly, liver fibrosis, steatosis and inflammation, all key drivers for NASH.", "object": {"text": "hepatomegaly, liver fibrosis, steatosis and inflammation", "keywords": [{"text": "liver fibrosis"}, {"text": "steatosis"}, {"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "hepatomegaly"}, {"type": "HealthCondition", "text": "liver fibrosis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "object": {"text": "presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019", "keywords": [{"text": "Keystone Symposia Integrated"}, {"text": "Santa Fe"}, {"text": "NAFLD meeting"}, {"text": "New Mexico"}], "entities": [{"type": "PrintMedia", "text": "Keystone Symposia Integrated Pathways of Disease"}, {"type": "Location", "text": "Santa Fe", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"type": "Location", "text": "New Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "a unique property", "keywords": [{"text": "unique property"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "the circulation or other tissues", "keywords": [{"text": "circulation"}, {"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "reduce risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "other tissues", "keywords": [{"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "helps reduce", "normalized": "help reduce"}}, {"subject": {"text": "Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "Chief Executive Officer"}, {"text": "Neil McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "JobTitle", "text": "Chief Executive Officer of Seal Rock Therapeutics"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "Company", "text": "SRT-015"}, {"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "we"}, "sentence": " \"Our preclinical findings are proving very robust, and we are pleased to be advancing with IND-enabling activities for SRT-015.\"", "object": {"text": "advancing with IND-enabling activities for SRT-015", "keywords": [{"text": "IND-enabling activities"}, {"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "object": {"text": "the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof", "keywords": [{"text": "ASK1 inhibitor compounds"}, {"text": "international PCT patent"}, {"text": "publication"}, {"text": "application"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The Patent Cooperation Treaty (PCT)", "keywords": [{"text": "Patent Cooperation Treaty"}, {"text": "PCT"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "151 countries", "keywords": [{"text": "countries"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine", "keywords": [{"text": "Chief Scientific Officer"}, {"text": "Vice President Research"}, {"text": "Neil McDonnell"}, {"text": "Artur Plonowski"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "Person", "text": "Artur Plonowski"}, {"type": "JobTitle", "text": "Chief Scientific Officer"}, {"type": "Person", "text": "Kathleen Elias"}, {"type": "JobTitle", "text": "Vice President Research & Translational Medicine"}]}, "sentence": " Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "object": {"text": "Seal Rock Therapeutics' founders", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "founders"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. McDonnell", "keywords": [{"text": "Dr. McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "object": {"text": "as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda", "keywords": [{"text": "senior vice president"}, {"text": "therapeutic area leader"}, {"text": "metabolic diseases"}, {"text": "Takeda"}], "entities": [{"type": "JobTitle", "text": "CEO"}, {"type": "Company", "text": "Metacrine"}, {"type": "JobTitle", "text": "senior vice president"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin)", "keywords": [{"text": "diabetes drugs"}, {"text": "pioglitazone"}, {"text": "metformin"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "has been involved", "normalized": "have be involve"}}, {"subject": {"text": "Dr. Plonowski", "keywords": [{"text": "Dr. Plonowski"}], "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones", "keywords": [{"text": "NASH start-up"}, {"text": "Akarna Therapeutics"}, {"text": "Allergan"}, {"text": "pharmacology"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Akarna Therapeutics"}, {"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"type": "Quantity", "text": "$50 million"}, {"type": "Quantity", "text": "$1 billion"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "acquired by Allergan in 2016", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Allergan", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "was acquired", "normalized": "be acquire"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "object": {"text": "the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals,", "keywords": [{"text": "metabolic disease pharmacology"}, {"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "HealthCondition", "text": "metabolic disease", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "preclinical research"}, {"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}, {"text": "efforts"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry", "keywords": [{"text": "Senior Vice President"}, {"text": "Terry Porter"}, {"text": "Business Development"}, {"text": "PhD"}], "entities": [{"type": "Person", "text": "Terry Porter"}, {"type": "JobTitle", "text": "Senior Vice President, Business Development"}, {"type": "Person", "text": "David Brown", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"type": "JobTitle", "text": "director"}]}, "sentence": " Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "object": {"text": "Additional members of the Seal Rock leadership team", "keywords": [{"text": "Seal Rock leadership"}, {"text": "Additional members"}, {"text": "team"}], "entities": [{"type": "Organization", "text": "Seal Rock"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. Porter", "keywords": [{"text": "Dr. Porter"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "object": {"text": "as vice president of search & evaluation within global business development at Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "vice president"}, {"text": "global business development"}, {"text": "search"}], "entities": [{"type": "JobTitle", "text": "vice president"}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Prior to that, he was managing director at the corporate advisory group AquaPartners.", "object": {"text": "managing director at the corporate advisory group AquaPartners", "keywords": [{"text": "corporate advisory group"}, {"text": "director"}, {"text": "AquaPartners"}], "entities": [{"type": "JobTitle", "text": "managing director"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "action": {"verb": {"text": "create", "tense": "past"}, "text": "created", "normalized": "create"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "object": {"text": "the external science and technology group", "keywords": [{"text": "external science"}, {"text": "technology group"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Brown", "keywords": [{"text": "Dr."}], "entities": [{"type": "Person", "text": "David Brown"}]}, "sentence": " Dr. Brown recently directed the medicinal chemistry team at Pathway Therapeutics, which led to the selective PI3Kdelta kinase inhibitor PWT143/MEI-401.", "object": {"text": "the medicinal chemistry team", "keywords": [{"text": "medicinal chemistry team"}]}, "action": {"verb": {"text": "direct", "tense": "past"}, "text": "directed", "normalized": "direct"}}, {"subject": {"text": "he"}, "sentence": " Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "object": {"text": "12 years", "entities": [{"type": "Quantity", "text": "12 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "NASH", "keywords": [{"text": "NASH"}]}, "sentence": " NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "a form of non-alcoholic fatty liver disease", "keywords": [{"text": "non-alcoholic fatty liver"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a form of non-alcoholic fatty liver disease (NAFLD)", "keywords": [{"text": "non-alcoholic fatty liver"}, {"text": "form"}, {"text": "disease"}, {"text": "NAFLD"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "sentence": " NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "it"}, "sentence": " NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one of the most common chronic liver diseases", "keywords": [{"text": "common chronic liver"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "associated with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "is associated", "normalized": "be associate"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "typically characterized as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "Fatty liver", "keywords": [{"text": "Fatty liver"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "sentence": " Fatty liver is generally non-progressive or progresses slowly compared to steatohepatitis.", "object": {"text": "generally non-progressive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.963298, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Fatty liver", "relevance": 0.942477, "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.90593, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Patent Cooperation Treaty", "relevance": 0.750999, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Cooperation_Treaty"}, {"text": "Hepatitis", "relevance": 0.741113, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Hepatology", "relevance": 0.623541, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Obesity", "relevance": 0.620192, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Steatosis", "relevance": 0.490008, "dbpedia_resource": "http://dbpedia.org/resource/Steatosis"}, {"text": "Liver", "relevance": 0.472576, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Cancer", "relevance": 0.460056, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Pharmacology", "relevance": 0.457789, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Metabolic syndrome", "relevance": 0.454612, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Inborn error of metabolism", "relevance": 0.422805, "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}, {"text": "Hepatocellular carcinoma", "relevance": 0.41513, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Liver disease", "relevance": 0.407709, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Liver transplantation", "relevance": 0.404576, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Hepatitis C", "relevance": 0.393684, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Medicine", "relevance": 0.393186, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Patent", "relevance": 0.390684, "dbpedia_resource": "http://dbpedia.org/resource/Patent"}, {"text": "Vice President of the United States", "relevance": 0.382104, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Drug discovery", "relevance": 0.381316, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Metabolism", "relevance": 0.376673, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Metformin", "relevance": 0.374912, "dbpedia_resource": "http://dbpedia.org/resource/Metformin"}, {"text": "Steatohepatitis", "relevance": 0.369431, "dbpedia_resource": "http://dbpedia.org/resource/Steatohepatitis"}, {"text": "Chronic liver disease", "relevance": 0.352756, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_liver_disease"}, {"text": "Patent law", "relevance": 0.348369, "dbpedia_resource": "http://dbpedia.org/resource/Patent_law"}, {"text": "Patent application", "relevance": 0.334883, "dbpedia_resource": "http://dbpedia.org/resource/Patent_application"}, {"text": "Drug design", "relevance": 0.329462, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Hepatitis B", "relevance": 0.322842, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Gastroenterology", "relevance": 0.310914, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Drug development", "relevance": 0.310209, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Management occupations", "relevance": 0.309487, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Pre-clinical development", "relevance": 0.30931, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Liver biopsy", "relevance": 0.306823, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Therapy", "relevance": 0.305791, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Chief executive officer", "relevance": 0.304313, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Enzyme inhibitor", "relevance": 0.281876, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_inhibitor"}, {"text": "Classification of Pharmaco-Therapeutic Referrals", "relevance": 0.270038, "dbpedia_resource": "http://dbpedia.org/resource/Classification_of_Pharmaco-Therapeutic_Referrals"}, {"text": "Medicinal chemistry", "relevance": 0.262567, "dbpedia_resource": "http://dbpedia.org/resource/Medicinal_chemistry"}, {"text": "President pro tempore of the United States Senate", "relevance": 0.254334, "dbpedia_resource": "http://dbpedia.org/resource/President_pro_tempore_of_the_United_States_Senate"}, {"text": "Paris Convention for the Protection of Industrial Property", "relevance": 0.253708, "dbpedia_resource": "http://dbpedia.org/resource/Paris_Convention_for_the_Protection_of_Industrial_Property"}, {"text": "Richard Nixon", "relevance": 0.253353, "dbpedia_resource": "http://dbpedia.org/resource/Richard_Nixon"}, {"text": "President of the United States", "relevance": 0.253156, "dbpedia_resource": "http://dbpedia.org/resource/President_of_the_United_States"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.248327, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "John Adams", "relevance": 0.242063, "dbpedia_resource": "http://dbpedia.org/resource/John_Adams"}, {"text": "Vice president", "relevance": 0.241662, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "Patent Law Treaty", "relevance": 0.236171, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Law_Treaty"}, {"text": "Lactic acidosis", "relevance": 0.233997, "dbpedia_resource": "http://dbpedia.org/resource/Lactic_acidosis"}, {"text": "Gerald Ford", "relevance": 0.231511, "dbpedia_resource": "http://dbpedia.org/resource/Gerald_Ford"}, {"text": "ASK1", "relevance": 0.23042, "dbpedia_resource": "http://dbpedia.org/resource/ASK1"}], "categories": [{"score": 0.687573, "label": "/health and fitness/disease"}, {"score": 0.42132, "label": "/health and fitness/therapy"}, {"score": 0.384275, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "agentOf", "sentence": "SEATTLE , Nov. 9, 2018 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.698062, "arguments": [{"text": "Seal Rock Therapeutics, Inc.", "location": [39, 67], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}, {"text": "announced", "location": [205, 214], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "\" Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "score": 0.994786, "arguments": [{"text": "Seal Rock Therapeutics", "location": [1739, 1761], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}, {"text": "announced", "location": [1762, 1771], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.854132, "arguments": [{"text": "meeting", "location": [1186, 1193], "entities": [{"type": "EventMeeting", "text": "meeting"}]}, {"text": "Santa Fe", "location": [1198, 1206], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.995901, "arguments": [{"text": "Santa Fe", "location": [1198, 1206], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}, {"text": "New Mexico", "location": [1208, 1218], "entities": [{"type": "GeopoliticalEntity", "text": "New Mexico"}]}]}, {"type": "agentOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.920089, "arguments": [{"text": "Neil McDonnell", "location": [1528, 1542], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "said", "location": [1523, 1527], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.71758, "arguments": [{"text": "Chief Executive Officer", "location": [1545, 1568], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "Seal Rock Therapeutics", "location": [1572, 1594], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}]}, {"type": "employedBy", "sentence": "Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "score": 0.417282, "arguments": [{"text": "founders", "location": [2081, 2089], "entities": [{"type": "Person", "text": "founders"}]}, {"text": "Seal Rock Therapeutics", "location": [2057, 2079], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}]}, {"type": "residesIn", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.300954, "arguments": [{"text": "leader", "location": [2352, 2358], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "area", "location": [2347, 2351], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "hasAttribute", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.580563, "arguments": [{"text": "leader", "location": [2352, 2358], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "cardiovascular", "location": [2363, 2377], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "employedBy", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.799635, "arguments": [{"text": "leader", "location": [2352, 2358], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "Takeda", "location": [2404, 2410], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "score": 0.758695, "arguments": [{"text": "partner", "location": [2581, 2588], "entities": [{"type": "Person", "text": "Orexigen"}]}, {"text": "Takeda", "location": [2572, 2578], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.528062, "arguments": [{"text": "director of pharmacology", "location": [2686, 2710], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "Akarna Therapeutics", "location": [2714, 2733], "entities": [{"type": "Organization", "text": "Akarna Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "SEATTLE , Nov. 9, 2018 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.670641, "arguments": [{"text": "today", "location": [199, 204], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [205, 214], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.474504, "arguments": [{"text": "Allergan", "location": [2777, 2785], "entities": [{"type": "Organization", "text": "Allergan"}]}, {"text": "acquired", "location": [2765, 2773], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.97932, "arguments": [{"text": "2016", "location": [2789, 2793], "entities": [{"type": "Date", "text": "2016"}]}, {"text": "acquired", "location": [2765, 2773], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.802833, "arguments": [{"text": "he", "location": [2857, 2859], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "cardiovascular", "location": [2868, 2882], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.489941, "arguments": [{"text": "he", "location": [2857, 2859], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "metabolic disease", "location": [2894, 2911], "entities": [{"type": "HealthCondition", "text": "metabolic diseases"}]}]}, {"type": "partOf", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.849637, "arguments": [{"text": "pharmacology group", "location": [2912, 2930], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}, {"text": "Takeda Pharmaceuticals", "location": [2934, 2956], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "score": 0.74674, "arguments": [{"text": "director of preclinical research", "location": [3144, 3176], "entities": [{"type": "Person", "text": "Elias"}]}, {"text": "Takeda", "location": [3180, 3186], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "score": 0.763089, "arguments": [{"text": "she", "location": [3349, 3352], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "heart failure", "location": [3474, 3487], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "partOfMany", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.79386, "arguments": [{"text": "members", "location": [3581, 3588], "entities": [{"type": "Person", "text": "members"}]}, {"text": "leadership team", "location": [3606, 3621], "entities": [{"type": "Person", "text": "leadership team"}]}]}, {"type": "employedBy", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.452223, "arguments": [{"text": "leadership team", "location": [3606, 3621], "entities": [{"type": "Person", "text": "leadership team"}]}, {"text": "Seal Rock", "location": [3596, 3605], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}]}, {"type": "residesIn", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.67597, "arguments": [{"text": "David Brown", "location": [3699, 3710], "entities": [{"type": "Person", "text": "David Brown"}]}, {"text": "PhD", "location": [3713, 3716], "entities": [{"type": "GeopoliticalEntity", "text": "PhD"}]}]}, {"type": "affectedBy", "sentence": "SEATTLE , Nov. 9, 2018 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.424521, "arguments": [{"text": "its", "location": [215, 218], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}, {"text": "announced", "location": [205, 214], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "score": 0.571629, "arguments": [{"text": "vice president", "location": [3771, 3785], "entities": [{"type": "Person", "text": "Terry Porter"}]}, {"text": "Takeda Pharmaceuticals", "location": [3847, 3869], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, he was managing director at the corporate advisory group AquaPartners.", "score": 0.786842, "arguments": [{"text": "managing director", "location": [3893, 3910], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [3937, 3942], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "employedBy", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.477414, "arguments": [{"text": "member", "location": [3978, 3984], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [4023, 4028], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "partOf", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.78002, "arguments": [{"text": "group", "location": [4023, 4028], "entities": [{"type": "Organization", "text": "AquaPartners"}]}, {"text": "GlaxoSmithKline", "location": [4032, 4047], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "score": 0.667072, "arguments": [{"text": "GSK", "location": [4166, 4169], "entities": [{"type": "Organization", "text": "GSK"}]}, {"text": "acquisition", "location": [4185, 4196], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "residesIn", "sentence": "Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "score": 0.421297, "arguments": [{"text": "candidates", "location": [4455, 4465], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "areas", "location": [4473, 4478], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "hasAttribute", "sentence": "About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "score": 0.608891, "arguments": [{"text": "NASH\nNASH", "location": [4515, 4524], "entities": [{"type": "Person", "text": "NASH\nNASH"}]}, {"text": "disease", "location": [4564, 4571], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "score": 0.790092, "arguments": [{"text": "NAFLD", "location": [4685, 4690], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "diabetes", "location": [4748, 4756], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}]}, {"type": "agentOf", "sentence": "NAFLD is typically characterized as either fatty liver or steatohepatitis.", "score": 0.969466, "arguments": [{"text": "NAFLD", "location": [4780, 4785], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "characterized", "location": [4799, 4812], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "agentOf", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.702372, "arguments": [{"text": "NASH", "location": [4946, 4950], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "characterized", "location": [5003, 5016], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "hasAttribute", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.561306, "arguments": [{"text": "individuals", "location": [5111, 5122], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "cirrhosis", "location": [5148, 5157], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "timeOf", "sentence": "SEATTLE , Nov. 9, 2018 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.637208, "arguments": [{"text": "SRT-015", "location": [234, 241], "entities": [{"type": "Date", "text": "SRT-015"}]}, {"text": "announced", "location": [205, 214], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.694633, "arguments": [{"text": "NASH", "location": [5231, 5235], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "liver transplantation", "location": [5277, 5298], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.676101, "arguments": [{"text": "women", "location": [5333, 5338], "entities": [{"type": "Person", "text": "women"}]}, {"text": "liver transplantation", "location": [5277, 5298], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "locatedAt", "sentence": "About Seal Rock Therapeutics Seal Rock Therapeutics is a privately held, discovery stage company based in Seattle focused on the development of best-in-class treatments for inflammatory and fibrotic diseases with no available therapies.", "score": 0.738152, "arguments": [{"text": "company", "location": [5535, 5542], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}, {"text": "Seattle", "location": [5552, 5559], "entities": [{"type": "GeopoliticalEntity", "text": "SEATTLE"}]}]}, {"type": "employedBy", "sentence": "The company's lead product candidate, SRT-015, is a differentiated ASK1 inhibitor for NASH.", "score": 0.408221, "arguments": [{"text": "candidate", "location": [5710, 5719], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "company", "location": [5687, 5694], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}]}, {"type": "educatedAt", "sentence": "The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "score": 0.365602, "arguments": [{"text": "candidate", "location": [525, 534], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Seal Rock Therapeutics", "location": [578, 600], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics\nSeal Rock Therapeutics"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.592035, "arguments": [{"text": "Keystone Symposia Integrated Pathways", "location": [1119, 1156], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "meeting", "location": [1186, 1193], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "hasAttribute", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.658529, "arguments": [{"text": "NASH", "location": [1171, 1175], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Disease", "location": [1160, 1167], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.67241, "arguments": [{"text": "NASH", "location": [1171, 1175], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "meeting", "location": [1186, 1193], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.960106, "arguments": [{"text": "NAFLD", "location": [1180, 1185], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "meeting", "location": [1186, 1193], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}], "keywords": [{"text": "Seal Rock Therapeutics", "sentiment": {"score": 0.304231, "label": "positive"}, "relevance": 0.938166}, {"text": "vice president", "sentiment": {"score": -0.535413, "label": "negative"}, "relevance": 0.55619}, {"text": "discovery stage company", "sentiment": {"score": -0.570696, "label": "negative"}, "relevance": 0.550836}, {"text": "senior vice president", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.547131}, {"text": "Gubra therapeutic NASH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543102}, {"text": "ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.541599}, {"text": "fatty liver", "sentiment": {"score": -0.396179, "label": "negative"}, "relevance": 0.527516}, {"text": "Seal Rock leadership", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514779}, {"text": "liver-selective ASK1 inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511179}, {"text": "business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.507981}, {"text": "SOURCE Seal Rock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507567}, {"text": "fatty liver disease", "sentiment": {"score": -0.369421, "label": "negative"}, "relevance": 0.505599}, {"text": "preclinical proof-of-concept findings", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.504718}, {"text": "PI3Kdelta kinase inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499924}, {"text": "chronic liver diseases", "sentiment": {"score": -0.695458, "label": "negative"}, "relevance": 0.499344}, {"text": "ASK1 inhibitor compounds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498773}, {"text": "preclinical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498504}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": -0.520894, "label": "negative"}, "relevance": 0.497737}, {"text": "metabolic disease pharmacology", "sentiment": {"score": -0.499214, "label": "negative"}, "relevance": 0.496186}, {"text": "worldwide patent application", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.493579}, {"text": "best-in-class treatments", "sentiment": {"score": -0.570696, "label": "negative"}, "relevance": 0.491321}, {"text": "differentiated ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.490939}, {"text": "NASH start-up", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.489079}, {"text": "inflammation therapeutic areas", "sentiment": {"score": -0.409165, "label": "negative"}, "relevance": 0.48834}, {"text": "Akarna Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487167}, {"text": "international PCT patent", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485852}, {"text": "Vice President Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485686}, {"text": "Neil McDonnell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48551}, {"text": "worldwide business development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485376}, {"text": "global business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.482776}, {"text": "fibrotic diseases", "sentiment": {"score": -0.570696, "label": "negative"}, "relevance": 0.481705}, {"text": "significant positive effects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481651}, {"text": "Pathway Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481476}, {"text": "international patent law", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481004}, {"text": "available therapies", "sentiment": {"score": -0.570696, "label": "negative"}, "relevance": 0.478878}, {"text": "therapeutic area leader", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.478763}, {"text": "myosin activator therapeutic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478606}, {"text": "obesity drug Contrave", "sentiment": {"score": -0.205465, "label": "negative"}, "relevance": 0.478589}, {"text": "Patent Cooperation Treaty", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477827}, {"text": "drug development efforts", "sentiment": {"score": -0.486984, "label": "negative"}, "relevance": 0.477768}, {"text": "major pharmaceutical markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476952}, {"text": "Symposia Integrated Pathways", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476217}, {"text": "corporate advisory group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475676}, {"text": "liver fibrosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473573}, {"text": "differentiated inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472575}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472313}, {"text": "Chief Scientific Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471298}, {"text": "medicinal chemistry team", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471162}, {"text": "successful drug discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.469404}]}, "extracted_metadata": {"sha1": "1f0a02ad2c941940a64e5843fd1bbd8547616449", "filename": "1541770369547.zip-ab6ec0ea8118ccbf7f6e99d3870ff38f.xml", "file_type": "json"}, "external_links": ["https://www.prnewswire.com/news-releases/seal-rock-therapeutics-advancing-differentiated-ask1-inhibitor-lead-candidate-srt-015-in-nonalcoholic-steatohepatitis-nash-300747392.html", "https://www.sealrocktx.com/"], "title": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "forum_title": "Stock Market News | Financial &amp; Business News | Markets Insider"}, {"id": "WuslXJf6XpVmSAcwFn7bc0pZNvIAT2AbUrMCerSE0yexhJhCJoc7HoioO1fEn94W", "result_metadata": {"score": 34.23307}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Non-alcoholic fatty liver disease", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}], "categories": [{"score": 0.630798, "label": "/health and fitness/disease/cancer"}, {"score": 0.453057, "label": "/health and fitness/therapy"}, {"score": 0.414034, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "employedBy", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "score": 0.485089, "arguments": [{"text": "ASK1 Inhibitor", "location": [48, 62], "entities": [{"type": "Person", "text": "ASK1 Inhibitor"}]}, {"text": "Seal Rock Therapeutics Advancing Differentiated", "location": [0, 47], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}], "keywords": [{"text": "Differentiated ASK1 Inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.96316}, {"text": "Seal Rock Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.869618}, {"text": "Lead Candidate S-015", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.715194}, {"text": "Nonalcoholic Steatohepatitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620981}]}, "crawl_date": "2018-11-09T14:53:16Z", "url": "https://www.biospace.com/article/releases/seal-rock-therapeutics-advancing-differentiated-ask1-inhibitor-lead-candidate-srt-015-in-nonalcoholic-steatohepatitis-nash-/", "host": "biospace.com", "text": "Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T00:00:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.342035, "label": "positive"}, "text": "Seal Rock Therapeutics", "relevance": 0.935273, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock Therapeutics Seal Rock Therapeutics", "relevance": 0.751773, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.621638, "label": "positive"}, "text": "SRT-015", "relevance": 0.633141, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.266259, "label": "positive"}, "text": "Seal Rock Therapeutics, Inc.", "relevance": 0.535274, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer of Seal Rock Therapeutics", "relevance": 0.509432, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.405581, "label": "negative"}, "text": "NASH", "relevance": 0.459302, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.422937, "label": "negative"}, "text": "fatty liver", "relevance": 0.402581, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}, {"count": 1, "sentiment": {"score": -0.337896, "label": "negative"}, "text": "non-alcoholic fatty liver disease", "relevance": 0.397335, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}, {"count": 2, "sentiment": {"score": -0.520894, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.397291, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 3, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Neil McDonnell", "relevance": 0.360136, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Takeda", "relevance": 0.355163, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock", "relevance": 0.348558, "type": "Organization"}, {"count": 2, "sentiment": {"score": -0.570916, "label": "negative"}, "text": "fibrotic diseases", "relevance": 0.348117, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna Therapeutics", "relevance": 0.33892, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.132338, "label": "negative"}, "text": "SEATTLE", "relevance": 0.331631, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pathway Therapeutics", "relevance": 0.329725, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver fibrosis", "relevance": 0.326714, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "director", "relevance": 0.321428, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kathleen Elias", "relevance": 0.31074, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.499214, "label": "negative"}, "text": "metabolic disease", "relevance": 0.305419, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Business Development", "relevance": 0.300588, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Brown", "relevance": 0.298609, "type": "Person", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Artur Plonowski", "relevance": 0.298457, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Exelixis", "relevance": 0.295995, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President Research & Translational Medicine", "relevance": 0.287626, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "senior vice president", "relevance": 0.287071, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Keystone Symposia Integrated Pathways of Disease", "relevance": 0.285787, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.273391, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "vice president", "relevance": 0.26762, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.371387, "label": "positive"}, "text": "New Mexico", "relevance": 0.260126, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}, {"count": 1, "sentiment": {"score": -0.580282, "label": "negative"}, "text": "obesity", "relevance": 0.257837, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.256933, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0.310571, "label": "positive"}, "text": "Santa Fe", "relevance": 0.255807, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "diabetes", "relevance": 0.255053, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 2, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "Terry Porter", "relevance": 0.254039, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "managing director", "relevance": 0.253595, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.24706, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan", "relevance": 0.245481, "type": "Company", "disambiguation": {"subtype": [], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatocellular carcinoma", "relevance": 0.244269, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Scientific Officer", "relevance": 0.242653, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna", "relevance": 0.235156, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cytokinetics", "relevance": 0.234568, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.23185, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatomegaly", "relevance": 0.224906, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pioglitazone", "relevance": 0.223805, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "metformin", "relevance": 0.222456, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Metacrine", "relevance": 0.220405, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "CEO", "relevance": 0.21991, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazano", "relevance": 0.219019, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orexigen", "relevance": 0.218771, "type": "Company"}], "sentiment": {"document": {"score": -0.14083, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a discovery stage company", "keywords": [{"text": "discovery stage company"}]}, "sentence": " SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "best-in-class treatments", "keywords": [{"text": "best-in-class treatments"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies,", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "discovery stage company"}, {"text": "best-in-class treatments"}, {"text": "available therapies"}], "entities": [{"type": "Location", "text": "SEATTLE", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Seal Rock Therapeutics, Inc."}, {"type": "HealthCondition", "text": "fibrotic diseases"}]}, "sentence": " SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued", "keywords": [{"text": "preclinical proof-of-concept findings"}, {"text": "differentiated inhibitor"}, {"text": "recent worldwide patent"}, {"text": "nonalcoholic steatohepatitis"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}]}, "sentence": " SRT-015 is a potent, liver-selective ASK1 inhibitor for NASH.", "object": {"text": "a potent, liver-selective ASK1 inhibitor for NASH", "keywords": [{"text": "liver-selective ASK1 inhibitor"}, {"text": "NASH"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "action": {"verb": {"text": "optimize", "tense": "past"}, "text": "was internally discovered and optimized", "normalized": "be internally discover and optimize"}}, {"subject": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities demonstrated by other investigative approaches", "keywords": [{"text": "investigative approaches"}, {"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "avoid", "tense": "present"}, "text": "avoid", "normalized": "avoid"}}, {"subject": {"text": "by other investigative approaches", "keywords": [{"text": "investigative approaches"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities", "keywords": [{"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}, {"text": "Gubra"}, {"text": "model"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "efficacy", "keywords": [{"text": "efficacy"}]}, "action": {"verb": {"text": "promise", "tense": "present"}, "text": "has demonstrated promising", "normalized": "have demonstrate promise"}}, {"subject": {"text": "statistically significant positive effects on both metabolic parameters and liver-specific pathology", "keywords": [{"text": "significant positive effects"}, {"text": "metabolic parameters"}, {"text": "liver-specific pathology"}]}, "sentence": " This includes statistically significant positive effects on both metabolic parameters and liver-specific pathology.", "object": {"text": "This"}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " In addition, SRT-015 significantly reduced hepatomegaly, liver fibrosis, steatosis and inflammation, all key drivers for NASH.", "object": {"text": "hepatomegaly, liver fibrosis, steatosis and inflammation", "keywords": [{"text": "liver fibrosis"}, {"text": "steatosis"}, {"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "hepatomegaly"}, {"type": "HealthCondition", "text": "liver fibrosis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "object": {"text": "presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019", "keywords": [{"text": "Keystone Symposia Integrated"}, {"text": "Santa Fe"}, {"text": "NAFLD meeting"}, {"text": "New Mexico"}], "entities": [{"type": "PrintMedia", "text": "Keystone Symposia Integrated Pathways of Disease"}, {"type": "Location", "text": "Santa Fe", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"type": "Location", "text": "New Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "a unique property", "keywords": [{"text": "unique property"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "the circulation or other tissues", "keywords": [{"text": "circulation"}, {"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "reduce risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "other tissues", "keywords": [{"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "helps reduce", "normalized": "help reduce"}}, {"subject": {"text": "Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "Chief Executive Officer"}, {"text": "Neil McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "JobTitle", "text": "Chief Executive Officer of Seal Rock Therapeutics"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "Company", "text": "SRT-015"}, {"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "we"}, "sentence": " \"Our preclinical findings are proving very robust, and we are pleased to be advancing with IND-enabling activities for SRT-015.\"", "object": {"text": "advancing with IND-enabling activities for SRT-015", "keywords": [{"text": "IND-enabling activities"}, {"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "object": {"text": "the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof", "keywords": [{"text": "ASK1 inhibitor compounds"}, {"text": "international PCT patent"}, {"text": "publication"}, {"text": "application"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The Patent Cooperation Treaty (PCT)", "keywords": [{"text": "Patent Cooperation Treaty"}, {"text": "PCT"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "151 countries", "keywords": [{"text": "countries"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine", "keywords": [{"text": "Chief Scientific Officer"}, {"text": "Vice President Research"}, {"text": "Neil McDonnell"}, {"text": "Artur Plonowski"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "Person", "text": "Artur Plonowski"}, {"type": "JobTitle", "text": "Chief Scientific Officer"}, {"type": "Person", "text": "Kathleen Elias"}, {"type": "JobTitle", "text": "Vice President Research & Translational Medicine"}]}, "sentence": " Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "object": {"text": "Seal Rock Therapeutics' founders", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "founders"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. McDonnell", "keywords": [{"text": "Dr. McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "object": {"text": "as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda", "keywords": [{"text": "senior vice president"}, {"text": "therapeutic area leader"}, {"text": "metabolic diseases"}, {"text": "Takeda"}], "entities": [{"type": "JobTitle", "text": "CEO"}, {"type": "Company", "text": "Metacrine"}, {"type": "JobTitle", "text": "senior vice president"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin)", "keywords": [{"text": "diabetes drugs"}, {"text": "pioglitazone"}, {"text": "metformin"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "has been involved", "normalized": "have be involve"}}, {"subject": {"text": "Dr. Plonowski", "keywords": [{"text": "Dr. Plonowski"}], "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones", "keywords": [{"text": "NASH start-up"}, {"text": "Akarna Therapeutics"}, {"text": "Allergan"}, {"text": "pharmacology"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Akarna Therapeutics"}, {"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"type": "Quantity", "text": "$50 million"}, {"type": "Quantity", "text": "$1 billion"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "acquired by Allergan in 2016", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Allergan", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "was acquired", "normalized": "be acquire"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "object": {"text": "the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals,", "keywords": [{"text": "metabolic disease pharmacology"}, {"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "HealthCondition", "text": "metabolic disease", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "preclinical research"}, {"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}, {"text": "efforts"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry", "keywords": [{"text": "Senior Vice President"}, {"text": "Terry Porter"}, {"text": "Business Development"}, {"text": "PhD"}], "entities": [{"type": "Person", "text": "Terry Porter"}, {"type": "JobTitle", "text": "Senior Vice President, Business Development"}, {"type": "Person", "text": "David Brown", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"type": "JobTitle", "text": "director"}]}, "sentence": " Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "object": {"text": "Additional members of the Seal Rock leadership team", "keywords": [{"text": "Seal Rock leadership"}, {"text": "Additional members"}, {"text": "team"}], "entities": [{"type": "Organization", "text": "Seal Rock"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. Porter", "keywords": [{"text": "Dr. Porter"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "object": {"text": "as vice president of search & evaluation within global business development at Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "vice president"}, {"text": "global business development"}, {"text": "search"}], "entities": [{"type": "JobTitle", "text": "vice president"}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Prior to that, he was managing director at the corporate advisory group AquaPartners.", "object": {"text": "managing director at the corporate advisory group AquaPartners", "keywords": [{"text": "corporate advisory group"}, {"text": "director"}, {"text": "AquaPartners"}], "entities": [{"type": "JobTitle", "text": "managing director"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "action": {"verb": {"text": "create", "tense": "past"}, "text": "created", "normalized": "create"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "object": {"text": "the external science and technology group", "keywords": [{"text": "external science"}, {"text": "technology group"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Brown", "keywords": [{"text": "Dr."}], "entities": [{"type": "Person", "text": "David Brown"}]}, "sentence": " Dr. Brown recently directed the medicinal chemistry team at Pathway Therapeutics, which led to the selective PI3Kdelta kinase inhibitor PWT143/MEI-401.", "object": {"text": "the medicinal chemistry team", "keywords": [{"text": "medicinal chemistry team"}]}, "action": {"verb": {"text": "direct", "tense": "past"}, "text": "directed", "normalized": "direct"}}, {"subject": {"text": "he"}, "sentence": " Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "object": {"text": "12 years", "entities": [{"type": "Quantity", "text": "12 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "About NASH NASH", "keywords": [{"text": "NASH NASH"}]}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "a form of non-alcoholic fatty liver disease", "keywords": [{"text": "non-alcoholic fatty liver"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a form of non-alcoholic fatty liver disease (NAFLD)", "keywords": [{"text": "non-alcoholic fatty liver"}, {"text": "form"}, {"text": "disease"}, {"text": "NAFLD"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "it"}, "sentence": " About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one of the most common chronic liver diseases", "keywords": [{"text": "common chronic liver"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "associated with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "is associated", "normalized": "be associate"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "typically characterized as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "Fatty liver", "keywords": [{"text": "Fatty liver"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "sentence": " Fatty liver is generally non-progressive or progresses slowly compared to steatohepatitis.", "object": {"text": "generally non-progressive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.955967, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Fatty liver", "relevance": 0.898268, "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.882008, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Patent Cooperation Treaty", "relevance": 0.719156, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Cooperation_Treaty"}, {"text": "Hepatitis", "relevance": 0.714395, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Obesity", "relevance": 0.601716, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Hepatology", "relevance": 0.594492, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Steatosis", "relevance": 0.475685, "dbpedia_resource": "http://dbpedia.org/resource/Steatosis"}, {"text": "Liver", "relevance": 0.450072, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Pharmacology", "relevance": 0.449124, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Cancer", "relevance": 0.441955, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Metabolic syndrome", "relevance": 0.441683, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Drug discovery", "relevance": 0.405994, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Inborn error of metabolism", "relevance": 0.403482, "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}, {"text": "Liver disease", "relevance": 0.39722, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Hepatocellular carcinoma", "relevance": 0.396426, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Metformin", "relevance": 0.395711, "dbpedia_resource": "http://dbpedia.org/resource/Metformin"}, {"text": "Liver transplantation", "relevance": 0.385615, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Medicine", "relevance": 0.378571, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Hepatitis C", "relevance": 0.376309, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Patent", "relevance": 0.375957, "dbpedia_resource": "http://dbpedia.org/resource/Patent"}, {"text": "Vice President of the United States", "relevance": 0.364397, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Steatohepatitis", "relevance": 0.36197, "dbpedia_resource": "http://dbpedia.org/resource/Steatohepatitis"}, {"text": "Metabolism", "relevance": 0.359132, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Chronic liver disease", "relevance": 0.335958, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_liver_disease"}, {"text": "Patent law", "relevance": 0.335089, "dbpedia_resource": "http://dbpedia.org/resource/Patent_law"}, {"text": "Drug design", "relevance": 0.331327, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Patent application", "relevance": 0.320427, "dbpedia_resource": "http://dbpedia.org/resource/Patent_application"}, {"text": "Gastroenterology", "relevance": 0.317065, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Drug development", "relevance": 0.314477, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Hepatitis B", "relevance": 0.308818, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Pre-clinical development", "relevance": 0.303119, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Management occupations", "relevance": 0.297732, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Chief executive officer", "relevance": 0.292404, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Liver biopsy", "relevance": 0.292212, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Therapy", "relevance": 0.292096, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Enzyme inhibitor", "relevance": 0.270992, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_inhibitor"}, {"text": "Medicinal chemistry", "relevance": 0.266527, "dbpedia_resource": "http://dbpedia.org/resource/Medicinal_chemistry"}, {"text": "Classification of Pharmaco-Therapeutic Referrals", "relevance": 0.259453, "dbpedia_resource": "http://dbpedia.org/resource/Classification_of_Pharmaco-Therapeutic_Referrals"}, {"text": "Paris Convention for the Protection of Industrial Property", "relevance": 0.245242, "dbpedia_resource": "http://dbpedia.org/resource/Paris_Convention_for_the_Protection_of_Industrial_Property"}, {"text": "President of the United States", "relevance": 0.244632, "dbpedia_resource": "http://dbpedia.org/resource/President_of_the_United_States"}, {"text": "Richard Nixon", "relevance": 0.243223, "dbpedia_resource": "http://dbpedia.org/resource/Richard_Nixon"}, {"text": "President pro tempore of the United States Senate", "relevance": 0.242673, "dbpedia_resource": "http://dbpedia.org/resource/President_pro_tempore_of_the_United_States_Senate"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.236517, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "John Adams", "relevance": 0.232304, "dbpedia_resource": "http://dbpedia.org/resource/John_Adams"}, {"text": "Vice president", "relevance": 0.23017, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "ASK1", "relevance": 0.229181, "dbpedia_resource": "http://dbpedia.org/resource/ASK1"}, {"text": "Patent Law Treaty", "relevance": 0.226533, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Law_Treaty"}, {"text": "Lactic acidosis", "relevance": 0.224542, "dbpedia_resource": "http://dbpedia.org/resource/Lactic_acidosis"}, {"text": "Gerald Ford", "relevance": 0.223659, "dbpedia_resource": "http://dbpedia.org/resource/Gerald_Ford"}], "categories": [{"score": 0.690028, "label": "/health and fitness/disease"}, {"score": 0.421319, "label": "/health and fitness/therapy"}, {"score": 0.38157, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "employedBy", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH) SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.486451, "arguments": [{"text": "ASK1 Inhibitor", "location": [48, 62], "entities": [{"type": "Person", "text": "ASK1 Inhibitor"}]}, {"text": "Seal Rock Therapeutics Advancing Differentiated", "location": [0, 47], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.67241, "arguments": [{"text": "NASH", "location": [1283, 1287], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "meeting", "location": [1298, 1305], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.960106, "arguments": [{"text": "NAFLD", "location": [1292, 1297], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "meeting", "location": [1298, 1305], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.854132, "arguments": [{"text": "meeting", "location": [1298, 1305], "entities": [{"type": "EventMeeting", "text": "meeting"}]}, {"text": "Santa Fe", "location": [1310, 1318], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.995901, "arguments": [{"text": "Santa Fe", "location": [1310, 1318], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}, {"text": "New Mexico", "location": [1320, 1330], "entities": [{"type": "GeopoliticalEntity", "text": "New Mexico"}]}]}, {"type": "agentOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.920089, "arguments": [{"text": "Neil McDonnell", "location": [1640, 1654], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "said", "location": [1635, 1639], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.71758, "arguments": [{"text": "Chief Executive Officer", "location": [1657, 1680], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "Seal Rock Therapeutics", "location": [1684, 1706], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}, {"type": "agentOf", "sentence": "\" Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "score": 0.994786, "arguments": [{"text": "Seal Rock Therapeutics", "location": [1851, 1873], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}, {"text": "announced", "location": [1874, 1883], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "score": 0.417282, "arguments": [{"text": "founders", "location": [2193, 2201], "entities": [{"type": "Person", "text": "founders"}]}, {"text": "Seal Rock Therapeutics", "location": [2169, 2191], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}, {"type": "residesIn", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.300954, "arguments": [{"text": "leader", "location": [2464, 2470], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "area", "location": [2459, 2463], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "hasAttribute", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.580563, "arguments": [{"text": "leader", "location": [2464, 2470], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "cardiovascular", "location": [2475, 2489], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "locatedAt", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH) SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.543086, "arguments": [{"text": "Nonalcoholic Steatohepatitis", "location": [89, 117], "entities": [{"type": "GeopoliticalEntity", "text": "Nonalcoholic Steatohepatitis"}]}, {"text": "SEATTLE", "location": [125, 132], "entities": [{"type": "GeopoliticalEntity", "text": "Seattle"}]}]}, {"type": "employedBy", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.799635, "arguments": [{"text": "leader", "location": [2464, 2470], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "Takeda", "location": [2516, 2522], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "score": 0.758695, "arguments": [{"text": "partner", "location": [2693, 2700], "entities": [{"type": "Person", "text": "Orexigen"}]}, {"text": "Takeda", "location": [2684, 2690], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.528062, "arguments": [{"text": "director of pharmacology", "location": [2798, 2822], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "Akarna Therapeutics", "location": [2826, 2845], "entities": [{"type": "Organization", "text": "Akarna Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.474504, "arguments": [{"text": "Allergan", "location": [2889, 2897], "entities": [{"type": "Organization", "text": "Allergan"}]}, {"text": "acquired", "location": [2877, 2885], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.97932, "arguments": [{"text": "2016", "location": [2901, 2905], "entities": [{"type": "Date", "text": "2016"}]}, {"text": "acquired", "location": [2877, 2885], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.802833, "arguments": [{"text": "he", "location": [2969, 2971], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "cardiovascular", "location": [2980, 2994], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.489941, "arguments": [{"text": "he", "location": [2969, 2971], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "metabolic disease", "location": [3006, 3023], "entities": [{"type": "HealthCondition", "text": "metabolic diseases"}]}]}, {"type": "partOf", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.849637, "arguments": [{"text": "pharmacology group", "location": [3024, 3042], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}, {"text": "Takeda Pharmaceuticals", "location": [3046, 3068], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "score": 0.74674, "arguments": [{"text": "director of preclinical research", "location": [3256, 3288], "entities": [{"type": "Person", "text": "Elias"}]}, {"text": "Takeda", "location": [3292, 3298], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "score": 0.763089, "arguments": [{"text": "she", "location": [3461, 3464], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "heart failure", "location": [3586, 3599], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "residesIn", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH) SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.553754, "arguments": [{"text": "NASH", "location": [119, 123], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "SEATTLE", "location": [125, 132], "entities": [{"type": "GeopoliticalEntity", "text": "Seattle"}]}]}, {"type": "partOfMany", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.79386, "arguments": [{"text": "members", "location": [3693, 3700], "entities": [{"type": "Person", "text": "members"}]}, {"text": "leadership team", "location": [3718, 3733], "entities": [{"type": "Person", "text": "leadership team"}]}]}, {"type": "employedBy", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.452223, "arguments": [{"text": "leadership team", "location": [3718, 3733], "entities": [{"type": "Person", "text": "leadership team"}]}, {"text": "Seal Rock", "location": [3708, 3717], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}, {"type": "residesIn", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.67597, "arguments": [{"text": "David Brown", "location": [3811, 3822], "entities": [{"type": "Person", "text": "David Brown"}]}, {"text": "PhD", "location": [3825, 3828], "entities": [{"type": "GeopoliticalEntity", "text": "PhD"}]}]}, {"type": "employedBy", "sentence": "Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "score": 0.571629, "arguments": [{"text": "vice president", "location": [3883, 3897], "entities": [{"type": "Person", "text": "Terry Porter"}]}, {"text": "Takeda Pharmaceuticals", "location": [3959, 3981], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, he was managing director at the corporate advisory group AquaPartners.", "score": 0.786842, "arguments": [{"text": "managing director", "location": [4005, 4022], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [4049, 4054], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "employedBy", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.477414, "arguments": [{"text": "member", "location": [4090, 4096], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [4135, 4140], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "partOf", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.78002, "arguments": [{"text": "group", "location": [4135, 4140], "entities": [{"type": "Organization", "text": "AquaPartners"}]}, {"text": "GlaxoSmithKline", "location": [4144, 4159], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "score": 0.667072, "arguments": [{"text": "GSK", "location": [4278, 4281], "entities": [{"type": "Organization", "text": "GSK"}]}, {"text": "acquisition", "location": [4297, 4308], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "managerOf", "sentence": "Dr. Brown recently directed the medicinal chemistry team at Pathway Therapeutics, which led to the selective PI3Kdelta kinase inhibitor PWT143/MEI-401.", "score": 0.349292, "arguments": [{"text": "PI3Kdelta kinase inhibitor", "location": [4431, 4457], "entities": [{"type": "Person", "text": "PI3Kdelta kinase inhibitor"}]}, {"text": "which", "location": [4404, 4409], "entities": [{"type": "Organization", "text": "Pathway Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "score": 0.421297, "arguments": [{"text": "candidates", "location": [4567, 4577], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "areas", "location": [4585, 4590], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "hasAttribute", "sentence": "About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "score": 0.608891, "arguments": [{"text": "NASH NASH", "location": [4627, 4636], "entities": [{"type": "Person", "text": "NASH NASH"}]}, {"text": "disease", "location": [4676, 4683], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH) SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.494428, "arguments": [{"text": "/PRNewswire/", "location": [135, 147], "entities": [{"type": "Person", "text": "/PRNewswire/"}]}, {"text": "diseases", "location": [273, 281], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "score": 0.790092, "arguments": [{"text": "NAFLD", "location": [4797, 4802], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "diabetes", "location": [4860, 4868], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}]}, {"type": "agentOf", "sentence": "NAFLD is typically characterized as either fatty liver or steatohepatitis.", "score": 0.969466, "arguments": [{"text": "NAFLD", "location": [4892, 4897], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "characterized", "location": [4911, 4924], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "agentOf", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.702372, "arguments": [{"text": "NASH", "location": [5058, 5062], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "characterized", "location": [5115, 5128], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "hasAttribute", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.561306, "arguments": [{"text": "individuals", "location": [5223, 5234], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "cirrhosis", "location": [5260, 5269], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.694633, "arguments": [{"text": "NASH", "location": [5343, 5347], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "liver transplantation", "location": [5389, 5410], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.676101, "arguments": [{"text": "women", "location": [5445, 5450], "entities": [{"type": "Person", "text": "women"}]}, {"text": "liver transplantation", "location": [5389, 5410], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "locatedAt", "sentence": "About Seal Rock Therapeutics Seal Rock Therapeutics is a privately held, discovery stage company based in Seattle focused on the development of best-in-class treatments for inflammatory and fibrotic diseases with no available therapies.", "score": 0.734803, "arguments": [{"text": "company", "location": [5647, 5654], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc."}]}, {"text": "Seattle", "location": [5664, 5671], "entities": [{"type": "GeopoliticalEntity", "text": "Seattle"}]}]}, {"type": "employedBy", "sentence": "The company's lead product candidate, SRT-015, is a differentiated ASK1 inhibitor for NASH.", "score": 0.408221, "arguments": [{"text": "candidate", "location": [5822, 5831], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "company", "location": [5799, 5806], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc."}]}]}, {"type": "timeOf", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH) SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.553177, "arguments": [{"text": "today", "location": [311, 316], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [317, 326], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH) SEATTLE , /PRNewswire/ -- Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.50576, "arguments": [{"text": "SRT-015", "location": [346, 353], "entities": [{"type": "Date", "text": "SRT-015"}]}, {"text": "announced", "location": [317, 326], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "educatedAt", "sentence": "The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "score": 0.365602, "arguments": [{"text": "candidate", "location": [637, 646], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Seal Rock Therapeutics", "location": [690, 712], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.592035, "arguments": [{"text": "Keystone Symposia Integrated Pathways", "location": [1231, 1268], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "meeting", "location": [1298, 1305], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "hasAttribute", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.658529, "arguments": [{"text": "NASH", "location": [1283, 1287], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Disease", "location": [1272, 1279], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}], "keywords": [{"text": "Seal Rock Therapeutics", "sentiment": {"score": 0.304147, "label": "positive"}, "relevance": 0.904842}, {"text": "ask1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.587526}, {"text": "differentiated ask1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.58687}, {"text": "discovery stage company", "sentiment": {"score": -0.570916, "label": "negative"}, "relevance": 0.551073}, {"text": "senior vice president", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.547131}, {"text": "Rock Therapeutics Seal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546835}, {"text": "Gubra therapeutic NASH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542867}, {"text": "NASH NASH", "sentiment": {"score": -0.337896, "label": "negative"}, "relevance": 0.542293}, {"text": "fatty liver", "sentiment": {"score": -0.380416, "label": "negative"}, "relevance": 0.527141}, {"text": "ASK1 Inhibitor Lead", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524976}, {"text": "liver-selective ASK1 inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52118}, {"text": "Seal Rock leadership", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514525}, {"text": "business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.507621}, {"text": "ASK1 inhibitor compounds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507473}, {"text": "PI3Kdelta kinase inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505646}, {"text": "preclinical proof-of-concept findings", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.505516}, {"text": "fatty liver disease", "sentiment": {"score": -0.337896, "label": "negative"}, "relevance": 0.505349}, {"text": "chronic liver diseases", "sentiment": {"score": -0.694965, "label": "negative"}, "relevance": 0.499092}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": -0.520894, "label": "negative"}, "relevance": 0.497684}, {"text": "metabolic disease pharmacology", "sentiment": {"score": -0.499214, "label": "negative"}, "relevance": 0.496197}, {"text": "preclinical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496135}, {"text": "NASH start-up", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.494851}, {"text": "worldwide patent application", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.494109}, {"text": "nonalcoholic steatohepatitis", "sentiment": {"score": -0.272157, "label": "negative"}, "relevance": 0.491722}, {"text": "best-in-class treatments", "sentiment": {"score": -0.570916, "label": "negative"}, "relevance": 0.491533}, {"text": "inflammation therapeutic areas", "sentiment": {"score": -0.409165, "label": "negative"}, "relevance": 0.488354}, {"text": "Akarna Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487251}, {"text": "international PCT patent", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486043}, {"text": "differentiated inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48599}, {"text": "Vice President Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485863}, {"text": "Neil McDonnell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485809}, {"text": "worldwide business development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484959}, {"text": "global business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.482485}, {"text": "fibrotic diseases", "sentiment": {"score": -0.570916, "label": "negative"}, "relevance": 0.481804}, {"text": "Pathway Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481219}, {"text": "international patent law", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481123}, {"text": "available therapies", "sentiment": {"score": -0.570916, "label": "negative"}, "relevance": 0.479047}, {"text": "therapeutic area leader", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.478889}, {"text": "obesity drug Contrave", "sentiment": {"score": -0.205465, "label": "negative"}, "relevance": 0.478622}, {"text": "myosin activator therapeutic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478565}, {"text": "Patent Cooperation Treaty", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477995}, {"text": "significant positive effects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477963}, {"text": "drug development efforts", "sentiment": {"score": -0.486984, "label": "negative"}, "relevance": 0.477218}, {"text": "major pharmaceutical markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477119}, {"text": "Symposia Integrated Pathways", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47657}, {"text": "corporate advisory group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475424}, {"text": "lead product candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474405}, {"text": "liver fibrosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474009}, {"text": "successful drug discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472628}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472614}]}, "extracted_metadata": {"sha1": "4d5cdf5d87a905963cba5b89eb1aaadd5ad42268", "filename": "1541775196914.zip-5c4f03cc4f96eac79b343a08d70a8b8f.xml", "file_type": "json"}, "external_links": ["http://www.sealrocktx.com/"], "title": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in Nonalcoholic Steatohepatitis (NASH)", "forum_title": "Pre-Clinical Research News | BioSpace"}, {"id": "B-3INJ-ZxPnyo2dLwomll8toDS8u6ga75t0USZhdxUgyvnlOtOYsV6wJe_SvDezA", "result_metadata": {"score": 33.617874}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Peptide Therapeutics Market", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.10%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.528096, "label": "/real estate/buying and selling homes"}, {"score": 0.486185, "label": "/finance/investing/day trading"}, {"score": 0.485697, "label": "/health and fitness/disease/cancer"}], "relations": [], "keywords": [{"text": "Peptide Therapeutics Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.924241}, {"text": "CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237611}]}, "crawl_date": "2018-11-08T16:34:47Z", "url": "http://www.sbwire.com/press-releases/peptide-therapeutics-market-to-expand-at-a-cagr-of-910-during-2016-2024-1079429.htm", "host": "sbwire.com", "text": "At the forefront of this market are Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co.", "main_image_url": "http://media.releasewire.com/photos/show/?id=69214", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T16:39:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Peptide Therapeutics Market", "relevance": 0.763019, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.575127, "label": "negative"}, "text": "cancer", "relevance": 0.223118, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.192182, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Albany", "relevance": 0.160833, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Albany, New York", "dbpedia_resource": "http://dbpedia.org/resource/Albany,_New_York"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.158495, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NY", "relevance": 0.153393, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.138394, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": -0.541295, "label": "negative"}, "text": "key contributor", "relevance": 0.136042, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Media Relations Contact", "relevance": 0.134193, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "gastrointestinal tract", "relevance": 0.13243, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.127967, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.126754, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CVD", "relevance": 0.122785, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.122455, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amgen Inc", "relevance": 0.121935, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly and Co.", "relevance": 0.117685, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.117164, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.113442, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.112891, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.112115, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.111278, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bachem Holding AG", "relevance": 0.111011, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.109481, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.0997535, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.10%", "relevance": 0.0997535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "38.8%", "relevance": 0.0997535, "type": "Quantity"}], "sentiment": {"document": {"score": 0.0616686, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The global market for peptide therapeutics", "keywords": [{"text": "peptide therapeutics"}, {"text": "global market"}], "entities": []}, "sentence": " Albany, NY -- ( SBWIRE ) -- 11/08/2018 -- Global Peptide Therapeutics Market: Snapshot The global market for peptide therapeutics has been witnessing a substantial rise in its size and valuation since the last few years.", "object": {"text": "witnessing a substantial rise in its size and valuation since the last few years", "keywords": [{"text": "substantial rise"}, {"text": "valuation"}, {"text": "size"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "peptide therapeutics", "keywords": [{"text": "peptide therapeutics"}]}, "sentence": " Albany, NY -- ( SBWIRE ) -- 11/08/2018 -- Global Peptide Therapeutics Market: Snapshot The global market for peptide therapeutics has been witnessing a substantial rise in its size and valuation since the last few years.", "object": {"text": "a substantial rise in its size and valuation since the last few years", "keywords": [{"text": "substantial rise"}, {"text": "valuation"}, {"text": "size"}]}, "action": {"verb": {"text": "witness", "tense": "past"}, "text": "has been witnessing", "normalized": "have be witness"}}, {"subject": {"text": "The major factors", "keywords": [{"text": "major factors"}]}, "sentence": " The major factors that are driving the growth of this market are the rising prevalence of metabolic disorders and the increasing pool of cancer patients.", "object": {"text": "driving the growth of this market are the rising prevalence of metabolic disorders and the increasing pool of cancer patients", "keywords": [{"text": "metabolic disorders"}, {"text": "cancer patients"}, {"text": "prevalence"}, {"text": "growth"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The major factors that are driving the growth of this market", "keywords": [{"text": "major factors"}, {"text": "growth"}, {"text": "market"}], "entities": []}, "sentence": " The major factors that are driving the growth of this market are the rising prevalence of metabolic disorders and the increasing pool of cancer patients.", "object": {"text": "the rising prevalence of metabolic disorders and the increasing pool of cancer patients", "keywords": [{"text": "metabolic disorders"}, {"text": "cancer patients"}, {"text": "prevalence"}, {"text": "pool"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "research activities and development pipeline of peptide drugs", "keywords": [{"text": "peptide drugs"}, {"text": "development pipeline"}, {"text": "research activities"}]}, "sentence": " View Report- https://www.transparencymarketresearch.com/peptide-therapeutics-market.html The rise in research activities and development pipeline of peptide drugs is projected to bring significant growth in this market over the next few years.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Report- https://www.transparencymarketresearch.com/peptide-therapeutics-market.html The rise in research activities and development pipeline of peptide drugs", "keywords": [{"text": "peptide drugs"}, {"text": "development pipeline"}, {"text": "research activities"}, {"text": "rise"}]}, "sentence": " View Report- https://www.transparencymarketresearch.com/peptide-therapeutics-market.html The rise in research activities and development pipeline of peptide drugs is projected to bring significant growth in this market over the next few years.", "object": {"text": "significant growth", "keywords": [{"text": "significant growth"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "is projected to bring", "normalized": "be project to bring"}}, {"subject": {"text": "the high complexity of peptides", "keywords": [{"text": "high complexity"}, {"text": "peptides"}]}, "sentence": " However, the high complexity of peptides may obstruct the manufacturing of peptide drugs over the forthcoming years, reflecting poorly on the overall progress of the market.", "object": {"text": "the manufacturing of peptide drugs", "keywords": [{"text": "peptide drugs"}, {"text": "manufacturing"}]}, "action": {"verb": {"text": "obstruct", "tense": "future"}, "text": "may obstruct", "normalized": "may obstruct"}}, {"subject": {"text": "the worldwide market for peptide therapeutics", "keywords": [{"text": "peptide therapeutics"}, {"text": "worldwide market"}]}, "sentence": " In 2015, the worldwide market for peptide therapeutics was worth US$21.3 bn.", "object": {"text": "worth US$21.3 bn", "keywords": [{"text": "bn"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Researchers", "keywords": [{"text": "Researchers"}]}, "sentence": " Researchers project the opportunity in this market to expand at a healthy CAGR of 9.10% between 2016 and 2024 and reach a value of US$46.6 mn by the end of 2024.", "object": {"text": "the opportunity in this market to expand at a healthy CAGR of 9.10% between 2016 and 2024 and reach a value of US$46.6 mn by the end of 2024", "keywords": [{"text": "healthy CAGR"}, {"text": "mn"}, {"text": "opportunity"}, {"text": "market"}], "entities": [{"type": "Quantity", "text": "9.10"}]}, "action": {"verb": {"text": "project", "tense": "present"}, "text": "project", "normalized": "project"}}, {"subject": {"text": "Researchers project the opportunity in this market", "keywords": [{"text": "Researchers"}, {"text": "opportunity"}, {"text": "market"}], "entities": []}, "sentence": " Researchers project the opportunity in this market to expand at a healthy CAGR of 9.10% between 2016 and 2024 and reach a value of US$46.6 mn by the end of 2024.", "object": {"text": "a value of US$46.6 mn", "keywords": [{"text": "mn"}, {"text": "value"}]}, "action": {"verb": {"text": "reach", "tense": "present"}, "text": "reach", "normalized": "reach"}}, {"subject": {"text": "Peptide Therapeutics", "keywords": [{"text": "Peptide Therapeutics"}]}, "sentence": " Cancer Treatment to Surface as Key Application Area of Peptide Therapeutics Based on the application, the global peptide therapeutics market is classified into cancer treatment, drugs for metabolic disorders, cardiovascular disease (CVD) therapeutics, respiratory disorder therapeutics, gastrointestinal tract (GIT) therapeutics, anti-infective drugs, dermatology therapeutics, central nervous systems (CNS) therapeutics, and renal therapeutics.", "object": {"text": "on the application", "keywords": [{"text": "application"}]}, "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "the global peptide therapeutics market", "keywords": [{"text": "global peptide therapeutics"}], "entities": []}, "sentence": " Cancer Treatment to Surface as Key Application Area of Peptide Therapeutics Based on the application, the global peptide therapeutics market is classified into cancer treatment, drugs for metabolic disorders, cardiovascular disease (CVD) therapeutics, respiratory disorder therapeutics, gastrointestinal tract (GIT) therapeutics, anti-infective drugs, dermatology therapeutics, central nervous systems (CNS) therapeutics, and renal therapeutics.", "object": {"text": "classified into cancer treatment, drugs for metabolic disorders, cardiovascular disease (CVD) therapeutics, respiratory disorder therapeutics", "keywords": [{"text": "respiratory disorder therapeutics"}, {"text": "metabolic disorders"}, {"text": "cardiovascular disease"}, {"text": "cancer treatment"}], "entities": [{"type": "HealthCondition", "text": "CVD"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global peptide therapeutics market", "keywords": [{"text": "global peptide therapeutics"}], "entities": []}, "sentence": " Cancer Treatment to Surface as Key Application Area of Peptide Therapeutics Based on the application, the global peptide therapeutics market is classified into cancer treatment, drugs for metabolic disorders, cardiovascular disease (CVD) therapeutics, respiratory disorder therapeutics, gastrointestinal tract (GIT) therapeutics, anti-infective drugs, dermatology therapeutics, central nervous systems (CNS) therapeutics, and renal therapeutics.", "object": {"text": "into cancer treatment, drugs for metabolic disorders, cardiovascular disease (CVD) therapeutics, respiratory disorder therapeutics, gastrointestinal tract (GIT) therapeutics, anti-infective drugs, dermatology therapeutics, central nervous systems (CNS) therapeutics, and renal therapeutics", "keywords": [{"text": "respiratory disorder therapeutics"}, {"text": "dermatology therapeutics"}, {"text": "renal therapeutics"}, {"text": "anti-infective drugs"}], "entities": [{"type": "HealthCondition", "text": "CVD"}, {"type": "Anatomy", "text": "gastrointestinal tract"}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "peptides", "keywords": [{"text": "peptides"}]}, "sentence": " With peptides evolving as a potential therapeutic agent for the treatment of cancer, the cancer segment emerged as the key contributor to this market in 2015.", "object": {"text": "as a potential therapeutic agent", "keywords": [{"text": "potential therapeutic agent"}]}, "action": {"verb": {"text": "evolve", "tense": "present"}, "text": "evolving", "normalized": "evolve"}}, {"subject": {"text": "the cancer segment", "keywords": [{"text": "cancer segment"}]}, "sentence": " With peptides evolving as a potential therapeutic agent for the treatment of cancer, the cancer segment emerged as the key contributor to this market in 2015.", "object": {"text": "as the key contributor to this market", "keywords": [{"text": "key contributor"}, {"text": "market"}], "entities": [{"type": "JobTitle", "text": "key contributor"}]}, "action": {"verb": {"text": "emerge", "tense": "past"}, "text": "emerged", "normalized": "emerge"}}, {"subject": {"text": "by cancer", "keywords": [{"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "sentence": " The rising mortality rate, caused by cancer, has led to an increased focus of players towards the development of new drugs and products to combat the situation, which is influencing the market substantially.", "object": {"text": "The rising mortality rate", "keywords": [{"text": "mortality rate"}], "entities": []}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "the situation", "keywords": [{"text": "situation"}]}, "sentence": " The rising mortality rate, caused by cancer, has led to an increased focus of players towards the development of new drugs and products to combat the situation, which is influencing the market substantially.", "object": {"text": "influencing the market substantially", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the situation", "keywords": [{"text": "situation"}]}, "sentence": " The rising mortality rate, caused by cancer, has led to an increased focus of players towards the development of new drugs and products to combat the situation, which is influencing the market substantially.", "object": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "influence", "tense": "present"}, "text": "is influencing", "normalized": "be influence"}}, {"subject": {"text": "the uptake of peptide therapeutics for the treatment of cancer over the next few years", "keywords": [{"text": "peptide therapeutics"}, {"text": "uptake"}, {"text": "treatment"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "sentence": " The technological advancements and extensive research and development activities are likely to fuel the uptake of peptide therapeutics for the treatment of cancer over the next few years.", "object": {"text": "The technological advancements and extensive research and development activities", "keywords": [{"text": "technological advancements"}, {"text": "extensive research"}, {"text": "development activities"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "to fuel", "normalized": "to fuel"}}, {"subject": {"text": "A Sample- https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418 Peptide therapeutics", "keywords": [{"text": "Peptide therapeutics"}, {"text": "Sample"}]}, "sentence": " Request A Sample- https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418 Peptide therapeutics mainly follow two routes of administration: Oral and parenteral.", "object": {"text": "two routes of administration: Oral and parenteral", "keywords": [{"text": "parenteral"}, {"text": "routes"}, {"text": "Oral"}, {"text": "administration"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "follow", "normalized": "follow"}}, {"subject": {"text": "The parenteral segment", "keywords": [{"text": "parenteral segment"}]}, "sentence": " The parenteral segment led the global market for peptide therapeutics in 2015 due to the easy availability of peptide drugs for the parenteral route of administration compared to other routes.", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "the parenteral route of administration", "keywords": [{"text": "parenteral route"}, {"text": "administration"}]}, "sentence": " The parenteral segment led the global market for peptide therapeutics in 2015 due to the easy availability of peptide drugs for the parenteral route of administration compared to other routes.", "object": {"text": "to other routes", "keywords": [{"text": "routes"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "the oral administration of these drugs", "keywords": [{"text": "oral administration"}, {"text": "drugs"}]}, "sentence": " However, the oral administration of these drugs is likely to increase significantly over the next few years.", "object": {"text": "likely to increase significantly"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the oral administration of these drugs", "keywords": [{"text": "oral administration"}, {"text": "drugs"}]}, "sentence": " However, the oral administration of these drugs is likely to increase significantly over the next few years.", "action": {"verb": {"text": "increase", "tense": "future"}, "text": "to increase", "normalized": "to increase"}}, {"subject": {"text": "Dominance", "keywords": [{"text": "Dominance"}]}, "sentence": " Continued Dominance of North America in Global Peptide Therapeutics Market Geographically, the worldwide market for peptide therapeutics has been segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.", "action": {"verb": {"text": "Continued", "tense": "past"}, "text": "Continued", "normalized": "Continued"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America led the global market with a share of 38.8% in 2015 and is expected to maintain its dominance over the next few years.", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America led the global market with a share of 38.8% in 2015 and is expected to maintain its dominance over the next few years.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected to maintain", "normalized": "be expect to maintain"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America led the global market with a share of 38.8% in 2015 and is expected to maintain its dominance over the next few years.", "object": {"text": "its dominance", "keywords": [{"text": "dominance"}]}, "action": {"verb": {"text": "maintain", "tense": "future"}, "text": "is expected to maintain", "normalized": "be expect to maintain"}}, {"subject": {"text": "a highly potent drug", "keywords": [{"text": "highly potent drug"}]}, "sentence": " The advancements in the healthcare infrastructure and the advent of peptide therapeutics as a highly potent drug used in oncology and hormonal therapies are likely to boost the growth of the North America peptide therapeutics market in the near future.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "The advancements in the healthcare infrastructure and the advent of peptide therapeutics as a highly potent drug used in oncology and hormonal therapies", "keywords": [{"text": "highly potent drug"}, {"text": "peptide therapeutics"}, {"text": "hormonal therapies"}, {"text": "healthcare infrastructure"}]}, "sentence": " The advancements in the healthcare infrastructure and the advent of peptide therapeutics as a highly potent drug used in oncology and hormonal therapies are likely to boost the growth of the North America peptide therapeutics market in the near future.", "object": {"text": "the growth of the North America peptide therapeutics market", "keywords": [{"text": "America peptide therapeutics"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "to boost", "normalized": "to boost"}}, {"subject": {"text": "the presence of well-established players in the U.S.", "keywords": [{"text": "well-established players"}, {"text": "presence"}, {"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Apart from this, the presence of well-established players in the U.S. is also projected to support this regional market over the forthcoming years.", "action": {"verb": {"text": "project", "tense": "past"}, "text": "is also projected to support", "normalized": "be also project to support"}}, {"subject": {"text": "the presence of well-established players", "keywords": [{"text": "well-established players"}, {"text": "presence"}]}, "sentence": " Apart from this, the presence of well-established players in the U.S. is also projected to support this regional market over the forthcoming years.", "object": {"text": "this regional market", "keywords": [{"text": "regional market"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "is also projected to support", "normalized": "be also project to support"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe, which stood second in 2015, is also anticipated to witness healthy growth in the years to come.", "object": {"text": "second"}, "action": {"verb": {"text": "stand", "tense": "past"}, "text": "stood", "normalized": "stand"}}, {"subject": {"text": "Europe, which stood second in 2015,", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe, which stood second in 2015, is also anticipated to witness healthy growth in the years to come.", "object": {"text": "anticipated to witness healthy growth", "keywords": [{"text": "healthy growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Europe, which stood second in 2015,", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe, which stood second in 2015, is also anticipated to witness healthy growth in the years to come.", "object": {"text": "to witness healthy growth", "keywords": [{"text": "healthy growth"}]}, "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "is also anticipated", "normalized": "be also anticipate"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe, which stood second in 2015, is also anticipated to witness healthy growth in the years to come.", "object": {"text": "healthy growth", "keywords": [{"text": "healthy growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "to witness", "normalized": "to witness"}}, {"subject": {"text": "Request Brochure- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=418 The global peptide therapeutics market", "keywords": [{"text": "global peptide therapeutics"}, {"text": "Request Brochure"}, {"text": "market"}]}, "sentence": " Request Brochure- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=418 The global peptide therapeutics market is extremely consolidated in nature.", "object": {"text": "extremely consolidated in nature", "keywords": [{"text": "nature"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "At the forefront of this market", "keywords": [{"text": "forefront"}, {"text": "market"}], "entities": []}, "sentence": " At the forefront of this market are Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi, Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Co., Bachem Holding AG, and Amgen Inc.", "object": {"text": "Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi, Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Co., Bachem Holding AG, and Amgen Inc", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Bachem Holding AG"}, {"text": "F. Hoffmann-La Roche"}, {"text": "Pharmaceutical Co. Ltd."}], "entities": [{"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "GlaxoSmithKline Plc", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Roche Ltd."}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "Bachem Holding AG"}, {"type": "Company", "text": "Amgen Inc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Hoffmann\u2013La Roche", "relevance": 0.96638, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Route of administration", "relevance": 0.793728, "dbpedia_resource": "http://dbpedia.org/resource/Route_of_administration"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.756388, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Pharmaceutical industry", "relevance": 0.745316, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "United States", "relevance": 0.578528, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Pharmacology", "relevance": 0.510832, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Genentech", "relevance": 0.508896, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Central nervous system", "relevance": 0.497954, "dbpedia_resource": "http://dbpedia.org/resource/Central_nervous_system"}, {"text": "Medicine", "relevance": 0.48773, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Metabolism", "relevance": 0.484034, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "North America", "relevance": 0.483515, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Americas", "relevance": 0.466191, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Routes of administration", "relevance": 0.46482, "dbpedia_resource": "http://dbpedia.org/resource/Routes_of_administration"}, {"text": "Americas", "relevance": 0.448647, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Latin America", "relevance": 0.439717, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Hoffmann-La Roche", "relevance": 0.436568, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}, {"text": "Nervous system", "relevance": 0.428893, "dbpedia_resource": "http://dbpedia.org/resource/Nervous_system"}, {"text": "GlaxoSmithKline", "relevance": 0.426083, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Basel", "relevance": 0.424564, "dbpedia_resource": "http://dbpedia.org/resource/Basel"}, {"text": "Chugai Pharmaceutical Co.", "relevance": 0.419181, "dbpedia_resource": "http://dbpedia.org/resource/Chugai_Pharmaceutical_Co."}, {"text": "Protein", "relevance": 0.413999, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}, {"text": "Oncology", "relevance": 0.411737, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "InnoMed PredTox", "relevance": 0.411489, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}, {"text": "Pfizer", "relevance": 0.410308, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Peptide", "relevance": 0.408028, "dbpedia_resource": "http://dbpedia.org/resource/Peptide"}, {"text": "Novartis", "relevance": 0.39805, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Multinational companies", "relevance": 0.391779, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Parenteral", "relevance": 0.386384, "dbpedia_resource": "http://dbpedia.org/resource/Parenteral"}, {"text": "Peptide bond", "relevance": 0.385948, "dbpedia_resource": "http://dbpedia.org/resource/Peptide_bond"}, {"text": "Chemotherapy", "relevance": 0.382443, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "The Rising", "relevance": 0.378411, "dbpedia_resource": "http://dbpedia.org/resource/The_Rising"}, {"text": "Peptides", "relevance": 0.373034, "dbpedia_resource": "http://dbpedia.org/resource/Peptides"}, {"text": "2016", "relevance": 0.372513, "dbpedia_resource": "http://dbpedia.org/resource/2016"}, {"text": "Drugs", "relevance": 0.371899, "dbpedia_resource": "http://dbpedia.org/resource/Drugs"}], "categories": [{"score": 0.717844, "label": "/health and fitness"}, {"score": 0.411063, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.360263, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "hasAttribute", "sentence": "The major factors that are driving the growth of this market are the rising prevalence of metabolic disorders and the increasing pool of cancer patients.", "score": 0.853519, "arguments": [{"text": "patients", "location": [439, 447], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [432, 438], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "partOf", "sentence": "Cancer Treatment to Surface as Key Application Area of Peptide Therapeutics Based on the application, the global peptide therapeutics market is classified into cancer treatment, drugs for metabolic disorders, cardiovascular disease (CVD) therapeutics, respiratory disorder therapeutics, gastrointestinal tract (GIT) therapeutics, anti-infective drugs, dermatology therapeutics, central nervous systems (CNS) therapeutics, and renal therapeutics.", "score": 0.682787, "arguments": [{"text": "Key Application Area", "location": [1288, 1308], "entities": [{"type": "Organization", "text": "Key Application Area", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Peptide Therapeutics", "location": [1312, 1332], "entities": [{"type": "Organization", "text": "Peptide Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "With peptides evolving as a potential therapeutic agent for the treatment of cancer, the cancer segment emerged as the key contributor to this market in 2015.", "score": 0.669398, "arguments": [{"text": "agent", "location": [1753, 1758], "entities": [{"type": "Person", "text": "agent"}]}, {"text": "cancer", "location": [1780, 1786], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "hasAttribute", "sentence": "The rising mortality rate, caused by cancer, has led to an increased focus of players towards the development of new drugs and products to combat the situation, which is influencing the market substantially.", "score": 0.540039, "arguments": [{"text": "players", "location": [1940, 1947], "entities": [{"type": "Person", "text": "players"}]}, {"text": "cancer", "location": [1899, 1905], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "locatedAt", "sentence": "Continued Dominance of North America in Global Peptide Therapeutics Market Geographically, the worldwide market for peptide therapeutics has been segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.", "score": 0.70307, "arguments": [{"text": "Asia", "location": [2927, 2931], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2932, 2939], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Apart from this, the presence of well-established players in the U.S. is also projected to support this regional market over the forthcoming years.", "score": 0.401246, "arguments": [{"text": "players", "location": [3424, 3431], "entities": [{"type": "Person", "text": "players"}]}, {"text": "U.S.", "location": [3439, 3443], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "peptide therapeutics", "sentiment": {"score": 0.157329, "label": "positive"}, "relevance": 0.917016}, {"text": "peptide therapeutics market", "sentiment": {"score": 0.221373, "label": "positive"}, "relevance": 0.719983}, {"text": "global peptide therapeutics", "sentiment": {"score": -0.629511, "label": "negative"}, "relevance": 0.571816}, {"text": "America peptide therapeutics", "sentiment": {"score": 0.850884, "label": "positive"}, "relevance": 0.288884}, {"text": "peptide drugs", "sentiment": {"score": 0.26197, "label": "positive"}, "relevance": 0.287437}, {"text": "Therapeutics Market Geographically", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.213993}, {"text": "respiratory disorder therapeutics", "sentiment": {"score": -0.521985, "label": "negative"}, "relevance": 0.206955}]}, "extracted_metadata": {"sha1": "6c71cdd71f6d9b52f38e0916c1b15baef9c32155", "filename": "1541694887921.zip-d9027aa6abddd6a05d5ba1e528dce172.xml", "file_type": "json"}, "external_links": ["https://www.transparencymarketresearch.com/peptide-therapeutics-market.html", "https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=418", "https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418"], "title": "Peptide Therapeutics Market to Expand at a CAGR of 9.10% During 2016-2024", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "Qh92sEN-BhMxvyZlFokfNoSG1Tlb9OeVKVA6PJFhhxNi2S-37rKN3lFEojekRshv", "result_metadata": {"score": 33.270653}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.911637, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Biggest Emerging Market", "keywords": [{"text": "Biggest Emerging Market"}]}, "sentence": "Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027", "action": {"verb": {"text": "Be", "tense": "future"}, "text": "Be", "normalized": "Be"}}], "concepts": [{"text": "Inflammation", "relevance": 0.895888, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Anti-inflammatory", "relevance": 0.857806, "dbpedia_resource": "http://dbpedia.org/resource/Anti-inflammatory"}], "categories": [{"score": 0.559962, "label": "/health and fitness/disease"}, {"score": 0.479825, "label": "/finance/investing/day trading"}, {"score": 0.46002, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Inflammatory Diseases", "sentiment": {"score": -0.911637, "label": "negative"}, "relevance": 0.940519}, {"text": "Market", "sentiment": {"score": -0.911637, "label": "negative"}, "relevance": 0.599905}]}, "crawl_date": "2018-11-09T01:36:27Z", "url": "http://www.sbwire.com/press-releases/inflammatory-diseases-expected-to-be-biggest-emerging-market-by-2027-1082245.htm", "host": "sbwire.com", "text": "Other emerging competitors like Enlivex Therapeutics Ltd., Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma Corporation, Neovacs, Prometheus Laboratories, Sandoz, and Takeda Pharmaceuticals are developing drug pipeline and launch of new products as key strategies.", "main_image_url": "http://media.releasewire.com/photos/show/?id=79336", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T01:29:00Z", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.661931, "label": "negative"}, "text": "Inflammation", "relevance": 0.830426, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}, {"count": 3, "sentiment": {"score": -0.710025, "label": "negative"}, "text": "degenerative disease", "relevance": 0.701447, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Degenerative disease", "dbpedia_resource": "http://dbpedia.org/resource/Degenerative_disease"}}, {"count": 2, "sentiment": {"score": -0.785393, "label": "negative"}, "text": "bone disease", "relevance": 0.657088, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Bone disease", "dbpedia_resource": "http://dbpedia.org/resource/Bone_disease"}}, {"count": 2, "sentiment": {"score": -0.781777, "label": "negative"}, "text": "bowel disease", "relevance": 0.590553, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.889603, "label": "negative"}, "text": "Heart disease", "relevance": 0.586885, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}, {"count": 4, "sentiment": {"score": -0.898084, "label": "negative"}, "text": "asthma", "relevance": 0.527078, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}, {"count": 3, "sentiment": {"score": -0.711492, "label": "negative"}, "text": "Psoriasis", "relevance": 0.450775, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Psoriasis", "dbpedia_resource": "http://dbpedia.org/resource/Psoriasis"}}, {"count": 1, "sentiment": {"score": -0.917413, "label": "negative"}, "text": "ulcerative disease", "relevance": 0.407092, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.285138, "label": "positive"}, "text": "Valley Cottage", "relevance": 0.400156, "type": "Facility", "disambiguation": {"subtype": [], "name": "Valley Cottage (Georgetown, Maryland)", "dbpedia_resource": "http://dbpedia.org/resource/Valley_Cottage_(Georgetown,_Maryland)"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.385256, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.941193, "label": "negative"}, "text": "psoriatic arthritis", "relevance": 0.383417, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Psoriatic arthritis", "dbpedia_resource": "http://dbpedia.org/resource/Psoriatic_arthritis"}}, {"count": 1, "sentiment": {"score": -0.517817, "label": "negative"}, "text": "NY", "relevance": 0.376136, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.340728, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 2, "sentiment": {"score": -0.611368, "label": "negative"}, "text": "Asia Pacific", "relevance": 0.339705, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.611368, "label": "negative"}, "text": "Latin America", "relevance": 0.331949, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": -0.329352, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.328435, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.90288, "label": "negative"}, "text": "North Amrica", "relevance": 0.32326, "type": "GeographicFeature"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi", "relevance": 0.319979, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": -0.605789, "label": "negative"}, "text": "COPD", "relevance": 0.318243, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}, {"count": 1, "sentiment": {"score": -0.733129, "label": "negative"}, "text": "AstraZeneca", "relevance": 0.317275, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": -0.255979, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.313685, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.309385, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": -0.697242, "label": "negative"}, "text": "cardiomyopathy", "relevance": 0.299199, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Enlivex Therapeutics Ltd.", "relevance": 0.296235, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.917413, "label": "negative"}, "text": "crohn", "relevance": 0.294945, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Crohn's disease", "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilead Sciences", "relevance": 0.292677, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Gilead Sciences", "dbpedia_resource": "http://dbpedia.org/resource/Gilead_Sciences"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East Africa", "relevance": 0.282068, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mitsubishi Tanabe Pharma Corporation", "relevance": 0.279727, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.276192, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sandoz", "relevance": 0.269735, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.258983, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prometheus Laboratories", "relevance": 0.252826, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2027", "relevance": 0.252826, "type": "Quantity"}], "sentiment": {"document": {"score": -0.794513, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "RSS Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027 Future Market Insights", "keywords": [{"text": "Inflammatory Diseases Expected"}, {"text": "Future Market Insights"}, {"text": "RSS"}]}, "sentence": "RSS Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027 Future Market Insights has announced the addition of the \u201cInflammatory Diseases Market: Global Industry Analysis and Opportunity Assessment 2017-2027 \" report to their offering.", "object": {"text": "announced the addition of the \u201cInflammatory Diseases Market: Global Industry Analysis and Opportunity Assessment 2017-2027 \" report to their offering", "keywords": [{"text": "Inflammatory Diseases Market"}, {"text": "Global Industry Analysis"}, {"text": "Opportunity Assessment"}, {"text": "addition"}], "entities": [{"type": "Quantity", "text": "2027 \""}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "RSS Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027 Future Market Insights", "keywords": [{"text": "Inflammatory Diseases Expected"}, {"text": "Future Market Insights"}, {"text": "RSS"}]}, "sentence": "RSS Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027 Future Market Insights has announced the addition of the \u201cInflammatory Diseases Market: Global Industry Analysis and Opportunity Assessment 2017-2027 \" report to their offering.", "object": {"text": "the addition of the \u201cInflammatory Diseases Market: Global Industry Analysis and Opportunity Assessment 2017-2027 \" report to their offering", "keywords": [{"text": "Inflammatory Diseases Market"}, {"text": "Global Industry Analysis"}, {"text": "Opportunity Assessment"}, {"text": "addition"}], "entities": [{"type": "Quantity", "text": "2027 \""}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "has announced", "normalized": "have announce"}}, {"subject": {"text": "Valley Cottage, NY A new understanding of inflammatory diseases", "keywords": [{"text": "Valley Cottage"}, {"text": "inflammatory diseases"}, {"text": "new understanding"}, {"text": "NY"}], "entities": [{"type": "Facility", "text": "Valley Cottage", "disambiguation": {"subtype": [], "name": "Valley Cottage (Georgetown, Maryland)", "dbpedia_resource": "http://dbpedia.org/resource/Valley_Cottage_(Georgetown,_Maryland)"}}, {"type": "Location", "text": "NY", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}]}, "sentence": " Valley Cottage, NY A new understanding of inflammatory diseases has changed the drug development landscape for several major diseases that are affecting millions of people in the world.", "object": {"text": "changed the drug development landscape", "keywords": [{"text": "drug development landscape"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Valley Cottage, NY A new understanding of inflammatory diseases", "keywords": [{"text": "Valley Cottage"}, {"text": "inflammatory diseases"}, {"text": "new understanding"}, {"text": "NY"}], "entities": [{"type": "Facility", "text": "Valley Cottage", "disambiguation": {"subtype": [], "name": "Valley Cottage (Georgetown, Maryland)", "dbpedia_resource": "http://dbpedia.org/resource/Valley_Cottage_(Georgetown,_Maryland)"}}, {"type": "Location", "text": "NY", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}]}, "sentence": " Valley Cottage, NY A new understanding of inflammatory diseases has changed the drug development landscape for several major diseases that are affecting millions of people in the world.", "object": {"text": "the drug development landscape", "keywords": [{"text": "drug development landscape"}]}, "action": {"verb": {"text": "change", "tense": "past"}, "text": "has changed", "normalized": "have change"}}, {"subject": {"text": "several major diseases", "keywords": [{"text": "major diseases"}]}, "sentence": " Valley Cottage, NY A new understanding of inflammatory diseases has changed the drug development landscape for several major diseases that are affecting millions of people in the world.", "object": {"text": "millions of people", "keywords": [{"text": "millions"}, {"text": "people"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "are affecting", "normalized": "be affect"}}, {"subject": {"text": "Inflammation", "keywords": [{"text": "Inflammation"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}]}, "sentence": " Inflammation describes the primary response of the body that eliminates the cause of injury.", "object": {"text": "the primary response of the body that eliminates the cause of injury", "keywords": [{"text": "primary response"}, {"text": "cause"}, {"text": "body"}, {"text": "injury"}]}, "action": {"verb": {"text": "describe", "tense": "present"}, "text": "describes", "normalized": "describe"}}, {"subject": {"text": "the body", "keywords": [{"text": "body"}]}, "sentence": " Inflammation describes the primary response of the body that eliminates the cause of injury.", "object": {"text": "the cause of injury", "keywords": [{"text": "cause"}, {"text": "injury"}]}, "action": {"verb": {"text": "eliminate", "tense": "present"}, "text": "eliminates", "normalized": "eliminate"}}, {"subject": {"text": "body's defense mechanism", "keywords": [{"text": "defense mechanism"}, {"text": "body"}]}, "sentence": " Periodically, body's defense mechanism works inappropriately that leads to inflammation.", "object": {"text": "that leads to inflammation", "keywords": [{"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}]}, "action": {"verb": {"text": "work", "tense": "present"}, "text": "works", "normalized": "work"}}, {"subject": {"text": "inflammatory diseases", "keywords": [{"text": "inflammatory diseases"}]}, "sentence": " The discovery of drugs to treat inflammatory diseases related with immune system is driving the market towards growth.", "object": {"text": "with immune system", "entities": []}, "action": {"verb": {"text": "relate", "tense": "past"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "The discovery of drugs to treat inflammatory diseases related with immune system", "keywords": [{"text": "inflammatory diseases"}, {"text": "drugs"}, {"text": "discovery"}], "entities": []}, "sentence": " The discovery of drugs to treat inflammatory diseases related with immune system is driving the market towards growth.", "object": {"text": "driving the market towards growth", "keywords": [{"text": "market"}, {"text": "growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The discovery of drugs to treat inflammatory diseases related with immune system", "keywords": [{"text": "inflammatory diseases"}, {"text": "drugs"}, {"text": "discovery"}], "entities": []}, "sentence": " The discovery of drugs to treat inflammatory diseases related with immune system is driving the market towards growth.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "is driving", "normalized": "be drive"}}, {"subject": {"text": "Immune Mediated Inflammatory diseases", "keywords": [{"text": "Immune Mediated Inflammatory"}]}, "sentence": " Immune Mediated Inflammatory diseases represent a global threat in terms of quality of life, morbidity and mortality that leads to increasing opportunity to develop new treatments to conquer the inflammatory diseases and increase market share.", "object": {"text": "a global threat", "keywords": [{"text": "global threat"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represent", "normalized": "represent"}}, {"subject": {"text": "new treatments", "keywords": [{"text": "new treatments"}]}, "sentence": " Immune Mediated Inflammatory diseases represent a global threat in terms of quality of life, morbidity and mortality that leads to increasing opportunity to develop new treatments to conquer the inflammatory diseases and increase market share.", "object": {"text": "the inflammatory diseases", "keywords": [{"text": "inflammatory diseases"}]}, "action": {"verb": {"text": "conquer", "tense": "future"}, "text": "to conquer", "normalized": "to conquer"}}, {"subject": {"text": "On the top inflammatory diseases", "keywords": [{"text": "inflammatory diseases"}]}, "sentence": " On the top inflammatory diseases are most common in human beings.", "object": {"text": "most common in human beings", "keywords": [{"text": "human beings"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Increasing popularity of inflammatory diseases and treatment followed by anti-inflammatory drugs with lesser side effects", "keywords": [{"text": "anti-inflammatory drugs"}, {"text": "inflammatory diseases"}, {"text": "lesser side effects"}, {"text": "popularity"}]}, "sentence": " Increasing popularity of inflammatory diseases and treatment followed by anti-inflammatory drugs with lesser side effects is driving the global inflammatory diseases market.", "object": {"text": "driving the global inflammatory diseases market", "keywords": [{"text": "global inflammatory diseases"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Increasing popularity of inflammatory diseases and treatment followed by anti-inflammatory drugs with lesser side effects", "keywords": [{"text": "anti-inflammatory drugs"}, {"text": "inflammatory diseases"}, {"text": "lesser side effects"}, {"text": "popularity"}]}, "sentence": " Increasing popularity of inflammatory diseases and treatment followed by anti-inflammatory drugs with lesser side effects is driving the global inflammatory diseases market.", "object": {"text": "the global inflammatory diseases market", "keywords": [{"text": "global inflammatory diseases"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "is driving", "normalized": "be drive"}}, {"subject": {"text": "global inflammatory diseases market", "keywords": [{"text": "global inflammatory diseases"}, {"text": "market"}]}, "sentence": " Based on type of diseases, global inflammatory diseases market can be segmented into following Respiratory Diseases Based on type of drug class, global inflammatory diseases market can be segmented into following Anti-inflammatory Biologics Based on type of distribution channel, global inflammatory diseases market can be segmented into following Hospital pharmacy Drug stores Online pharmacy On the basis of type of disease global inflammatory diseases market is segmented into respiratory diseases, heart disease, multiple sclerosis, Psoriasis, inflammatory bowel disease, bone disease and others.", "object": {"text": "segmented into following Respiratory Diseases Based on type of drug class", "keywords": [{"text": "Respiratory Diseases"}, {"text": "drug class"}, {"text": "type"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "global inflammatory diseases market", "keywords": [{"text": "global inflammatory diseases"}, {"text": "market"}]}, "sentence": " Based on type of diseases, global inflammatory diseases market can be segmented into following Respiratory Diseases Based on type of drug class, global inflammatory diseases market can be segmented into following Anti-inflammatory Biologics Based on type of distribution channel, global inflammatory diseases market can be segmented into following Hospital pharmacy Drug stores Online pharmacy On the basis of type of disease global inflammatory diseases market is segmented into respiratory diseases, heart disease, multiple sclerosis, Psoriasis, inflammatory bowel disease, bone disease and others.", "object": {"text": "into following Respiratory Diseases Based", "keywords": [{"text": "Respiratory Diseases"}]}, "action": {"verb": {"text": "segment", "tense": "future"}, "text": "can be segmented", "normalized": "can be segment"}}, {"subject": {"text": "global inflammatory diseases market", "keywords": [{"text": "global inflammatory diseases"}, {"text": "market"}]}, "sentence": " Based on type of diseases, global inflammatory diseases market can be segmented into following Respiratory Diseases Based on type of drug class, global inflammatory diseases market can be segmented into following Anti-inflammatory Biologics Based on type of distribution channel, global inflammatory diseases market can be segmented into following Hospital pharmacy Drug stores Online pharmacy On the basis of type of disease global inflammatory diseases market is segmented into respiratory diseases, heart disease, multiple sclerosis, Psoriasis, inflammatory bowel disease, bone disease and others.", "action": {"verb": {"text": "segment", "tense": "future"}, "text": "can be segmented", "normalized": "can be segment"}}, {"subject": {"text": "Anti-inflammatory Biologics", "keywords": [{"text": "Anti-inflammatory Biologics"}]}, "sentence": " Based on type of diseases, global inflammatory diseases market can be segmented into following Respiratory Diseases Based on type of drug class, global inflammatory diseases market can be segmented into following Anti-inflammatory Biologics Based on type of distribution channel, global inflammatory diseases market can be segmented into following Hospital pharmacy Drug stores Online pharmacy On the basis of type of disease global inflammatory diseases market is segmented into respiratory diseases, heart disease, multiple sclerosis, Psoriasis, inflammatory bowel disease, bone disease and others.", "object": {"text": "on type of distribution channel", "keywords": [{"text": "distribution channel"}, {"text": "type"}]}, "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "global inflammatory diseases market", "keywords": [{"text": "global inflammatory diseases"}, {"text": "market"}]}, "sentence": " Based on type of diseases, global inflammatory diseases market can be segmented into following Respiratory Diseases Based on type of drug class, global inflammatory diseases market can be segmented into following Anti-inflammatory Biologics Based on type of distribution channel, global inflammatory diseases market can be segmented into following Hospital pharmacy Drug stores Online pharmacy On the basis of type of disease global inflammatory diseases market is segmented into respiratory diseases, heart disease, multiple sclerosis, Psoriasis, inflammatory bowel disease, bone disease and others.", "object": {"text": "into following Hospital pharmacy Drug stores Online pharmacy On the basis of type of disease global inflammatory diseases market is segmented into respiratory diseases, heart disease, multiple sclerosis, Psoriasis, inflammatory bowel disease, bone disease and others", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "pharmacy Drug stores"}, {"text": "global inflammatory diseases"}, {"text": "Online pharmacy"}], "entities": [{"type": "HealthCondition", "text": "degenerative disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Degenerative disease", "dbpedia_resource": "http://dbpedia.org/resource/Degenerative_disease"}}, {"type": "HealthCondition", "text": "Psoriasis", "disambiguation": {"subtype": ["Disease"], "name": "Psoriasis", "dbpedia_resource": "http://dbpedia.org/resource/Psoriasis"}}, {"type": "HealthCondition", "text": "bowel disease"}, {"type": "HealthCondition", "text": "bone disease", "disambiguation": {"subtype": ["Disease"], "name": "Bone disease", "dbpedia_resource": "http://dbpedia.org/resource/Bone_disease"}}]}, "action": {"verb": {"text": "segment", "tense": "future"}, "text": "can be segmented", "normalized": "can be segment"}}, {"subject": {"text": "Respiratory diseases", "keywords": [{"text": "Respiratory diseases"}]}, "sentence": " Respiratory diseases are further classified into asthma and chronic obstructive pulmonary disease, where asthma is a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD) is name for a group of lung conditions that causes due to smoking in adults that leads to breathing difficulties.", "object": {"text": "further classified into asthma", "keywords": [{"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Respiratory diseases", "keywords": [{"text": "Respiratory diseases"}]}, "sentence": " Respiratory diseases are further classified into asthma and chronic obstructive pulmonary disease, where asthma is a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD) is name for a group of lung conditions that causes due to smoking in adults that leads to breathing difficulties.", "object": {"text": "into asthma", "keywords": [{"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "are further classified", "normalized": "be further classify"}}, {"subject": {"text": "asthma", "keywords": [{"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "sentence": " Respiratory diseases are further classified into asthma and chronic obstructive pulmonary disease, where asthma is a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD) is name for a group of lung conditions that causes due to smoking in adults that leads to breathing difficulties.", "object": {"text": "a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD", "keywords": [{"text": "obstructive pulmonary disease"}, {"text": "extra mucus"}, {"text": "COPD"}, {"text": "airways"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}, {"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD)", "keywords": [{"text": "obstructive pulmonary disease"}, {"text": "extra mucus"}, {"text": "COPD"}, {"text": "airways"}], "entities": [{"type": "HealthCondition", "text": "COPD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Chronic obstructive pulmonary disease", "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}}]}, "sentence": " Respiratory diseases are further classified into asthma and chronic obstructive pulmonary disease, where asthma is a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD) is name for a group of lung conditions that causes due to smoking in adults that leads to breathing difficulties.", "object": {"text": "name"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Heart disease or heart disorders", "keywords": [{"text": "Heart disease"}, {"text": "heart disorders"}], "entities": [{"type": "HealthCondition", "text": "Heart disease", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " Heart disease or heart disorders are conditions in that heart stops functioning, there are several types of heart diseases like arrhythmias heart disease, atherosclerotic and cardiomyopathy.", "object": {"text": "conditions", "keywords": [{"text": "conditions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "heart", "keywords": [{"text": "heart"}]}, "sentence": " Heart disease or heart disorders are conditions in that heart stops functioning, there are several types of heart diseases like arrhythmias heart disease, atherosclerotic and cardiomyopathy.", "object": {"text": "functioning"}, "action": {"verb": {"text": "stop", "tense": "present"}, "text": "stops", "normalized": "stop"}}, {"subject": {"text": "Multiple sclerosis", "keywords": [{"text": "Multiple sclerosis"}], "entities": [{"type": "HealthCondition", "text": "degenerative disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Degenerative disease", "dbpedia_resource": "http://dbpedia.org/resource/Degenerative_disease"}}]}, "sentence": " Multiple sclerosis is a degenerative disease that attack central nervous system and disrupts the flow of information within the brain.", "object": {"text": "a degenerative disease", "keywords": [{"text": "degenerative disease"}], "entities": [{"type": "HealthCondition", "text": "degenerative disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Degenerative disease", "dbpedia_resource": "http://dbpedia.org/resource/Degenerative_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a degenerative disease", "keywords": [{"text": "degenerative disease"}], "entities": [{"type": "HealthCondition", "text": "degenerative disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Degenerative disease", "dbpedia_resource": "http://dbpedia.org/resource/Degenerative_disease"}}]}, "sentence": " Multiple sclerosis is a degenerative disease that attack central nervous system and disrupts the flow of information within the brain.", "object": {"text": "central nervous system", "entities": []}, "action": {"verb": {"text": "attack", "tense": "present"}, "text": "attack", "normalized": "attack"}}, {"subject": {"text": "a degenerative disease", "keywords": [{"text": "degenerative disease"}], "entities": [{"type": "HealthCondition", "text": "degenerative disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Degenerative disease", "dbpedia_resource": "http://dbpedia.org/resource/Degenerative_disease"}}]}, "sentence": " Multiple sclerosis is a degenerative disease that attack central nervous system and disrupts the flow of information within the brain.", "object": {"text": "the flow of information", "keywords": [{"text": "flow"}, {"text": "information"}]}, "action": {"verb": {"text": "disrupt", "tense": "present"}, "text": "disrupts", "normalized": "disrupt"}}, {"subject": {"text": "Psoriasis", "keywords": [{"text": "Psoriasis"}], "entities": [{"type": "HealthCondition", "text": "Psoriasis", "disambiguation": {"subtype": ["Disease"], "name": "Psoriasis", "dbpedia_resource": "http://dbpedia.org/resource/Psoriasis"}}]}, "sentence": " Psoriasis is systemic inflammation that causes red and flaky plaques with joint pain of psoriatic arthritis.", "object": {"text": "systemic inflammation", "keywords": [{"text": "systemic inflammation"}], "entities": [{"type": "HealthCondition", "text": "Psoriasis", "disambiguation": {"subtype": ["Disease"], "name": "Psoriasis", "dbpedia_resource": "http://dbpedia.org/resource/Psoriasis"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "systemic inflammation", "keywords": [{"text": "systemic inflammation"}], "entities": [{"type": "HealthCondition", "text": "Psoriasis", "disambiguation": {"subtype": ["Disease"], "name": "Psoriasis", "dbpedia_resource": "http://dbpedia.org/resource/Psoriasis"}}]}, "sentence": " Psoriasis is systemic inflammation that causes red and flaky plaques with joint pain of psoriatic arthritis.", "object": {"text": "red and flaky plaques with joint pain of psoriatic arthritis", "keywords": [{"text": "psoriatic arthritis"}, {"text": "flaky plaques"}, {"text": "joint pain"}], "entities": [{"type": "HealthCondition", "text": "psoriatic arthritis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Psoriatic arthritis", "dbpedia_resource": "http://dbpedia.org/resource/Psoriatic_arthritis"}}]}, "action": {"verb": {"text": "cause", "tense": "present"}, "text": "causes", "normalized": "cause"}}, {"subject": {"text": "inflammation related with gastro intestinal tract, includes to most common diseases of gastro intestinal tract that are crohn's disease and ulcerative disease", "keywords": [{"text": "gastro intestinal tract"}, {"text": "ulcerative disease"}, {"text": "common diseases"}, {"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}, {"type": "HealthCondition", "text": "crohn", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Crohn's disease", "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}}, {"type": "HealthCondition", "text": "ulcerative disease"}]}, "sentence": " Inflammatory bowel disease involves inflammation related with gastro intestinal tract, includes to most common diseases of gastro intestinal tract that are crohn's disease and ulcerative disease.", "object": {"text": "Inflammatory bowel disease", "keywords": [{"text": "Inflammatory bowel disease"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involves", "normalized": "involve"}}, {"subject": {"text": "inflammation", "keywords": [{"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}]}, "sentence": " Inflammatory bowel disease involves inflammation related with gastro intestinal tract, includes to most common diseases of gastro intestinal tract that are crohn's disease and ulcerative disease.", "object": {"text": "with gastro intestinal tract", "keywords": [{"text": "gastro intestinal tract"}]}, "action": {"verb": {"text": "relate", "tense": "past"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "to most common diseases of gastro intestinal tract that are crohn's disease and ulcerative disease", "keywords": [{"text": "gastro intestinal tract"}, {"text": "ulcerative disease"}, {"text": "common diseases"}, {"text": "crohn"}], "entities": [{"type": "HealthCondition", "text": "crohn", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Crohn's disease", "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}}, {"type": "HealthCondition", "text": "ulcerative disease"}]}, "sentence": " Inflammatory bowel disease involves inflammation related with gastro intestinal tract, includes to most common diseases of gastro intestinal tract that are crohn's disease and ulcerative disease.", "object": {"text": "inflammation related with gastro intestinal tract", "keywords": [{"text": "gastro intestinal tract"}, {"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "most common diseases of gastro intestinal tract that", "keywords": [{"text": "gastro intestinal tract"}, {"text": "common diseases"}]}, "sentence": " Inflammatory bowel disease involves inflammation related with gastro intestinal tract, includes to most common diseases of gastro intestinal tract that are crohn's disease and ulcerative disease.", "object": {"text": "crohn's disease and ulcerative disease", "keywords": [{"text": "ulcerative disease"}, {"text": "crohn"}], "entities": [{"type": "HealthCondition", "text": "crohn", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Crohn's disease", "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}}, {"type": "HealthCondition", "text": "ulcerative disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "rheumatoid arthritis and osteoarthritis", "keywords": [{"text": "rheumatoid arthritis"}, {"text": "osteoarthritis"}]}, "sentence": " Bone disease mostly includes rheumatoid arthritis and osteoarthritis.", "object": {"text": "Bone disease", "keywords": [{"text": "Bone disease"}], "entities": [{"type": "HealthCondition", "text": "bone disease", "disambiguation": {"subtype": ["Disease"], "name": "Bone disease", "dbpedia_resource": "http://dbpedia.org/resource/Bone_disease"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "drug class", "keywords": [{"text": "drug class"}]}, "sentence": " Moreover, on the basis of drug class used in treatment of inflammatory diseases global inflammatory diseases market is segmented into non-steroidal anti-inflammatory drugs, anti-inflammatory biologics and corticosteroids.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "the basis of drug class used in treatment of inflammatory diseases global inflammatory diseases market", "keywords": [{"text": "global inflammatory diseases"}, {"text": "drug class"}, {"text": "basis"}, {"text": "treatment"}]}, "sentence": " Moreover, on the basis of drug class used in treatment of inflammatory diseases global inflammatory diseases market is segmented into non-steroidal anti-inflammatory drugs, anti-inflammatory biologics and corticosteroids.", "object": {"text": "segmented into non-steroidal anti-inflammatory drugs, anti-inflammatory biologics and corticosteroids", "keywords": [{"text": "non-steroidal anti-inflammatory drugs"}, {"text": "anti-inflammatory biologics"}, {"text": "corticosteroids"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Non-steroidal anti-inflammatory drugs", "keywords": [{"text": "Non-steroidal anti-inflammatory drugs"}]}, "sentence": " Non-steroidal anti-inflammatory drugs bound the production of hormones in the body such as prostaglandins that is responsible for inflammation.", "object": {"text": "the production of hormones in the body such as prostaglandins that is responsible for inflammation", "keywords": [{"text": "prostaglandins"}, {"text": "hormones"}, {"text": "inflammation"}, {"text": "production"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}]}, "action": {"verb": {"text": "bind", "tense": "present"}, "text": "bound", "normalized": "bind"}}, {"subject": {"text": "hormones in the body such as prostaglandins", "keywords": [{"text": "prostaglandins"}, {"text": "hormones"}, {"text": "body"}]}, "sentence": " Non-steroidal anti-inflammatory drugs bound the production of hormones in the body such as prostaglandins that is responsible for inflammation.", "object": {"text": "responsible for inflammation", "keywords": [{"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Anti-inflammatory biologics", "keywords": [{"text": "Anti-inflammatory biologics"}]}, "sentence": " Anti-inflammatory biologics are mostly used in treatment of arthritis indications in rheumatoid arthritis and osteoarthritis that is one of the revenue generating segment followed by respiratory diseases like asthma and chronic obstructive pulmonary disease.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "are mostly used", "normalized": "be mostly use"}}, {"subject": {"text": "osteoarthritis", "keywords": [{"text": "osteoarthritis"}]}, "sentence": " Anti-inflammatory biologics are mostly used in treatment of arthritis indications in rheumatoid arthritis and osteoarthritis that is one of the revenue generating segment followed by respiratory diseases like asthma and chronic obstructive pulmonary disease.", "object": {"text": "one of the revenue generating segment followed by respiratory diseases like asthma and chronic obstructive pulmonary disease", "keywords": [{"text": "revenue generating segment"}, {"text": "obstructive pulmonary disease"}, {"text": "respiratory diseases"}, {"text": "asthma"}], "entities": [{"type": "HealthCondition", "text": "asthma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Asthma", "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "On the basis of distribution channel global inflammatory disease market", "keywords": [{"text": "global inflammatory disease"}, {"text": "distribution channel"}, {"text": "basis"}, {"text": "market"}], "entities": [{"type": "HealthCondition", "text": "Inflammation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Inflammation", "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}}]}, "sentence": " On the basis of distribution channel global inflammatory disease market is segmented into hospital pharmacy, retail pharmacy, drug stores and online pharmacy.", "object": {"text": "segmented into hospital pharmacy, retail pharmacy, drug stores and online pharmacy", "keywords": [{"text": "hospital pharmacy"}, {"text": "retail pharmacy"}, {"text": "online pharmacy"}, {"text": "drug stores"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "global inflammatory market", "keywords": [{"text": "global inflammatory market"}]}, "sentence": " Geographically, global inflammatory market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East Africa.", "object": {"text": "segmented into five key regions", "keywords": [{"text": "key regions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "global inflammatory market", "keywords": [{"text": "global inflammatory market"}]}, "sentence": " Geographically, global inflammatory market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East Africa.", "object": {"text": "into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East Africa", "keywords": [{"text": "Middle East Africa"}, {"text": "key regions"}, {"text": "Asia Pacific"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East Africa", "disambiguation": {"subtype": ["Region"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "North Amrica", "keywords": [{"text": "North Amrica"}], "entities": [{"type": "GeographicFeature", "text": "North Amrica"}]}, "sentence": " North Amrica is dominating in inflammatory diseases market as there is demand for branded medicines over the generic medicines.", "object": {"text": "dominating in inflammatory diseases market", "keywords": [{"text": "inflammatory diseases"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "North Amrica", "keywords": [{"text": "North Amrica"}], "entities": [{"type": "GeographicFeature", "text": "North Amrica"}]}, "sentence": " North Amrica is dominating in inflammatory diseases market as there is demand for branded medicines over the generic medicines.", "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "is dominating", "normalized": "be dominate"}}, {"subject": {"text": "Rising geriatric population", "keywords": [{"text": "geriatric population"}]}, "sentence": " Rising geriatric population is driving the inflammatory diseases market throughout the globe.", "object": {"text": "driving the inflammatory diseases market throughout the globe", "keywords": [{"text": "inflammatory diseases market"}, {"text": "globe"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Rising geriatric population", "keywords": [{"text": "geriatric population"}]}, "sentence": " Rising geriatric population is driving the inflammatory diseases market throughout the globe.", "object": {"text": "the inflammatory diseases market", "keywords": [{"text": "inflammatory diseases"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "is driving", "normalized": "be drive"}}], "concepts": [{"text": "Inflammation", "relevance": 0.950215, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Rheumatoid arthritis", "relevance": 0.707381, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatoid_arthritis"}, {"text": "Inflammatory bowel disease", "relevance": 0.61414, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Asthma", "relevance": 0.610236, "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}, {"text": "Anti-inflammatory", "relevance": 0.610223, "dbpedia_resource": "http://dbpedia.org/resource/Anti-inflammatory"}, {"text": "Immune system", "relevance": 0.600346, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Pharmacy", "relevance": 0.513138, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmacology", "relevance": 0.499877, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Arthritis", "relevance": 0.485722, "dbpedia_resource": "http://dbpedia.org/resource/Arthritis"}, {"text": "Diseases and disorders", "relevance": 0.475233, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Eicosanoid", "relevance": 0.455239, "dbpedia_resource": "http://dbpedia.org/resource/Eicosanoid"}, {"text": "Medicine", "relevance": 0.43476, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Heart", "relevance": 0.430471, "dbpedia_resource": "http://dbpedia.org/resource/Heart"}, {"text": "Genetic disorder", "relevance": 0.423981, "dbpedia_resource": "http://dbpedia.org/resource/Genetic_disorder"}, {"text": "Infection", "relevance": 0.423845, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Pneumonia", "relevance": 0.420193, "dbpedia_resource": "http://dbpedia.org/resource/Pneumonia"}, {"text": "Gastroenterology", "relevance": 0.41988, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Pharmaceutical drug", "relevance": 0.406282, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Hypertension", "relevance": 0.390104, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Ulcerative colitis", "relevance": 0.379692, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Chronic obstructive pulmonary disease", "relevance": 0.363164, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease"}, {"text": "Non-steroidal anti-inflammatory drug", "relevance": 0.357477, "dbpedia_resource": "http://dbpedia.org/resource/Non-steroidal_anti-inflammatory_drug"}, {"text": "Osteoarthritis", "relevance": 0.350753, "dbpedia_resource": "http://dbpedia.org/resource/Osteoarthritis"}, {"text": "Crohn's disease", "relevance": 0.331713, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Heart disease", "relevance": 0.327337, "dbpedia_resource": "http://dbpedia.org/resource/Heart_disease"}, {"text": "Atherosclerosis", "relevance": 0.317722, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Infliximab", "relevance": 0.310057, "dbpedia_resource": "http://dbpedia.org/resource/Infliximab"}, {"text": "Blood vessel", "relevance": 0.30494, "dbpedia_resource": "http://dbpedia.org/resource/Blood_vessel"}, {"text": "Psoriatic arthritis", "relevance": 0.29497, "dbpedia_resource": "http://dbpedia.org/resource/Psoriatic_arthritis"}, {"text": "Prostaglandin", "relevance": 0.293886, "dbpedia_resource": "http://dbpedia.org/resource/Prostaglandin"}, {"text": "Ankylosing spondylitis", "relevance": 0.290343, "dbpedia_resource": "http://dbpedia.org/resource/Ankylosing_spondylitis"}, {"text": "Glucocorticoid", "relevance": 0.28749, "dbpedia_resource": "http://dbpedia.org/resource/Glucocorticoid"}, {"text": "Vasculitis", "relevance": 0.286686, "dbpedia_resource": "http://dbpedia.org/resource/Vasculitis"}, {"text": "Tumor necrosis factor-alpha", "relevance": 0.285806, "dbpedia_resource": "http://dbpedia.org/resource/Tumor_necrosis_factor-alpha"}, {"text": "Inflammations", "relevance": 0.285581, "dbpedia_resource": "http://dbpedia.org/resource/Inflammations"}, {"text": "Interleukin", "relevance": 0.284968, "dbpedia_resource": "http://dbpedia.org/resource/Interleukin"}, {"text": "Paracetamol", "relevance": 0.279965, "dbpedia_resource": "http://dbpedia.org/resource/Paracetamol"}, {"text": "Autoimmune diseases", "relevance": 0.277186, "dbpedia_resource": "http://dbpedia.org/resource/Autoimmune_diseases"}, {"text": "C-reactive protein", "relevance": 0.277055, "dbpedia_resource": "http://dbpedia.org/resource/C-reactive_protein"}, {"text": "Disease", "relevance": 0.27531, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Methotrexate", "relevance": 0.274937, "dbpedia_resource": "http://dbpedia.org/resource/Methotrexate"}, {"text": "Rheumatology", "relevance": 0.274835, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatology"}, {"text": "Lung", "relevance": 0.271423, "dbpedia_resource": "http://dbpedia.org/resource/Lung"}, {"text": "Interleukin 1", "relevance": 0.270194, "dbpedia_resource": "http://dbpedia.org/resource/Interleukin_1"}, {"text": "Pulmonology", "relevance": 0.269094, "dbpedia_resource": "http://dbpedia.org/resource/Pulmonology"}, {"text": "Naproxen", "relevance": 0.269, "dbpedia_resource": "http://dbpedia.org/resource/Naproxen"}, {"text": "Abscess", "relevance": 0.26878, "dbpedia_resource": "http://dbpedia.org/resource/Abscess"}, {"text": "Corticosteroid", "relevance": 0.266949, "dbpedia_resource": "http://dbpedia.org/resource/Corticosteroid"}, {"text": "Mucus", "relevance": 0.266292, "dbpedia_resource": "http://dbpedia.org/resource/Mucus"}, {"text": "Hypertrophic cardiomyopathy", "relevance": 0.26081, "dbpedia_resource": "http://dbpedia.org/resource/Hypertrophic_cardiomyopathy"}], "categories": [{"score": 0.73203, "label": "/health and fitness/disease"}, {"score": 0.604656, "label": "/health and fitness/disease/asthma"}, {"score": 0.193122, "label": "/health and fitness/disease/arthritis"}], "relations": [{"type": "partOf", "sentence": "RSS Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027 Future Market Insights has announced the addition of the \"Inflammatory Diseases Market: Global Industry Analysis and Opportunity Assessment 2017-2027 \" report to their offering.", "score": 0.401138, "arguments": [{"text": "Future Market Insights", "location": [73, 95], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "Biggest Emerging Market", "location": [41, 64], "entities": [{"type": "Organization", "text": "Biggest Emerging Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Respiratory diseases are further classified into asthma and chronic obstructive pulmonary disease, where asthma is a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD) is name for a group of lung conditions that causes due to smoking in adults that leads to breathing difficulties.", "score": 0.776279, "arguments": [{"text": "group", "location": [2174, 2179], "entities": [{"type": "Person", "text": "group"}]}, {"text": "lung conditions", "location": [2183, 2198], "entities": [{"type": "HealthCondition", "text": "chronic obstructive pulmonary disease"}]}]}, {"type": "hasAttribute", "sentence": "Bone disease mostly includes rheumatoid arthritis and osteoarthritis.", "score": 0.911488, "arguments": [{"text": "Bone", "location": [2905, 2909], "entities": [{"type": "Person", "text": "Bone"}]}, {"text": "rheumatoid arthritis", "location": [2934, 2954], "entities": [{"type": "HealthCondition", "text": "rheumatoid arthritis"}]}]}, {"type": "hasAttribute", "sentence": "Non-steroidal anti-inflammatory drugs bound the production of hormones in the body such as prostaglandins that is responsible for inflammation.", "score": 0.4638, "arguments": [{"text": "body", "location": [3275, 3279], "entities": [{"type": "Person", "text": "body"}]}, {"text": "inflammation", "location": [3327, 3339], "entities": [{"type": "HealthCondition", "text": "inflammation"}]}]}, {"type": "locatedAt", "sentence": "On the basis of distribution channel global inflammatory disease market is segmented into hospital pharmacy, retail pharmacy, drug stores and online pharmacy.", "score": 0.230814, "arguments": [{"text": "drug", "location": [3726, 3730], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "stores", "location": [3731, 3737], "entities": [{"type": "Organization", "text": "stores", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Geographically, global inflammatory market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East Africa.", "score": 0.497383, "arguments": [{"text": "regions", "location": [3829, 3836], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [3905, 3911], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Geographically, global inflammatory market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East Africa.", "score": 0.740877, "arguments": [{"text": "Asia", "location": [3876, 3880], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3881, 3888], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Followed by North America, Asia Pacific and Latin America has shown increasing market share in inflammatory diseases.", "score": 0.698157, "arguments": [{"text": "Asia", "location": [4162, 4166], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [4167, 4174], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "hasAttribute", "sentence": "Rising geriatric population is driving the inflammatory diseases market throughout the globe.", "score": 0.838012, "arguments": [{"text": "population", "location": [4058, 4068], "entities": [{"type": "Person", "text": "population"}]}, {"text": "inflammatory diseases", "location": [4084, 4105], "entities": [{"type": "HealthCondition", "text": "chronic obstructive pulmonary disease"}]}]}, {"type": "partOfMany", "sentence": "Some of the major players in global inflammatory diseases market are AstraZeneca, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb, F-Hoffmann-La-Roche, Eli Lilly and Sanofi.", "score": 0.909356, "arguments": [{"text": "Some", "location": [4253, 4257], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [4271, 4278], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "hasAttribute", "sentence": "Some of the major players in global inflammatory diseases market are AstraZeneca, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb, F-Hoffmann-La-Roche, Eli Lilly and Sanofi.", "score": 0.645568, "arguments": [{"text": "players", "location": [4271, 4278], "entities": [{"type": "Person", "text": "players"}]}, {"text": "inflammatory diseases", "location": [4289, 4310], "entities": [{"type": "HealthCondition", "text": "chronic obstructive pulmonary disease"}]}]}, {"type": "basedIn", "sentence": "Some of the major players in global inflammatory diseases market are AstraZeneca, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb, F-Hoffmann-La-Roche, Eli Lilly and Sanofi.", "score": 0.510316, "arguments": [{"text": "Roche", "location": [4401, 4406], "entities": [{"type": "Organization", "text": "Roche", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "La", "location": [4398, 4400], "entities": [{"type": "GeopoliticalEntity", "text": "La"}]}]}, {"type": "agentOf", "sentence": "RSS Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027 Future Market Insights has announced the addition of the \"Inflammatory Diseases Market: Global Industry Analysis and Opportunity Assessment 2017-2027 \" report to their offering.", "score": 0.639652, "arguments": [{"text": "Future Market Insights", "location": [73, 95], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "announced", "location": [100, 109], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Other emerging competitors like Enlivex Therapeutics Ltd., Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma Corporation, Neovacs, Prometheus Laboratories, Sandoz, and Takeda Pharmaceuticals are developing drug pipeline and launch of new products as key strategies.", "score": 0.375817, "arguments": [{"text": "competitors", "location": [4445, 4456], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Enlivex Therapeutics Ltd.", "location": [4462, 4487], "entities": [{"type": "Organization", "text": "Enlivex Therapeutics Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Other emerging competitors like Enlivex Therapeutics Ltd., Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma Corporation, Neovacs, Prometheus Laboratories, Sandoz, and Takeda Pharmaceuticals are developing drug pipeline and launch of new products as key strategies.", "score": 0.673534, "arguments": [{"text": "Gilead Sciences", "location": [4489, 4504], "entities": [{"type": "Organization", "text": "Gilead Sciences", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [4445, 4456], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Other emerging competitors like Enlivex Therapeutics Ltd., Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma Corporation, Neovacs, Prometheus Laboratories, Sandoz, and Takeda Pharmaceuticals are developing drug pipeline and launch of new products as key strategies.", "score": 0.801046, "arguments": [{"text": "Immune Pharmaceuticals", "location": [4506, 4528], "entities": [{"type": "Organization", "text": "Immune Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [4445, 4456], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Other emerging competitors like Enlivex Therapeutics Ltd., Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma Corporation, Neovacs, Prometheus Laboratories, Sandoz, and Takeda Pharmaceuticals are developing drug pipeline and launch of new products as key strategies.", "score": 0.550796, "arguments": [{"text": "Merck", "location": [4530, 4535], "entities": [{"type": "Organization", "text": "Merck & Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [4445, 4456], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Other emerging competitors like Enlivex Therapeutics Ltd., Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma Corporation, Neovacs, Prometheus Laboratories, Sandoz, and Takeda Pharmaceuticals are developing drug pipeline and launch of new products as key strategies.", "score": 0.53967, "arguments": [{"text": "Mitsubishi Tanabe Pharma Corporation", "location": [4537, 4573], "entities": [{"type": "Organization", "text": "Mitsubishi Tanabe Pharma Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [4445, 4456], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Other emerging competitors like Enlivex Therapeutics Ltd., Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma Corporation, Neovacs, Prometheus Laboratories, Sandoz, and Takeda Pharmaceuticals are developing drug pipeline and launch of new products as key strategies.", "score": 0.485929, "arguments": [{"text": "Neovacs", "location": [4575, 4582], "entities": [{"type": "Organization", "text": "Neovacs", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "competitors", "location": [4445, 4456], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "RSS Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027 Future Market Insights has announced the addition of the \"Inflammatory Diseases Market: Global Industry Analysis and Opportunity Assessment 2017-2027 \" report to their offering.", "score": 0.87003, "arguments": [{"text": "2017-2027", "location": [213, 222], "entities": [{"type": "Date", "text": "2017-2027"}]}, {"text": "report", "location": [225, 231], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "hasAttribute", "sentence": "Valley Cottage, NY A new understanding of inflammatory diseases has changed the drug development landscape for several major diseases that are affecting millions of people in the world.", "score": 0.440926, "arguments": [{"text": "people", "location": [416, 422], "entities": [{"type": "Person", "text": "people"}]}, {"text": "diseases", "location": [376, 384], "entities": [{"type": "HealthCondition", "text": "chronic obstructive pulmonary disease"}]}]}, {"type": "locatedAt", "sentence": "Valley Cottage, NY A new understanding of inflammatory diseases has changed the drug development landscape for several major diseases that are affecting millions of people in the world.", "score": 0.542913, "arguments": [{"text": "people", "location": [416, 422], "entities": [{"type": "Person", "text": "people"}]}, {"text": "world", "location": [430, 435], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "On the top inflammatory diseases are most common in human beings.", "score": 0.768843, "arguments": [{"text": "human beings", "location": [1109, 1121], "entities": [{"type": "Person", "text": "human beings"}]}, {"text": "inflammatory diseases", "location": [1068, 1089], "entities": [{"type": "HealthCondition", "text": "chronic obstructive pulmonary disease"}]}]}, {"type": "ownerOf", "sentence": "Based on type of diseases, global inflammatory diseases market can be segmented into following Respiratory Diseases Based on type of drug class, global inflammatory diseases market can be segmented into following Anti-inflammatory Biologics Based on type of distribution channel, global inflammatory diseases market can be segmented into following Hospital pharmacy Drug stores Online pharmacy On the basis of type of disease global inflammatory diseases market is segmented into respiratory diseases, heart disease, multiple sclerosis, Psoriasis, inflammatory bowel disease, bone disease and others.", "score": 0.562025, "arguments": [{"text": "Hospital pharmacy Drug", "location": [1645, 1667], "entities": [{"type": "Organization", "text": "Hospital pharmacy Drug", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "stores", "location": [1668, 1674], "entities": [{"type": "Organization", "text": "stores", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Respiratory diseases are further classified into asthma and chronic obstructive pulmonary disease, where asthma is a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD) is name for a group of lung conditions that causes due to smoking in adults that leads to breathing difficulties.", "score": 0.487938, "arguments": [{"text": "person", "location": [2035, 2041], "entities": [{"type": "Person", "text": "person"}]}, {"text": "chronic obstructive pulmonary disease", "location": [1958, 1995], "entities": [{"type": "HealthCondition", "text": "chronic obstructive pulmonary disease"}]}]}, {"type": "ownerOf", "sentence": "Respiratory diseases are further classified into asthma and chronic obstructive pulmonary disease, where asthma is a condition in that a person's airways become swollen, narrow and inflamed to produce extra mucus and chronic obstructive pulmonary disease (COPD) is name for a group of lung conditions that causes due to smoking in adults that leads to breathing difficulties.", "score": 0.644818, "arguments": [{"text": "person", "location": [2035, 2041], "entities": [{"type": "Person", "text": "person"}]}, {"text": "airways", "location": [2044, 2051], "entities": [{"type": "Facility", "text": "airways"}]}]}], "keywords": [{"text": "inflammatory diseases", "sentiment": {"score": -0.788377, "label": "negative"}, "relevance": 0.901587}, {"text": "inflammatory diseases market", "sentiment": {"score": -0.814388, "label": "negative"}, "relevance": 0.822278}, {"text": "global inflammatory diseases", "sentiment": {"score": -0.811958, "label": "negative"}, "relevance": 0.666716}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.781777, "label": "negative"}, "relevance": 0.459978}, {"text": "Inflammatory Diseases Expected", "sentiment": {"score": -0.833733, "label": "negative"}, "relevance": 0.441667}, {"text": "Mediated Inflammatory diseases", "sentiment": {"score": -0.824104, "label": "negative"}, "relevance": 0.421092}, {"text": "inflammatory disease market", "sentiment": {"score": -0.637257, "label": "negative"}, "relevance": 0.402217}, {"text": "global inflammatory market", "sentiment": {"score": -0.532231, "label": "negative"}, "relevance": 0.395767}, {"text": "obstructive pulmonary disease", "sentiment": {"score": -0.890422, "label": "negative"}, "relevance": 0.394067}, {"text": "respiratory diseases", "sentiment": {"score": -0.894453, "label": "negative"}, "relevance": 0.344963}, {"text": "non-steroidal anti-inflammatory drugs", "sentiment": {"score": -0.591369, "label": "negative"}, "relevance": 0.343606}, {"text": "anti-inflammatory biologics", "sentiment": {"score": -0.882483, "label": "negative"}, "relevance": 0.342729}, {"text": "gastro intestinal tract", "sentiment": {"score": -0.891148, "label": "negative"}, "relevance": 0.32547}, {"text": "heart disease", "sentiment": {"score": -0.786783, "label": "negative"}, "relevance": 0.299894}, {"text": "Future Market Insights", "sentiment": {"score": -0.833733, "label": "negative"}, "relevance": 0.29787}, {"text": "Global Industry Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.292383}, {"text": "arrhythmias heart disease", "sentiment": {"score": -0.860211, "label": "negative"}, "relevance": 0.289314}, {"text": "drug development landscape", "sentiment": {"score": -0.517817, "label": "negative"}, "relevance": 0.286}, {"text": "market share", "sentiment": {"score": -0.742602, "label": "negative"}, "relevance": 0.283105}, {"text": "Hospital pharmacy Drug", "sentiment": {"score": -0.847934, "label": "negative"}, "relevance": 0.281592}, {"text": "bone disease", "sentiment": {"score": -0.785393, "label": "negative"}, "relevance": 0.280081}, {"text": "rheumatoid arthritis", "sentiment": {"score": -0.901029, "label": "negative"}, "relevance": 0.276556}, {"text": "multiple sclerosis", "sentiment": {"score": -0.631401, "label": "negative"}, "relevance": 0.276161}, {"text": "online pharmacy", "sentiment": {"score": -0.847934, "label": "negative"}, "relevance": 0.274842}, {"text": "drug class", "sentiment": {"score": -0.741927, "label": "negative"}, "relevance": 0.274811}, {"text": "distribution channel", "sentiment": {"score": -0.729255, "label": "negative"}, "relevance": 0.274334}, {"text": "stores Online pharmacy", "sentiment": {"score": -0.847934, "label": "negative"}, "relevance": 0.273716}, {"text": "major diseases", "sentiment": {"score": -0.517817, "label": "negative"}, "relevance": 0.271752}, {"text": "drug stores", "sentiment": {"score": -0.847934, "label": "negative"}, "relevance": 0.271049}, {"text": "Tanabe Pharma Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26862}, {"text": "heart diseases", "sentiment": {"score": -0.860211, "label": "negative"}, "relevance": 0.266535}, {"text": "Enlivex Therapeutics Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265609}, {"text": "Middle East Africa", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265155}, {"text": "Asia Pacific", "sentiment": {"score": -0.611368, "label": "negative"}, "relevance": 0.264239}, {"text": "revenue generating segment", "sentiment": {"score": -0.943715, "label": "negative"}, "relevance": 0.263356}, {"text": "Latin America", "sentiment": {"score": -0.611368, "label": "negative"}, "relevance": 0.26287}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261824}, {"text": "common diseases", "sentiment": {"score": -0.917413, "label": "negative"}, "relevance": 0.261097}, {"text": "disease symptoms", "sentiment": {"score": -0.528881, "label": "negative"}, "relevance": 0.256944}, {"text": "degenerative disease", "sentiment": {"score": -0.867274, "label": "negative"}, "relevance": 0.252827}, {"text": "ulcerative disease", "sentiment": {"score": -0.917413, "label": "negative"}, "relevance": 0.25214}, {"text": "systemic inflammation", "sentiment": {"score": -0.941193, "label": "negative"}, "relevance": 0.251462}, {"text": "global threat", "sentiment": {"score": -0.824104, "label": "negative"}, "relevance": 0.249273}, {"text": "new understanding", "sentiment": {"score": -0.517817, "label": "negative"}, "relevance": 0.244425}, {"text": "Opportunity Assessment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.243859}, {"text": "psoriatic arthritis", "sentiment": {"score": -0.941193, "label": "negative"}, "relevance": 0.243718}, {"text": "primary response", "sentiment": {"score": -0.691197, "label": "negative"}, "relevance": 0.243529}, {"text": "Valley Cottage", "sentiment": {"score": 0.285138, "label": "positive"}, "relevance": 0.242419}, {"text": "heart disorders", "sentiment": {"score": -0.889603, "label": "negative"}, "relevance": 0.242054}, {"text": "new treatments", "sentiment": {"score": -0.873837, "label": "negative"}, "relevance": 0.240723}]}, "extracted_metadata": {"sha1": "cfb5e392b7f9240622dbb53e6d515ed410efa509", "filename": "1541727387530.zip-aaec9f793f70ea35bb16d451e5fb1f36.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/inflammatory-diseases-market", "http://www.releasewire.com/rss/"], "title": "Inflammatory Diseases Expected to Be Biggest Emerging Market by 2027", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "DEvbQ8coa1SlAThDM4jBjcRcUn0CDhYQHXGIPkleC9ZbKtPiFT0AepZSDpvGCaEp", "result_metadata": {"score": 33.122627}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.585018, "label": "/law, govt and politics/legal issues/legislation/family laws"}, {"score": 0.498138, "label": "/law, govt and politics/legal issues/legislation/health care laws"}], "relations": [{"type": "partOf", "sentence": "Legal&Gen Inv Mgmnt Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.526347, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [31, 68], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Legal&Gen Inv Mgmnt Form", "location": [0, 24], "entities": [{"type": "Organization", "text": "Legal&Gen Inv Mgmnt Form"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.906815}, {"text": "Legal&Gen Inv Mgmnt", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.635536}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.212021}, {"text": "Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.211192}]}, "crawl_date": "2018-11-08T15:48:42Z", "url": "https://www.moneyam.com/action/news/showArticle?id=6200437", "host": "moneyam.com", "text": "Legal & General Investment Management Ltd.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T15:32:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "General Investment Management Ltd.", "relevance": 0.734286, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.596937, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.401175, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.341232, "type": "JobTitle"}], "sentiment": {"document": {"score": -0.463081, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\"", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Investment management", "relevance": 0.90459, "dbpedia_resource": "http://dbpedia.org/resource/Investment_management"}, {"text": "Collective investment scheme", "relevance": 0.843328, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}], "categories": [{"score": 0.526208, "label": "/real estate/buying and selling homes"}, {"score": 0.486887, "label": "/finance/investing"}, {"score": 0.486887, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "General Investment Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.951796}, {"text": "Investment Management Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.951163}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.828046}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.766596}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.749148}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.723069}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.697343}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531044}, {"text": "vehicle companies", "sentiment": {"score": -0.502369, "label": "negative"}, "relevance": 0.522784}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50141}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487498}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486775}, {"text": "Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47469}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310809}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.297659}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.295088}, {"text": "nominee", "sentiment": {"score": -0.502369, "label": "negative"}, "relevance": 0.292807}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.287501}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.286831}, {"text": "Legal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.283277}, {"text": "discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280792}, {"text": "naming", "sentiment": {"score": -0.502369, "label": "negative"}, "relevance": 0.274998}, {"text": "controller", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.272438}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.258109}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25763}, {"text": "interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252087}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249134}, {"text": "trust", "sentiment": {"score": 0.575723, "label": "positive"}, "relevance": 0.24793}]}, "extracted_metadata": {"sha1": "b5354387d92e48495144bdad97078d09bee75bb1", "filename": "1541692122007.zip-fbe22d9331ee6322b46c5398bc6de3a8.xml", "file_type": "json"}, "title": "Legal&Gen Inv Mgmnt Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "MoneyAM News"}, {"id": "0TuQCe9Er-wK7danOzMbxUtVGqTZuil_XSzn3g4qiWcL9LiAseIBNESLERhp0VhP", "result_metadata": {"score": 32.822277}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.625457, "label": "negative"}, "text": "Pertussis", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}], "sentiment": {"document": {"score": -0.625457, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Bordetella pertussis", "relevance": 0.94772, "dbpedia_resource": "http://dbpedia.org/resource/Bordetella_pertussis"}], "categories": [{"score": 0.728365, "label": "/health and fitness/disease"}, {"score": 0.405283, "label": "/health and fitness/disease/epidemic"}], "relations": [], "keywords": [{"text": "Bordetella Pertussis Infections", "sentiment": {"score": -0.625457, "label": "negative"}, "relevance": 0.977929}, {"text": "Witness Widespread Expansion", "sentiment": {"score": -0.625457, "label": "negative"}, "relevance": 0.778683}]}, "crawl_date": "2018-11-08T17:08:05Z", "url": "http://www.sbwire.com/press-releases/bordetella-pertussis-infections-market-to-witness-widespread-expansion-by-2020-1079451.htm", "host": "sbwire.com", "text": "(Novartis AG), Panacea Biotec Limited, Sanofi and Takeda Pharmaceutical Company Limited.", "main_image_url": "http://media.releasewire.com/photos/show/?id=69214", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T17:03:00Z", "enriched_text": {"entities": [{"count": 19, "sentiment": {"score": -0.582876, "label": "negative"}, "text": "Pertussis", "relevance": 0.897898, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}, {"count": 3, "sentiment": {"score": -0.347256, "label": "negative"}, "text": "CDC", "relevance": 0.125579, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis Vaccines and Diagnostics", "relevance": 0.124178, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.648625, "label": "negative"}, "text": "respiratory tract", "relevance": 0.118628, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": -0.315525, "label": "negative"}, "text": "cough", "relevance": 0.115571, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom"], "name": "Cough", "dbpedia_resource": "http://dbpedia.org/resource/Cough"}}, {"count": 1, "sentiment": {"score": 0.430808, "label": "positive"}, "text": "World Health Organization", "relevance": 0.113229, "type": "Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.108621, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.102703, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": -0.536377, "label": "negative"}, "text": "U.S.", "relevance": 0.0969931, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0967657, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Media Relations Contact", "relevance": 0.0948055, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.0906885, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.0878696, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prevenar", "relevance": 0.0875047, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prevnar", "relevance": 0.0865255, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Panacea Biotec Limited", "relevance": 0.0843436, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi", "relevance": 0.0843069, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "V419", "relevance": 0.0830534, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RotaTeq", "relevance": 0.0829883, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.081695, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LG Life Sciences, Ltd.", "relevance": 0.0784934, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.238377, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.077554, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "95%", "relevance": 0.077554, "type": "Quantity"}], "sentiment": {"document": {"score": -0.543591, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Pertussis", "keywords": [{"text": "Pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Pertussis, commonly known as whooping cough is caused due to a coccobacillus, aerobic, non motile, gram-negative bacteria called Bordetella pertussis.", "object": {"text": "as whooping cough", "keywords": [{"text": "whooping cough"}], "entities": [{"type": "HealthCondition", "text": "cough", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom"], "name": "Cough", "dbpedia_resource": "http://dbpedia.org/resource/Cough"}}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "commonly known", "normalized": "commonly know"}}, {"subject": {"text": "a coccobacillus, aerobic, non motile, gram-negative bacteria", "keywords": [{"text": "non motile"}, {"text": "gram-negative bacteria"}, {"text": "coccobacillus"}]}, "sentence": " Pertussis, commonly known as whooping cough is caused due to a coccobacillus, aerobic, non motile, gram-negative bacteria called Bordetella pertussis.", "object": {"text": "Bordetella pertussis", "keywords": [{"text": "Bordetella pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "call", "tense": "past"}, "text": "called", "normalized": "call"}}, {"subject": {"text": "filamentous hemagglutinin, pertussis toxin, fimbria, pertactin and tracheal cytotoxin", "keywords": [{"text": "pertussis toxin"}, {"text": "filamentous hemagglutinin"}, {"text": "tracheal cytotoxin"}, {"text": "fimbria"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " The virulence factors of B. pertussis include filamentous hemagglutinin, pertussis toxin, fimbria, pertactin and tracheal cytotoxin.", "object": {"text": "B. pertussis", "keywords": [{"text": "B. pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "These bacteria", "keywords": [{"text": "bacteria"}]}, "sentence": " These bacteria get transmitted to susceptible individuals from respiratory droplets of infected ones, as they mainly attack the mucosal layers of the respiratory tract.", "object": {"text": "transmitted to susceptible individuals from respiratory droplets of infected ones", "keywords": [{"text": "respiratory droplets"}, {"text": "infected ones"}, {"text": "susceptible individuals"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "they"}, "sentence": " These bacteria get transmitted to susceptible individuals from respiratory droplets of infected ones, as they mainly attack the mucosal layers of the respiratory tract.", "object": {"text": "the mucosal layers of the respiratory tract", "keywords": [{"text": "mucosal layers"}, {"text": "respiratory tract"}], "entities": [{"type": "Anatomy", "text": "respiratory tract"}]}, "action": {"verb": {"text": "attack", "tense": "present"}, "text": "mainly attack", "normalized": "mainly attack"}}, {"subject": {"text": "Pertussis", "keywords": [{"text": "Pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Pertussis can cause serious illnesses in children, newborns and even in adults, and can prove to be life threatening especially for newborns.", "object": {"text": "serious illnesses", "keywords": [{"text": "illnesses"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "can cause", "normalized": "can cause"}}, {"subject": {"text": "Immunization programs against pertussis", "keywords": [{"text": "Immunization programs"}, {"text": "pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Immunization programs against pertussis have been adopted in most of the countries of the world to protect their children against this disease.", "object": {"text": "adopted in most of the countries of the world", "keywords": [{"text": "countries"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Immunization programs against pertussis", "keywords": [{"text": "Immunization programs"}, {"text": "pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Immunization programs against pertussis have been adopted in most of the countries of the world to protect their children against this disease.", "action": {"verb": {"text": "adopt", "tense": "past"}, "text": "have been adopted", "normalized": "have be adopt"}}, {"subject": {"text": "their children", "keywords": [{"text": "children"}]}, "sentence": " Immunization programs against pertussis have been adopted in most of the countries of the world to protect their children against this disease.", "object": {"text": "against this disease", "keywords": [{"text": "disease"}]}, "action": {"verb": {"text": "protect", "tense": "future"}, "text": "to protect", "normalized": "to protect"}}, {"subject": {"text": "at present many pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}, {"text": "present"}], "entities": []}, "sentence": " However, at present many pharmaceutical companies have also concentrated their efforts in developing therapeutic drugs for effective management of this disease.", "object": {"text": "their efforts in developing therapeutic drugs for effective management of this disease", "keywords": [{"text": "therapeutic drugs"}, {"text": "effective management"}, {"text": "efforts"}, {"text": "disease"}]}, "action": {"verb": {"text": "concentrate", "tense": "past"}, "text": "have also concentrated", "normalized": "have also concentrate"}}, {"subject": {"text": "many pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " However, at present many pharmaceutical companies have also concentrated their efforts in developing therapeutic drugs for effective management of this disease.", "object": {"text": "therapeutic drugs", "keywords": [{"text": "therapeutic drugs"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "high prevalence of pertussis especially in low to medium income countries, high number of deaths among infants, increasing number of vaccination programs and rising demand for advanced therapeutics", "keywords": [{"text": "medium income countries"}, {"text": "high prevalence"}, {"text": "vaccination programs"}, {"text": "advanced therapeutics"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Some of the major driving factors for the growth of the Bordetella Pertussis Infections Market include high prevalence of pertussis especially in low to medium income countries, high number of deaths among infants, increasing number of vaccination programs and rising demand for advanced therapeutics.", "object": {"text": "Some of the major driving factors for the growth of the Bordetella Pertussis Infections Market", "keywords": [{"text": "Bordetella Pertussis Infections"}, {"text": "major driving factors"}, {"text": "growth"}, {"text": "Market"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "pertussis", "keywords": [{"text": "pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " According to the World Health Organization (WHO) estimates, around 16 million cases of pertussis were recorded worldwide in 2008, of which 95% cases were in developing nations.", "action": {"verb": {"text": "record", "tense": "past"}, "text": "were recorded", "normalized": "be record"}}, {"subject": {"text": "95% cases", "keywords": [{"text": "cases"}], "entities": [{"type": "Quantity", "text": "95"}]}, "sentence": " According to the World Health Organization (WHO) estimates, around 16 million cases of pertussis were recorded worldwide in 2008, of which 95% cases were in developing nations.", "object": {"text": "in developing nations", "keywords": [{"text": "nations"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " It was also estimated that it killed more than 195,000 children globally that year.", "object": {"text": "more than 195,000 children globally that year", "keywords": [{"text": "children"}]}, "action": {"verb": {"text": "kill", "tense": "past"}, "text": "killed", "normalized": "kill"}}, {"subject": {"text": "Infant immunization programs", "keywords": [{"text": "Infant immunization programs"}]}, "sentence": " Infant immunization programs that utilize different pertussis vaccines of listed quality have proven extremely successful in preventing pertussis in infants all over the world for several decades.", "object": {"text": "different pertussis vaccines of listed quality", "keywords": [{"text": "different pertussis vaccines"}, {"text": "listed quality"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "utilize", "tense": "present"}, "text": "utilize", "normalized": "utilize"}}, {"subject": {"text": "Infant immunization programs that utilize different pertussis vaccines of listed quality", "keywords": [{"text": "different pertussis vaccines"}, {"text": "Infant immunization programs"}, {"text": "listed quality"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Infant immunization programs that utilize different pertussis vaccines of listed quality have proven extremely successful in preventing pertussis in infants all over the world for several decades.", "object": {"text": "proven extremely successful in preventing pertussis in infants all over the world for several decades", "keywords": [{"text": "pertussis"}, {"text": "infants"}, {"text": "decades"}, {"text": "world"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Infant immunization programs that utilize different pertussis vaccines of listed quality", "keywords": [{"text": "different pertussis vaccines"}, {"text": "Infant immunization programs"}, {"text": "listed quality"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Infant immunization programs that utilize different pertussis vaccines of listed quality have proven extremely successful in preventing pertussis in infants all over the world for several decades.", "object": {"text": "extremely successful"}, "action": {"verb": {"text": "prove", "tense": "past"}, "text": "have proven", "normalized": "have prove"}}, {"subject": {"text": "Infant immunization programs that utilize different pertussis vaccines of listed quality", "keywords": [{"text": "different pertussis vaccines"}, {"text": "Infant immunization programs"}, {"text": "listed quality"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " Infant immunization programs that utilize different pertussis vaccines of listed quality have proven extremely successful in preventing pertussis in infants all over the world for several decades.", "object": {"text": "pertussis in infants all over the world", "keywords": [{"text": "pertussis"}, {"text": "infants"}, {"text": "world"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "prevent", "tense": "present"}, "text": "preventing", "normalized": "prevent"}}, {"subject": {"text": "many cases", "keywords": [{"text": "cases"}]}, "sentence": " Request to View Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However, according to Centers for Disease Control and Prevention (CDC), U.S., more than 48,000 cases of pertussis were reported only in the U.S. in 2012, where many cases also went undiagnosed and unreported.", "object": {"text": "undiagnosed and unreported"}, "action": {"verb": {"text": "go", "tense": "past"}, "text": "went", "normalized": "go"}}, {"subject": {"text": "the CDC", "keywords": [{"text": "CDC"}], "entities": [{"type": "Organization", "text": "CDC", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}]}, "sentence": " And, according to the CDC estimates it was concluded that this was the most number of pertussis cases that have been reported since 1995, when more than 62,000 pertussis cases were reported.", "object": {"text": "it was concluded that this was the most number of pertussis cases that have been reported since 1995, when more than 62,000 pertussis cases", "keywords": [{"text": "pertussis cases"}, {"text": "number"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}, {"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "estimate", "tense": "present"}, "text": "estimates", "normalized": "estimate"}}, {"subject": {"text": "it"}, "sentence": " And, according to the CDC estimates it was concluded that this was the most number of pertussis cases that have been reported since 1995, when more than 62,000 pertussis cases were reported.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was concluded", "normalized": "be conclude"}}, {"subject": {"text": "this"}, "sentence": " And, according to the CDC estimates it was concluded that this was the most number of pertussis cases that have been reported since 1995, when more than 62,000 pertussis cases were reported.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "pertussis cases", "keywords": [{"text": "pertussis cases"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "sentence": " And, according to the CDC estimates it was concluded that this was the most number of pertussis cases that have been reported since 1995, when more than 62,000 pertussis cases were reported.", "action": {"verb": {"text": "report", "tense": "past"}, "text": "have been reported", "normalized": "have be report"}}, {"subject": {"text": "rising awareness among people about the severity of the disease", "keywords": [{"text": "severity"}, {"text": "awareness"}, {"text": "people"}, {"text": "disease"}]}, "sentence": " Thus, rising awareness among people about the severity of the disease have caused increase in demand for advanced therapeutic drugs in the same category.", "object": {"text": "caused increase in demand for advanced therapeutic drugs in the same category", "keywords": [{"text": "advanced therapeutic drugs"}, {"text": "demand"}, {"text": "increase"}, {"text": "category"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "rising awareness among people about the severity of the disease", "keywords": [{"text": "severity"}, {"text": "awareness"}, {"text": "people"}, {"text": "disease"}]}, "sentence": " Thus, rising awareness among people about the severity of the disease have caused increase in demand for advanced therapeutic drugs in the same category.", "object": {"text": "increase in demand for advanced therapeutic drugs in the same category", "keywords": [{"text": "advanced therapeutic drugs"}, {"text": "demand"}, {"text": "category"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "have caused", "normalized": "have cause"}}, {"subject": {"text": "Several pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " Several pharmaceutical companies have range of molecules under clinical trials, which will soon be commercialized in the global market to give a boost to its future growth opportunities.", "object": {"text": "range of molecules", "keywords": [{"text": "molecules"}, {"text": "range"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "clinical trials", "keywords": [{"text": "clinical trials"}]}, "sentence": " Several pharmaceutical companies have range of molecules under clinical trials, which will soon be commercialized in the global market to give a boost to its future growth opportunities.", "object": {"text": "commercialized"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "molecules under clinical trials", "keywords": [{"text": "molecules"}, {"text": "clinical trials"}]}, "sentence": " Several pharmaceutical companies have range of molecules under clinical trials, which will soon be commercialized in the global market to give a boost to its future growth opportunities.", "action": {"verb": {"text": "commercialize", "tense": "future"}, "text": "commercialized", "normalized": "commercialize"}}, {"subject": {"text": "Some of the molecules", "keywords": [{"text": "molecules"}]}, "sentence": " Some of the molecules that are under different stages of clinical trials include, GSK2202083A + Prevenar 13 + Rotarix, V419 + Prevnar 13 + RotaTeq, TAK-361S, DtwP-HB-Hib and DTP-HepB-Polio-Hib among others.", "object": {"text": "under different stages of clinical trials", "keywords": [{"text": "different stages"}, {"text": "clinical trials"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "North America and Europe", "keywords": [{"text": "North America"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Among all the regions, North America and Europe are expected to dominate the global Bordetella pertussis infections market owing to the factors such as high demand for advanced therapeutic drugs for treating newly born babies along with high awareness, acceptability and affordability of the people in these regions.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "are expected to dominate", "normalized": "be expect to dominate"}}, {"subject": {"text": "North America and Europe", "keywords": [{"text": "North America"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Among all the regions, North America and Europe are expected to dominate the global Bordetella pertussis infections market owing to the factors such as high demand for advanced therapeutic drugs for treating newly born babies along with high awareness, acceptability and affordability of the people in these regions.", "object": {"text": "the global Bordetella pertussis infections market", "keywords": [{"text": "Bordetella pertussis infections"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "are expected to dominate", "normalized": "be expect to dominate"}}, {"subject": {"text": "to the factors such as high demand for advanced therapeutic drugs for treating newly born babies along with high awareness, acceptability and affordability of the people in these regions", "keywords": [{"text": "newly born babies"}, {"text": "advanced therapeutic drugs"}, {"text": "high demand"}, {"text": "high awareness"}]}, "sentence": " Among all the regions, North America and Europe are expected to dominate the global Bordetella pertussis infections market owing to the factors such as high demand for advanced therapeutic drugs for treating newly born babies along with high awareness, acceptability and affordability of the people in these regions.", "object": {"text": "Bordetella pertussis infections market", "keywords": [{"text": "Bordetella pertussis infections"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "owe", "tense": "present"}, "text": "owing", "normalized": "owe"}}, {"subject": {"text": "babies", "keywords": [{"text": "babies"}]}, "sentence": " Among all the regions, North America and Europe are expected to dominate the global Bordetella pertussis infections market owing to the factors such as high demand for advanced therapeutic drugs for treating newly born babies along with high awareness, acceptability and affordability of the people in these regions.", "action": {"verb": {"text": "bear", "tense": "past"}, "text": "born", "normalized": "bear"}}, {"subject": {"text": "Asia Pacific region", "keywords": [{"text": "Asia Pacific region"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " However, Asia Pacific region is expected to exhibit a rapid growth in this market in future due to factors like high prevalence of pertussis in the region along with increasing healthcare awareness and purchasing power of the population.", "object": {"text": "a rapid growth", "keywords": [{"text": "rapid growth"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "Most of the emerging economies of the world", "keywords": [{"text": "economies"}, {"text": "world"}]}, "sentence": " Most of the emerging economies of the world are located in this region and more than 95% cases of pertussis that have been reported globally are accounted by the developing regions of the world.", "object": {"text": "located in this region", "keywords": [{"text": "region"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Most of the emerging economies of the world", "keywords": [{"text": "economies"}, {"text": "world"}]}, "sentence": " Most of the emerging economies of the world are located in this region and more than 95% cases of pertussis that have been reported globally are accounted by the developing regions of the world.", "action": {"verb": {"text": "locate", "tense": "past"}, "text": "are located", "normalized": "be locate"}}, {"subject": {"text": "by the developing regions of the world", "keywords": [{"text": "regions"}, {"text": "world"}]}, "sentence": " Most of the emerging economies of the world are located in this region and more than 95% cases of pertussis that have been reported globally are accounted by the developing regions of the world.", "object": {"text": "pertussis that have been reported globally", "keywords": [{"text": "pertussis"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "are accounted", "normalized": "be account"}}, {"subject": {"text": "the region", "keywords": [{"text": "region"}]}, "sentence": " Hence, the region is bound to show a rapid growth in future.", "object": {"text": "a rapid growth", "keywords": [{"text": "rapid growth"}]}, "action": {"verb": {"text": "show", "tense": "future"}, "text": "is bound to show", "normalized": "be bind to show"}}, {"subject": {"text": "Various pharmaceutical manufacturers", "keywords": [{"text": "Various pharmaceutical manufacturers"}]}, "sentence": " Various pharmaceutical manufacturers are engaged in the development of therapeutic drugs and vaccines for effective management of pertussis globally.", "object": {"text": "engaged in the development of therapeutic drugs and vaccines", "keywords": [{"text": "therapeutic drugs"}, {"text": "vaccines"}, {"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Various pharmaceutical manufacturers", "keywords": [{"text": "Various pharmaceutical manufacturers"}]}, "sentence": " Various pharmaceutical manufacturers are engaged in the development of therapeutic drugs and vaccines for effective management of pertussis globally.", "object": {"text": "in the development of therapeutic drugs and vaccines for effective management of pertussis globally", "keywords": [{"text": "therapeutic drugs"}, {"text": "effective management"}, {"text": "pertussis"}, {"text": "vaccines"}], "entities": [{"type": "HealthCondition", "text": "Pertussis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Pertussis", "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}}]}, "action": {"verb": {"text": "engage", "tense": "past"}, "text": "are engaged", "normalized": "be engage"}}, {"subject": {"text": "the major players", "keywords": [{"text": "major players"}]}, "sentence": " Request to View ToC of the report - Some of the major players having their molecules in different stages of clinical trials are GlaxoSmithKline plc, LG Life Sciences, Ltd., Merck & Co., Inc., Novartis Vaccines and Diagnostics, Inc. (Novartis AG), Panacea Biotec Limited, Sanofi and Takeda Pharmaceutical Company Limited.", "object": {"text": "their molecules", "keywords": [{"text": "molecules"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "Some of the major players having their molecules in different stages of clinical trials", "keywords": [{"text": "different stages"}, {"text": "major players"}, {"text": "clinical trials"}, {"text": "molecules"}]}, "sentence": " Request to View ToC of the report - Some of the major players having their molecules in different stages of clinical trials are GlaxoSmithKline plc, LG Life Sciences, Ltd., Merck & Co., Inc., Novartis Vaccines and Diagnostics, Inc. (Novartis AG), Panacea Biotec Limited, Sanofi and Takeda Pharmaceutical Company Limited.", "object": {"text": "GlaxoSmithKline plc, LG Life Sciences, Ltd., Merck & Co., Inc., Novartis Vaccines and Diagnostics, Inc. (Novartis AG), Panacea Biotec Limited, Sanofi and Takeda Pharmaceutical Company Limited", "keywords": [{"text": "Panacea Biotec Limited"}, {"text": "Novartis Vaccines"}, {"text": "LG Life Sciences"}, {"text": "Novartis AG"}], "entities": [{"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "LG Life Sciences, Ltd."}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "JobTitle", "text": "Novartis Vaccines and Diagnostics"}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Panacea Biotec Limited"}, {"type": "Company", "text": "Sanofi", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Pharmaceutical industry", "relevance": 0.966353, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pertussis", "relevance": 0.925106, "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}, {"text": "Novartis", "relevance": 0.789981, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Bordetella pertussis", "relevance": 0.659704, "dbpedia_resource": "http://dbpedia.org/resource/Bordetella_pertussis"}, {"text": "Microbiology", "relevance": 0.633063, "dbpedia_resource": "http://dbpedia.org/resource/Microbiology"}, {"text": "Clinical trial", "relevance": 0.632472, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "GlaxoSmithKline", "relevance": 0.595383, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Vaccine", "relevance": 0.579535, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}, {"text": "Switzerland", "relevance": 0.540096, "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}, {"text": "Pharmacology", "relevance": 0.512241, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Infant", "relevance": 0.502221, "dbpedia_resource": "http://dbpedia.org/resource/Infant"}, {"text": "Medicine", "relevance": 0.489092, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.484166, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Immune system", "relevance": 0.468126, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Influenza vaccine", "relevance": 0.421514, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_vaccine"}, {"text": "Vaccination", "relevance": 0.417183, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination"}, {"text": "Sanofi-Aventis", "relevance": 0.413482, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}, {"text": "Disease", "relevance": 0.404987, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}], "categories": [{"score": 0.908111, "label": "/health and fitness/disease"}, {"score": 0.312878, "label": "/health and fitness/disease/epidemic"}], "relations": [{"type": "bornOn", "sentence": "Bordetella Pertussis Infections Market to Witness Widespread Expansion by 2020  Pertussis, commonly known as whooping cough is caused due to a coccobacillus, aerobic, non motile, gram-negative bacteria called Bordetella pertussis.", "score": 0.447394, "arguments": [{"text": "Widespread Expansion", "location": [50, 70], "entities": [{"type": "Person", "text": "Widespread Expansion"}]}, {"text": "2020\n Pertussis", "location": [74, 89], "entities": [{"type": "Date", "text": "2020\n Pertussis"}]}]}, {"type": "employedBy", "sentence": "Infant immunization programs that utilize different pertussis vaccines of listed quality have proven extremely successful in preventing pertussis in infants all over the world for several decades.", "score": 0.266836, "arguments": [{"text": "infants", "location": [1692, 1699], "entities": [{"type": "Person", "text": "infants"}]}, {"text": "world", "location": [1713, 1718], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "timeOf", "sentence": "Request to View Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However, according to Centers for Disease Control and Prevention (CDC), U.S., more than 48,000 cases of pertussis were reported only in the U.S. in 2012, where many cases also went undiagnosed and unreported.", "score": 0.873902, "arguments": [{"text": "https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However", "location": [1777, 1864], "entities": [{"type": "Time", "text": "https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However"}]}, {"text": "Request", "location": [1740, 1747], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "timeOf", "sentence": "Request to View Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However, according to Centers for Disease Control and Prevention (CDC), U.S., more than 48,000 cases of pertussis were reported only in the U.S. in 2012, where many cases also went undiagnosed and unreported.", "score": 0.495745, "arguments": [{"text": "https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However", "location": [1777, 1864], "entities": [{"type": "Time", "text": "https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However"}]}, {"text": "Report", "location": [1768, 1774], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "Request to View Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However, according to Centers for Disease Control and Prevention (CDC), U.S., more than 48,000 cases of pertussis were reported only in the U.S. in 2012, where many cases also went undiagnosed and unreported.", "score": 0.878111, "arguments": [{"text": "2012", "location": [2005, 2009], "entities": [{"type": "Date", "text": "2012"}]}, {"text": "reported", "location": [1976, 1984], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "populationOf", "sentence": "Request to View Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110 However, according to Centers for Disease Control and Prevention (CDC), U.S., more than 48,000 cases of pertussis were reported only in the U.S. in 2012, where many cases also went undiagnosed and unreported.", "score": 0.287137, "arguments": [{"text": "many", "location": [2017, 2021], "entities": [{"type": "Cardinal", "text": "many"}]}, {"text": "where", "location": [2011, 2016], "entities": [{"type": "GeopoliticalEntity", "text": "where"}]}]}, {"type": "timeOf", "sentence": "And, according to the CDC estimates it was concluded that this was the most number of pertussis cases that have been reported since 1995, when more than 62,000 pertussis cases were reported.", "score": 0.806022, "arguments": [{"text": "1995", "location": [2198, 2202], "entities": [{"type": "Date", "text": "1995"}]}, {"text": "reported", "location": [2183, 2191], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "timeOf", "sentence": "And, according to the CDC estimates it was concluded that this was the most number of pertussis cases that have been reported since 1995, when more than 62,000 pertussis cases were reported.", "score": 0.604547, "arguments": [{"text": "when", "location": [2204, 2208], "entities": [{"type": "Date", "text": "1995"}]}, {"text": "reported", "location": [2247, 2255], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "Thus, rising awareness among people about the severity of the disease have caused increase in demand for advanced therapeutic drugs in the same category.", "score": 0.813244, "arguments": [{"text": "people", "location": [2286, 2292], "entities": [{"type": "Person", "text": "people"}]}, {"text": "disease", "location": [2319, 2326], "entities": [{"type": "HealthCondition", "text": "pertussis"}]}]}, {"type": "partOf", "sentence": "Some of the molecules that are under different stages of clinical trials include, GSK2202083A + Prevenar 13 + Rotarix, V419 + Prevnar 13 + RotaTeq, TAK-361S, DtwP-HB-Hib and DTP-HepB-Polio-Hib among others.", "score": 0.41621, "arguments": [{"text": "Rotarix", "location": [2708, 2715], "entities": [{"type": "Organization", "text": "Rotarix", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "GSK2202083A + Prevenar", "location": [2680, 2702], "entities": [{"type": "Organization", "text": "GSK2202083A + Prevenar"}]}]}, {"type": "locatedAt", "sentence": "Among all the regions, North America and Europe are expected to dominate the global Bordetella pertussis infections market owing to the factors such as high demand for advanced therapeutic drugs for treating newly born babies along with high awareness, acceptability and affordability of the people in these regions.", "score": 0.5213, "arguments": [{"text": "regions", "location": [2819, 2826], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [2846, 2852], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "residesIn", "sentence": "Among all the regions, North America and Europe are expected to dominate the global Bordetella pertussis infections market owing to the factors such as high demand for advanced therapeutic drugs for treating newly born babies along with high awareness, acceptability and affordability of the people in these regions.", "score": 0.387135, "arguments": [{"text": "people", "location": [3097, 3103], "entities": [{"type": "Person", "text": "people"}]}, {"text": "regions", "location": [3113, 3120], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "partOfMany", "sentence": "Immunization programs against pertussis have been adopted in most of the countries of the world to protect their children against this disease.", "score": 0.192709, "arguments": [{"text": "countries", "location": [748, 757], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "world", "location": [765, 770], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "However, Asia Pacific region is expected to exhibit a rapid growth in this market in future due to factors like high prevalence of pertussis in the region along with increasing healthcare awareness and purchasing power of the population.", "score": 0.520715, "arguments": [{"text": "Asia", "location": [3131, 3135], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3136, 3143], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "However, Asia Pacific region is expected to exhibit a rapid growth in this market in future due to factors like high prevalence of pertussis in the region along with increasing healthcare awareness and purchasing power of the population.", "score": 0.520344, "arguments": [{"text": "region", "location": [3144, 3150], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}, {"text": "Pacific", "location": [3136, 3143], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Most of the emerging economies of the world are located in this region and more than 95% cases of pertussis that have been reported globally are accounted by the developing regions of the world.", "score": 0.487437, "arguments": [{"text": "reported", "location": [3483, 3491], "entities": [{"type": "EventCommunication", "text": "reported"}]}, {"text": "cases", "location": [3449, 3454], "entities": [{"type": "EventLegal", "text": "cases"}]}]}, {"type": "locatedAt", "sentence": "Most of the emerging economies of the world are located in this region and more than 95% cases of pertussis that have been reported globally are accounted by the developing regions of the world.", "score": 0.687165, "arguments": [{"text": "regions", "location": [3533, 3540], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "world", "location": [3548, 3553], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "parentOf", "sentence": "Immunization programs against pertussis have been adopted in most of the countries of the world to protect their children against this disease.", "score": 0.630282, "arguments": [{"text": "their", "location": [782, 787], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "children", "location": [788, 796], "entities": [{"type": "Person", "text": "children"}]}]}, {"type": "hasAttribute", "sentence": "Immunization programs against pertussis have been adopted in most of the countries of the world to protect their children against this disease.", "score": 0.802203, "arguments": [{"text": "children", "location": [788, 796], "entities": [{"type": "Person", "text": "children"}]}, {"text": "disease", "location": [810, 817], "entities": [{"type": "HealthCondition", "text": "pertussis"}]}]}, {"type": "employedBy", "sentence": "According to the World Health Organization (WHO) estimates, around 16 million cases of pertussis were recorded worldwide in 2008, of which 95% cases were in developing nations.", "score": 0.574985, "arguments": [{"text": "WHO", "location": [1326, 1329], "entities": [{"type": "Person", "text": "WHO"}]}, {"text": "World Health Organization", "location": [1299, 1324], "entities": [{"type": "Organization", "text": "World Health Organization", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "hasAttribute", "sentence": "According to the World Health Organization (WHO) estimates, around 16 million cases of pertussis were recorded worldwide in 2008, of which 95% cases were in developing nations.", "score": 0.473819, "arguments": [{"text": "WHO", "location": [1326, 1329], "entities": [{"type": "Person", "text": "WHO"}]}, {"text": "pertussis", "location": [1369, 1378], "entities": [{"type": "HealthCondition", "text": "pertussis"}]}]}, {"type": "timeOf", "sentence": "According to the World Health Organization (WHO) estimates, around 16 million cases of pertussis were recorded worldwide in 2008, of which 95% cases were in developing nations.", "score": 0.496032, "arguments": [{"text": "2008", "location": [1406, 1410], "entities": [{"type": "Date", "text": "2008"}]}, {"text": "cases", "location": [1425, 1430], "entities": [{"type": "EventLegal", "text": "cases"}]}]}, {"type": "agentOf", "sentence": "According to the World Health Organization (WHO) estimates, around 16 million cases of pertussis were recorded worldwide in 2008, of which 95% cases were in developing nations.", "score": 0.433836, "arguments": [{"text": "nations", "location": [1450, 1457], "entities": [{"type": "GeopoliticalEntity", "text": "nations", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "cases", "location": [1425, 1430], "entities": [{"type": "EventLegal", "text": "cases"}]}]}, {"type": "hasAttribute", "sentence": "Infant immunization programs that utilize different pertussis vaccines of listed quality have proven extremely successful in preventing pertussis in infants all over the world for several decades.", "score": 0.795452, "arguments": [{"text": "infants", "location": [1692, 1699], "entities": [{"type": "Person", "text": "infants"}]}, {"text": "pertussis", "location": [1679, 1688], "entities": [{"type": "HealthCondition", "text": "pertussis"}]}]}], "keywords": [{"text": "bordetella pertussis infections", "sentiment": {"score": -0.682957, "label": "negative"}, "relevance": 0.967354}, {"text": "pertussis infections market", "sentiment": {"score": -0.682957, "label": "negative"}, "relevance": 0.931463}, {"text": "different pertussis vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.657937}, {"text": "global Bordetella pertussis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.655176}, {"text": "pertussis toxin", "sentiment": {"score": -0.336995, "label": "negative"}, "relevance": 0.632119}, {"text": "B. pertussis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.631467}, {"text": "pertussis cases", "sentiment": {"score": -0.394646, "label": "negative"}, "relevance": 0.60971}, {"text": "therapeutic drugs", "sentiment": {"score": -0.499686, "label": "negative"}, "relevance": 0.581624}, {"text": "advanced therapeutic drugs", "sentiment": {"score": -0.672331, "label": "negative"}, "relevance": 0.532086}, {"text": "clinical trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47657}, {"text": "immunization programs", "sentiment": {"score": -0.816807, "label": "negative"}, "relevance": 0.439777}, {"text": "Witness Widespread Expansion", "sentiment": {"score": -0.625457, "label": "negative"}, "relevance": 0.436848}, {"text": "effective management", "sentiment": {"score": -0.32704, "label": "negative"}, "relevance": 0.432982}, {"text": "high prevalence", "sentiment": {"score": -0.740457, "label": "negative"}, "relevance": 0.432287}, {"text": "major driving factors", "sentiment": {"score": -0.740457, "label": "negative"}, "relevance": 0.431975}, {"text": "World Health Organization", "sentiment": {"score": 0.430808, "label": "positive"}, "relevance": 0.431592}, {"text": "pharmaceutical companies", "sentiment": {"score": -0.32704, "label": "negative"}, "relevance": 0.430723}, {"text": "Infant immunization programs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427882}, {"text": "medium income countries", "sentiment": {"score": -0.740457, "label": "negative"}, "relevance": 0.424918}, {"text": "future growth opportunities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422351}, {"text": "different stages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421602}, {"text": "Panacea Biotec Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421237}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421184}, {"text": "Various pharmaceutical manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420795}, {"text": "LG Life Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418556}, {"text": "Asia Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418198}, {"text": "rapid growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417494}, {"text": "newly born babies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413693}, {"text": "virulence factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384581}, {"text": "gram-negative bacteria", "sentiment": {"score": -0.496706, "label": "negative"}, "relevance": 0.380971}, {"text": "whooping cough", "sentiment": {"score": -0.315525, "label": "negative"}, "relevance": 0.380874}, {"text": "non motile", "sentiment": {"score": -0.281675, "label": "negative"}, "relevance": 0.380105}, {"text": "tracheal cytotoxin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380073}, {"text": "filamentous hemagglutinin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380025}, {"text": "respiratory droplets", "sentiment": {"score": -0.667401, "label": "negative"}, "relevance": 0.376736}, {"text": "Novartis Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.375819}, {"text": "mucosal layers", "sentiment": {"score": -0.648625, "label": "negative"}, "relevance": 0.374935}, {"text": "high number", "sentiment": {"score": -0.483734, "label": "negative"}, "relevance": 0.37484}, {"text": "susceptible individuals", "sentiment": {"score": -0.667401, "label": "negative"}, "relevance": 0.374748}, {"text": "respiratory tract", "sentiment": {"score": -0.648625, "label": "negative"}, "relevance": 0.371474}, {"text": "high demand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370158}, {"text": "advanced therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.36973}, {"text": "vaccination programs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369714}, {"text": "Disease Control", "sentiment": {"score": -0.347256, "label": "negative"}, "relevance": 0.369693}, {"text": "infected ones", "sentiment": {"score": -0.667401, "label": "negative"}, "relevance": 0.36898}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368729}, {"text": "high awareness", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368187}, {"text": "listed quality", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368097}, {"text": "Novartis AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366395}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364048}]}, "extracted_metadata": {"sha1": "5411f85eb469690f5fef83f8ea5e6ab6a867fc87", "filename": "1541696885837.zip-28f053a73053aebf5ac53fa7fdd79125.xml", "file_type": "json"}, "external_links": ["https://www.transparencymarketresearch.com/bordetella-pertussis-infections-market.html", "https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3110"], "title": "Bordetella Pertussis Infections Market to Witness Widespread Expansion by 2020", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "RH02t08fQ6u5z0JlyNPJ8hrfiqmOk6grWHX-c1c4BGD8BpZ527ZO2tqd3sE91geA", "result_metadata": {"score": 32.300568}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-08T16:06:49Z", "url": "https://www.businesswire.com/news/home/20181108005489/en/BARCLAYS-PLC-UK-Regulatory-Announcement-FORM-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T13:57:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.320442, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.306063, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.248222, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.247761, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.237472, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.232723, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.227409, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.219928, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.201946, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.194535, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,047,800 1.39%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,791,486 1.48%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,192,015 1.53%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,360,886 4.20%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,388,715 4.20%", "relevance": 0.194535, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.194535, "type": "Quantity"}], "sentiment": {"document": {"score": 0.106395, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,360,886 4.20% 33,388,715 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "33,360,886 4.20"}, {"type": "Quantity", "text": "33,388,715 4.20"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,047,800 1.39% 12,192,015 1.53% (2) Cash-settled derivatives: 11,791,486 1.48% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,360,886 4.20% 33,388,715 4.20% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,360,886 4.20% 33,388,715 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,360,886 4.20"}, {"type": "Quantity", "text": "33,388,715 4.20"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,047,800 1.39% 12,192,015 1.53% (2) Cash-settled derivatives: 11,791,486 1.48% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,360,886 4.20% 33,388,715 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658996 Time of Receipt (offset from UTC): 20181108T131813+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.944278, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.710929, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.682585, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.614163, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.4917, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Options", "relevance": 0.403685, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Option style", "relevance": 0.397567, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Moneyness", "relevance": 0.365428, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.341804, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Bond", "relevance": 0.31948, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Contract", "relevance": 0.315389, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "December", "relevance": 0.305022, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Unit type", "relevance": 0.296404, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.288645, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.574789, "label": "/real estate/buying and selling homes"}, {"score": 0.47036, "label": "/finance/financial news"}, {"score": 0.454446, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658996 Time of Receipt (offset from UTC): 20181108T131813+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [9824, 9827], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [9803, 9810], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "employedBy", "sentence": "Sale 102,600 4,654.2992 JPY Ordinary NPV Sale 222,200 4,650.7164 JPY Ordinary NPV Sale 223,700 4,650.5489 JPY Ordinary NPV Sale 373,200 4,648.5525 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 10,900 4,640.4992 JPY Ordinary NPV CFD Short 4,000 4,647.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (", "score": 0.500498, "arguments": [{"text": "Cash", "location": [4729, 4733], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [4775, 4789], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Sale 102,600 4,654.2992 JPY Ordinary NPV Sale 222,200 4,650.7164 JPY Ordinary NPV Sale 223,700 4,650.5489 JPY Ordinary NPV Sale 373,200 4,648.5525 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 10,900 4,640.4992 JPY Ordinary NPV CFD Short 4,000 4,647.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (", "score": 0.657678, "arguments": [{"text": "i", "location": [5028, 5029], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5031, 5038], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.444493, "arguments": [{"text": "Price", "location": [5628, 5633], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [5638, 5642], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6002, 6008], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6019, 6026], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 8 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [6927, 6933], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [6941, 6945], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7373, 7379], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7387, 7400], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7008, 7032], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7000, 7005], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9519, 9543], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9511, 9516], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7167, 7172], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7186, 7213], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9678, 9683], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9697, 9724], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7449, 7455], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7481, 7493], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.990515}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.770614}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.755431}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.439571}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435851}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43231}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4322}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.429349}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384621}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.3692}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.359256}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338262}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331767}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.273543}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.268248}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.267861}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265889}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265052}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264345}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.263618}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263215}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261317}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260553}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247046}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245918}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.24162}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.241577}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24132}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240738}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240398}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240276}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240076}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239888}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.239856}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239074}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23905}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238746}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.238599}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23844}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238157}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237959}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.237394}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237335}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237322}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237018}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236145}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235142}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235064}, {"text": "derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.234361}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234222}]}, "extracted_metadata": {"sha1": "6c609c08b3e90cbf36ea0025c3c24c38042969fc", "filename": "1541693209031.zip-0853e8bed4fd955945fac252f68e10a6.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: FORM 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "ZR5DEZsAqMqPHtSiZ68Ct9cXeiaTKmiF-EQ5Hp2-c4zfQ_1kf-cYcJzNI_ewKmVn", "result_metadata": {"score": 32.044033}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.558665, "label": "/law, govt and politics/legal issues/legislation/family laws"}, {"score": 0.475338, "label": "/law, govt and politics/government/state and local government"}, {"score": 0.465799, "label": "/law, govt and politics/legal issues/legislation/health care laws"}], "relations": [], "keywords": [{"text": "Shire Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.939689}, {"text": "Legal&Gen Inv Mgmnt", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.745215}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310104}]}, "crawl_date": "2018-11-08T15:48:42Z", "url": "https://www.moneyam.com/action/news/showArticle?id=6200435", "host": "moneyam.com", "text": "If it is a cash offer or possible cash offer, state \"N/A\" Yes - Takeda Pharmaceutical Company Limited 2.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-08T15:32:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "General Investment Management Ltd.", "relevance": 0.885952, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.604253, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.526492, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.467644, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.446786, "type": "JobTitle"}], "sentiment": {"document": {"score": -0.463081, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" Yes - Takeda Pharmaceutical Company Limited 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.920123, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Investment management", "relevance": 0.903554, "dbpedia_resource": "http://dbpedia.org/resource/Investment_management"}, {"text": "Offer and acceptance", "relevance": 0.901174, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.77415, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Collective investment scheme", "relevance": 0.738198, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}], "categories": [{"score": 0.505592, "label": "/real estate/buying and selling homes"}, {"score": 0.497204, "label": "/finance/investing"}, {"score": 0.497204, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "General Investment Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.954507}, {"text": "Investment Management Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.954265}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.775176}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.758216}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.720265}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.68324}, {"text": "offeror/offeree Shire Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.674694}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.669207}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.664251}, {"text": "possible cash offer", "sentiment": {"score": 0.408537, "label": "positive"}, "relevance": 0.659494}, {"text": "vehicle companies", "sentiment": {"score": -0.502369, "label": "negative"}, "relevance": 0.565711}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549253}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546701}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532084}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530239}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464843}, {"text": "Legal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452295}, {"text": "discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.451283}, {"text": "interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.449995}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.448005}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442016}, {"text": "nominee", "sentiment": {"score": -0.502369, "label": "negative"}, "relevance": 0.440865}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.439978}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43864}, {"text": "naming", "sentiment": {"score": -0.502369, "label": "negative"}, "relevance": 0.433764}, {"text": "controller", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432664}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427703}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427088}, {"text": "trust", "sentiment": {"score": 0.575723, "label": "positive"}, "relevance": 0.425976}, {"text": "settlor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425885}, {"text": "identity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424567}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423958}, {"text": "Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423273}]}, "extracted_metadata": {"sha1": "26459ec384a679b52c4374ac576bc5f3d7005008", "filename": "1541692122007.zip-668523c97ce8c0b075891f7edb6a3c42.xml", "file_type": "json"}, "title": "Legal&Gen Inv Mgmnt Form 8.3 - Shire Plc", "forum_title": "MoneyAM News"}]}